Study ID	Patient ID	Sample ID	Age at Diagnosis	Age At Procurement	Bone Marrow Blast Percentage	BRAF mutation	Cancer Type	Cancer Type Detailed	Cause of death source	CEBPA Biallelic Mutation	CEBPA Mutation	Sample collection center	Chemotherapy	Hematology serum creatinine laboratory result value in mg dl	Cumulative Treatment Regimens	Cumulative Treatment Regimen Count	Cumulative Treatment Stages	Number of Cumulative Treatment Stages	Cumulative Treatment Types	Cumulative Treatment Type Count	Current Regimen	Current Stage	FISH Results from Cytogenetics Report	Diagnosis	Diagnosis at Inclusion	DNMT3A Mutation	Drug Testing data in Analysis	Duration of Induction Treatment	ELN 2008 Risk Classification	ELN 2017 Risk Classification	Ethnicity Category	Exome Seq Analysis	Ex Vivo Drug Testing	FAB	FLT3-ITD Consensus Call	Negative for FLT3	Fusion	Group	Hematocrit Levels (%)	Hemoglobin level	IDH1 Mutation	IDH2 Negative	Response to Induction Treatment	JAK2 Negative	Karyotype	Karyotype and Sample Acquisition Interval Difference in Days	Negative for KIT	KRAS Mutation	Laboratory Procedure Lactate Dehydrogenase Result	MDS/MPN Diagnosis at Acquisition	MDS/MPN Two Months Prior to AML Diagnosis	MDS Two Months Prior to AML Diagnosis	Mean corpuscular volume (fL)	Most Recent Treatment Duration	Most Recent Treatment Type	MPN Two Months Prior to AML Diagnosis	Mutation Count	Non AML/MPN/MDS Diagnosis at Acquisition	NPM1 Consensus Call	NRAS Mutation	Oncotree Code	Overall Survival (Months)	Overall Survival Status	Albumin Levels in PB  (g/dL)	Alanine Aminotransferase Level in PB per litre	Aspartate Aminotransferase Level in PB per litre	Basophils Percent in Peripheral Blood	PB Blast Percentage	Eosinophils Percent in Peripheral Blood	Immature Granulocytes Percent in Peripheral Blood	Lymphocytes Percent in Peripherial Blood	Monocytes Percent in Peripherial Blood	Neutrophils Percent in Peripheral Blood	Nucleated RBCs Percent in Peripheral Blood	Platelet count	Platform	Prior Malignancy Radiation Therapy	Prior Diagnosis of Cancer	Prior MDS	Prior MDS/MPN	Prior MPN	RNA Sequenced	RNA Seq Analysis	Number of Samples Per Patient	Site of Sample	Sample Timepoint	Sex	Somatic Status	Specific Diagnosis at Acquisition	Specific Diagnosis at Inclusion	Surface Antigens	Total Protein Levels in the Blood (g/dL)	TP53 Mutation	Treatment Type	Type of Induction Treatment	WBC	Whole Exome Sequencing
aml_ohsu_2018	aml_ohsu_2018_163	aml_ohsu_2018_09-00705	73	73	94	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.79	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	M1	Positive	Negative	None	Initial Acute Leukemia Diagnosis	19.3	6.8	NA	NA	Complete Response	Negative	46,XY[20]	0	Negative	NA	441	False	No	No	100.5	30	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	13.98	DECEASED	4.1	19	28	0	97	0	NA	2	1	0	NA	89	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	7.6	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	94	Yes
aml_ohsu_2018	aml_ohsu_2018_174	aml_ohsu_2018_10-00136	69	69	80	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	Negative	1	Yes	1.68	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Signal copy for CEP 8 and ETO	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	4	Intermediate-II	Adverse	White	Yes	Yes	M4	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	7.7	NA	NA	Complete Response	NA	47,XY,+8[cp9]/46,XY[11]	0	NA	NA	4559	False	No	No	NA	3	Standard Chemotherapy	No	3	False	Negative	NA	AML	13.78	DECEASED	3.2	56	56	0	19	0	NA	5	3	11	NA	66	WES	No	NA	No	No	No	No	No	3	Leukapheresis	Denovo	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	5.4	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	282.1	Yes
aml_ohsu_2018	aml_ohsu_2018_175	aml_ohsu_2018_10-00172	59	59	91	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	Negative	1	Yes	0.86	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	trisomy 13	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Intermediate-II	Intermediate or Adverse	White	Yes	Yes	M4	Positive	Negative	None	Initial Acute Leukemia Diagnosis	22.9	7.9	NA	NA	Complete Response	Negative	47,XX,+13[18]/46,XX[2]	0	Negative	NA	3587	False	No	No	90.5	4	Standard Chemotherapy	No	4	False	Negative	NA	AML	17.8	DECEASED	1.9	84	90	0	99	0	NA	31	16	5	NA	48	WES	No	NA	No	No	No	No	No	1	Leukapheresis	Denovo	Female	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positi	4.6	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	29.7	Yes
aml_ohsu_2018	aml_ohsu_2018_45	aml_ohsu_2018_10-00507	70	70	97	NA	Leukemia	AML with Mutated NPM1	Dead-Other	No	NA	1	Yes	0.92	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	3	Consolidation | Induction	2	Standard Chemotherapy | Intrathecal	2	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-I	Favorable or Intermediate	White	Yes	No	M1	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	10.9	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	592	False	No	No	NA	5	Standard Chemotherapy	No	5	False	Positive	NA	AMLNPM1	16.81	DECEASED	2.8	30	38	0	97	0	NA	10	0	3	NA	8	WES	No	NA	No	No	No	No	No	2	Leukapheresis	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	5.8	NA	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	112.3	Yes
aml_ohsu_2018	aml_ohsu_2018_174	aml_ohsu_2018_10-00542	69	69	87	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	NA	1	Yes	0.67	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	4	Intermediate-II	Adverse	White	Yes	Yes	M4	Positive	NA	None	Relapse|Post-Chemotherapy	36	12.6	NA	NA	Complete Response	NA	47,XY,+8[cp20]	0	NA	NA	NA	False	No	No	91	3	Standard Chemotherapy	No	3	False	Negative	NA	AML	13.78	DECEASED	3.9	14	20	0	80	0	NA	11	0	9	NA	134	WES	No	NA	No	No	No	No	No	3	Peripheral Blood	Relapse	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	6.3	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	35.9	Yes
aml_ohsu_2018	aml_ohsu_2018_17	aml_ohsu_2018_10-00669	27	27	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	No Mutation info: RAF: 10-20%	1	Yes	0.69	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	2	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	17.7	6.3	NA	NA	Unknown	NA	46,XX[20]	3	NA	NA	426	False	No	No	101.6	105	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Positive	NA	AMLNPM1	48.13	DECEASED	2.3	8	15	0	NA	0	NA	7	2	2	NA	13	WES	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	5	Bone Marrow Aspirate	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5.4	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	58.8	Yes
aml_ohsu_2018	aml_ohsu_2018_201	aml_ohsu_2018_10-00692	60	60	40	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.8	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Induction | Experimental	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-I	Intermediate	White	Yes	Yes	NOS	Positive	NA	None	Initial Acute Leukemia Diagnosis	30.8	10.6	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	No	No	103.1	-1	Bone Marrow Transplant	No	4	False	Positive	NA	AMLNPM1	12.5	LIVING	3.1	23	31	0	51	0	NA	5	11	23	NA	136	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR, and partial TdT/positive	6.3	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	65.2	Yes
aml_ohsu_2018	aml_ohsu_2018_203	aml_ohsu_2018_10-00715	70	70	75	NA	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	Negative	1	Yes	0.9	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	4	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Intermediate-I	Intermediate	White	Yes	No	M0	Negative	Negative	None	Residual Disease	25.8	9.1	NA	NA	Complete Response	Negative	46,XY[18]	0	Negative	NA	137	False	No	No	89.5	155	Targeted Therapy - Kinase Inhibitor(s)	No	7	False	Negative	NA	AMLMD	13.16	DECEASED	3.7	16	22	1	30	0	NA	64	0	4	NA	43	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Unmatched	AML with minimal differentiation	AML with minimal differentiation	partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive	6.3	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	2.5	Yes
aml_ohsu_2018	aml_ohsu_2018_191	aml_ohsu_2018_10-00791	60	61	83	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.06	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-I	Intermediate	White	Yes	Yes	NOS	Positive	NA	None	Relapse	30.9	10.4	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	451	False	No	No	100.4	0	Supportive/Palliative Care	No	6	False	Positive	NA	AMLNPM1	12.96	DECEASED	3.7	42	45	0	41	0	NA	3	1	28	NA	57	WES	No	NA	No	No	No	No	No	3	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.3	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	48.2	Yes
aml_ohsu_2018	aml_ohsu_2018_163	aml_ohsu_2018_10-00792	73	74	95	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.04	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-I	Intermediate	White	Yes	Yes	M1	Positive	NA	None	Relapse|Post-Chemotherapy	27.8	9.9	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	195	False	No	No	101.8	30	Targeted Therapy - Kinase Inhibitor(s)	No	5	False	Positive	NA	AMLNPM1	13.98	DECEASED	3.8	21	26	0	84	0	NA	3	3	3	NA	20	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive; Negative for expression of CD34 and HLA-DR	5.8	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	53.5	Yes
aml_ohsu_2018	aml_ohsu_2018_127	aml_ohsu_2018_10-00819	74	77	85	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	NA	1	Yes	1.63	Decitabine|Quizartinib|Mitoxantrone	3	Induction | Experimental | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	1025	Intermediate-I	Adverse	White	Yes	Yes	M4	Positive	NA	None	Post-Chemotherapy|Residual Disease	31.3	10.7	NA	NA	Refractory	NA	46,XY[17]	0	NA	NA	419	False	No	No	103.3	18	Supportive/Palliative Care	No	3	False	Negative	NA	AML	41.58	DECEASED	4	14	23	0	77	0	NA	10	2	9	NA	69	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	6.4	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	16.1	Yes
aml_ohsu_2018	aml_ohsu_2018_174	aml_ohsu_2018_11-00049	69	70	90	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	NA	1	Yes	0.82	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	4	Intermediate-II	Intermediate or Adverse	White	Yes	No	M4	Positive	NA	None	Residual Disease|Post-Chemotherapy	26.3	9.2	NA	NA	Complete Response	NA	47,XY,+8[cp20]	0	NA	NA	575	False	No	No	88.3	3	Standard Chemotherapy	No	3	False	Negative	NA	AML	13.78	DECEASED	2.9	29	36	0	97	0	NA	5	0	1	NA	68	WES	No	NA	No	No	No	No	No	3	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	4.7	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	62.9	Yes
aml_ohsu_2018	aml_ohsu_2018_211	aml_ohsu_2018_11-00090	65	65	70	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	Negative	1	Yes	NA	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation | Induction | Experimental | CNS | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-I	Intermediate	White	Yes	Yes	NOS	Positive	Negative	None	Initial Acute Leukemia Diagnosis	25.9	9.1	NA	NA	Complete Response	Negative	46,XX[20]	0	Negative	NA	NA	False	No	Yes	94.3	-1	Bone Marrow Transplant	No	5	False	Positive	NA	AMLNPM1	12.73	DECEASED	NA	NA	NA	0	75	0	NA	6	3	8	NA	123	WES	No	NA	Yes	No	No	No	No	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	51.8	Yes
aml_ohsu_2018	aml_ohsu_2018_176	aml_ohsu_2018_11-00162	66	67	75	NA	Mastocytosis	Mastocytosis	Dead-Disease	No	NA	1	Yes	0.83	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myeloproliferative Neoplasms	NA	No	7	Not Enough Information	Favorable	White	Yes	Yes	NOS	Negative	NA	None	Residual Disease|Post-Chemotherapy	35	12	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	226	False	No	No	95.2	57	Targeted Therapy - Kinase Inhibitor(s)	Yes	4	False	Positive	NA	MCD	12.01	DECEASED	3.7	107	47	0	63	0	NA	8	0	23	NA	74	WES	No	NA	No	No	Yes	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with mutated NPM1	Mastocytosis	CD13, CD33, partial CD34, CD38, CD117 and CD123	5.6	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	11.9	Yes
aml_ohsu_2018	aml_ohsu_2018_203	aml_ohsu_2018_11-00170	70	71	80	NA	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	NA	1	Yes	1.04	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	4	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	22	7.4	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	89.7	155	Targeted Therapy - Kinase Inhibitor(s)	No	9	False	Positive	NA	AMLMD	13.16	DECEASED	2.2	36	29	0	80	0	NA	3	2	1	NA	10	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Male	Unmatched	AML with minimal differentiation	AML with minimal differentiation	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	4.6	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	23.1	Yes
aml_ohsu_2018	aml_ohsu_2018_191	aml_ohsu_2018_11-00178	60	61	95	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.06	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-I	Intermediate	White	Yes	No	NOS	Positive	NA	None	Residual Disease|Post-Chemotherapy	25.7	9.1	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	268	False	No	No	86.8	0	Supportive/Palliative Care	No	6	False	Positive	NA	AMLNPM1	12.96	DECEASED	3.4	34	28	1	60	0	NA	17	14	6	NA	18	WES	No	NA	No	No	No	No	No	3	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.1	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	21.5	Yes
aml_ohsu_2018	aml_ohsu_2018_191	aml_ohsu_2018_11-00254	60	61	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.6	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-I	Intermediate	White	Yes	No	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy	27	9.3	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	NA	False	No	No	81.8	0	Supportive/Palliative Care	No	6	False	Positive	NA	AMLNPM1	12.96	DECEASED	2.6	67	67	0	NA	0	NA	2	1	0	NA	21	WES	No	NA	No	No	No	No	No	3	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5.9	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	79.7	Yes
aml_ohsu_2018	aml_ohsu_2018_127	aml_ohsu_2018_11-00261	74	77	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	NA	1	Yes	1.48	Decitabine|Quizartinib|Mitoxantrone	3	Induction | Experimental | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	1025	Not Enough Information	Intermediate	White	Yes	Yes	M4	Positive	NA	None	Post-Chemotherapy|Residual Disease	NA	8.7	NA	NA	Refractory	NA	46,XY[20]	-20	NA	NA	696	False	No	No	NA	18	Supportive/Palliative Care	No	3	False	Negative	NA	AML	41.58	DECEASED	3	13	24	0	96	0	NA	2	1	0	NA	15	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	5.4	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	459.6	Yes
aml_ohsu_2018	aml_ohsu_2018_45	aml_ohsu_2018_11-00295	70	71	92	NA	Leukemia	AML with Mutated NPM1	Dead-Other	No	NA	1	Yes	0.85	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	3	Consolidation | Induction	2	Standard Chemotherapy | Intrathecal	2	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-I	Favorable or Intermediate	White	Yes	No	M1	Positive	NA	None	Relapse|Post-Chemotherapy	32.5	11.2	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	386	False	No	No	98.3	5	Standard Chemotherapy	No	5	False	Positive	NA	AMLNPM1	16.81	DECEASED	4.1	26	41	2	66	0	NA	11	0	18	NA	25	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD56, CD117, and MPO positive	6.7	NA	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	31.1	Yes
aml_ohsu_2018	aml_ohsu_2018_211	aml_ohsu_2018_11-00319	65	66	72	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	0.74	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation | Induction | Experimental | CNS | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-II	Intermediate	White	Yes	Yes	NOS	Positive	Negative	None	Post-Chemotherapy|Residual Disease	33.1	11.7	NA	NA	Complete Response	NA	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	0	NA	NA	443	False	No	Yes	95	-1	Bone Marrow Transplant	No	6	False	Positive	NA	AMLNPM1	12.73	DECEASED	4.1	61	44	0	45	0	NA	19	5	30	NA	93	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	6.6	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	18.4	Yes
aml_ohsu_2018	aml_ohsu_2018_550	aml_ohsu_2018_12-00023	71	71	68	G596R	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	1	Yes	0.85	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-I	Intermediate	White	No	Yes	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.9	7.6	Negative	Negative	Refractory	Negative	46,XX[20]	0	Negative	Negative	313	False	No	No	102.9	-1	Bone Marrow Transplant	No	NA	False	Negative	Negative	AMOL	13.06	DECEASED	3	14	18	0	NA	1	NA	30	49	3	NA	125	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	5.5	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	14.9	No
aml_ohsu_2018	aml_ohsu_2018_635	aml_ohsu_2018_12-00051	55	55	88	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	0.88	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-I	Favorable or Intermediate	White	No	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	28.2	9.6	Negative	Negative	Complete Response	Negative	46,XX[20]	0	Negative	Negative	678	False	No	No	99.9	-1	Bone Marrow Transplant	No	NA	False	Positive	Negative	AMLNPM1	23.26	DECEASED	3.4	19	26	0	93	0	NA	6	0	1	NA	19	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	17.9	No
aml_ohsu_2018	aml_ohsu_2018_559	aml_ohsu_2018_12-00066	70	70	36	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Dead-Disease	No	NA	1	Yes	1.18	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	153	Intermediate-I	Intermediate	White	No	Yes	M4	Positive	Negative	None	Initial Acute Leukemia Diagnosis	28.7	9.7	Negative	Negative	Refractory	Negative	46,XY[20]	0	Negative	Negative	231	False	Yes	No	99.6	4	Standard Chemotherapy	No	NA	False	Negative	Negative	CMML	10.23	DECEASED	3.6	19	22	5	9	5	NA	21	38	22	NA	47	RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	7.1	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	21	No
aml_ohsu_2018	aml_ohsu_2018_652	aml_ohsu_2018_12-00069	71	71	81	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	1	Yes	0.93	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-I	Adverse	HispNative	Yes	Yes	NOS	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	8.7	Negative	Negative	Refractory	Negative	46,XY[20]	1	Negative	Negative	673	False	No	No	NA	9	Supportive/Palliative Care	No	5	False	Negative	Negative	AMLNOS	10.16	DECEASED	3.3	42	45	0	60	0	NA	5	24	4	NA	83	WES	No	NA	No	No	No	No	No	3	Peripheral Blood	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD13, CD34, CD38, CD117, CD123, HLA-DR	6.9	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	179.1	Yes
aml_ohsu_2018	aml_ohsu_2018_707	aml_ohsu_2018_12-00127	53	53	93	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	1.03	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	23	Favorable	Favorable	White	Yes	Yes	M1	Negative	NA	None	Initial Acute Leukemia Diagnosis	24	8.2	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	92.7	-1	Bone Marrow Transplant	No	21	False	Positive	Negative	AMLNPM1	24.34	DECEASED	1.7	15	19	0	99	0	NA	1	3	1	NA	62	WES	No	NA	No	No	No	No	No	1	Leukapheresis	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	4.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	64.3	Yes
aml_ohsu_2018	aml_ohsu_2018_722	aml_ohsu_2018_12-00150	NA	18	NA	NA	Leukemia	Acute Myeloid Leukemia	NA	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	AdmixedBlack	No	Yes	NA	Negative	NA	Unknown	Unknown	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	NA	True	Negative	NA	AML	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	unknown	unknown	NA	NA	NA	NA	NA	NA	No
aml_ohsu_2018	aml_ohsu_2018_764	aml_ohsu_2018_12-00211	50	50	90	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.86	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	27	Intermediate-II	Favorable	White	No	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.4	9.1	Negative	Negative	Complete Response	Negative	46,XX,t(11;17)(q13;q21)[20]	0	Negative	Negative	1165	False	No	No	97.7	-1	Bone Marrow Transplant	No	NA	False	Positive	Negative	AMLNPM1	45.92	LIVING	2.8	19	30	0	82	0	NA	1	0	2	NA	8	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	5.3	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	84.1	No
aml_ohsu_2018	aml_ohsu_2018_799	aml_ohsu_2018_12-00258	81	81	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	1.08	Azacitidine	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Azacitidine	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	No	Yes	M5	Negative	NA	None	Post-Chemotherapy|Residual Disease	26.6	8.8	NA	NA	NA	NA	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	-112	NA	NA	2700	False	No	No	92.4	42	Supportive/Palliative Care	No	NA	False	Negative	NA	TMN	4.84	DECEASED	3.2	60	64	0	NA	0	NA	12	33	7	NA	46	RNA-seq	Yes	Anal carcinoma|Breast Cancer	No	Yes	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	6.3	NA	Supportive/Palliative Care	NA	37.1	No
aml_ohsu_2018	aml_ohsu_2018_825	aml_ohsu_2018_12-00294	72	72	95	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	1	No	0.96	NA	0	NA	0	NA	0	NONE	NONE	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Adverse	White	No	Yes	M4	Positive	Negative	None	Initial Acute Leukemia Diagnosis	16.5	5.6	Negative	NA	NA	Negative	46,XY[20]	0	Negative	NA	697	False	No	No	114	NA	NONE	No	NA	False	Negative	Negative	AMLMRC	0.1	DECEASED	2.7	47	58	0	96	0	NA	3	0	1	NA	51	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Leukapheresis	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive	4.9	NA	NA	NA	97	No
aml_ohsu_2018	aml_ohsu_2018_829	aml_ohsu_2018_12-00301	65	65	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Other	No	Negative	1	Yes	1.54	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	CBFB rearrangement	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Favorable	Favorable	White	No	Yes	M4	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	25.9	8.8	Negative	NA	Complete Response	Negative	46,XY,inv(16)(p13q22)[20]	-4	Negative	Negative	454	False	No	No	95.9	108	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLCBFBMYH11	42.34	DECEASED	2.7	71	48	0	15	0	NA	11	71	2	NA	14	WES + RNA-seq	No	NA	No	No	No	Yes	No	1	Peripheral Blood	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	6.1	NA	Standard Chemotherapy	Standard Chemotherapy	20.7	No
aml_ohsu_2018	aml_ohsu_2018_652	aml_ohsu_2018_12-00362	71	71	34	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	1	Yes	0.63	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-I	Adverse	HispNative	Yes	Yes	NOS	Positive	NA	None	Post-Chemotherapy|Residual Disease	21.8	7.3	NA	NA	Refractory	NA	46,XY[20]	-36	NA	NA	477	False	No	No	94.3	9	Supportive/Palliative Care	No	6	False	Negative	NA	AMLNOS	10.16	DECEASED	3.7	90	37	3	33	1	NA	28	5	23	NA	322	WES	No	NA	No	No	No	No	No	3	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	6.5	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	7.6	Yes
aml_ohsu_2018	aml_ohsu_2018_555	aml_ohsu_2018_12-00371	56	60	77.5	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	8	Consolidation | Salvage | Induction | Experimental | Re-induction	5	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Cytarabine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	Asian	Yes	Yes	NOS	Positive	NA	None	Post-Chemotherapy|Relapse	26.3	9.3	NA	NA	Complete Response	NA	46,XY[4]	-121	NA	NA	NA	False	No	No	87.8	64	Standard Chemotherapy	No	6	False	Positive	NA	AMLNPM1	57.07	DECEASED	NA	NA	NA	0	75	1	NA	16	1	4	NA	9	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	7.9	Yes
aml_ohsu_2018	aml_ohsu_2018_555	aml_ohsu_2018_12-00372	56	60	77.5	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	8	Consolidation | Salvage | Induction | Experimental | Re-induction	5	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Cytarabine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	Asian	No	Yes	NOS	Positive	NA	None	Relapse|Post-Chemotherapy	26.3	9.3	NA	NA	Complete Response	NA	46,XY[4]	-121	NA	NA	NA	False	No	No	87.8	64	Standard Chemotherapy	No	NA	False	Positive	NA	AMLNPM1	57.07	DECEASED	NA	NA	NA	0	75	1	NA	16	1	4	NA	9	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	7.9	No
aml_ohsu_2018	aml_ohsu_2018_923	aml_ohsu_2018_12-00423	61	61	46	NA	Leukemia	AML with Maturation	NA	No	NA	1	Yes	1.05	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Intermediate	White	No	Yes	M2	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.4	8.8	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	551	False	No	No	89.1	7	Standard Chemotherapy	No	NA	False	Negative	NA	AM	NA	NA	3.2	18	34	0	66	1	NA	24	5	4	NA	72	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with maturation	AML with maturation	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	7	NA	Standard Chemotherapy	Standard Chemotherapy	16.5	No
aml_ohsu_2018	aml_ohsu_2018_50	aml_ohsu_2018_12-00426	11	14	80	NA	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	Dead-Disease	No	NA	1	Yes	0.66	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High	13	Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Intensification | Re-induction | Allogeneic - Matched Unrelated Donor	8	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s) | Intrathecal	5	Sorafenib	Experimental	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	9	Adverse	Adverse	White	No	Yes	M2	Positive	NA	DEK-NUP214	Relapse|Post-Transplant|Post-Chemotherapy	41.6	14.3	NA	NA	Refractory	NA	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]	0	NA	NA	NA	False	No	No	102.9	187	Targeted Therapy - Kinase Inhibitor(s)	No	NA	False	NA	NA	AMLDEKNUP214	54.44	DECEASED	4.3	42	38	0	0	3	NA	78	3	16	NA	50	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Relapse	Male	Matched	AML with t(6;9)(p23;q34); DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO	7.6	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal	Standard Chemotherapy	2.2	No
aml_ohsu_2018	aml_ohsu_2018_652	aml_ohsu_2018_13-00004	71	72	65	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	1	Yes	0.91	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Not Enough Information	Adverse	HispNative	Yes	Yes	NOS	Positive	NA	None	Post-Chemotherapy|Residual Disease	23.3	7.7	NA	NA	Refractory	NA	46,XY[20]	-71	NA	NA	888	False	No	No	91	9	Supportive/Palliative Care	No	5	False	Negative	NA	AMLNOS	10.16	DECEASED	2.3	47	54	11	13	11	NA	52	3	10	NA	49	WES	No	NA	No	No	No	No	No	3	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	5.8	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	6.8	Yes
aml_ohsu_2018	aml_ohsu_2018_29	aml_ohsu_2018_13-00007	34	36	90	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	0.92	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Salvage | Induction | Re-induction	4	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Intermediate	White	No	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Relapse	25.5	9.1	NA	NA	Complete Response	NA	46,XY,add(17)(p13)[19]/46,XY[1]	0	NA	NA	123	False	No	No	85	43	Standard Chemotherapy	No	NA	False	Positive	NA	AMLNPM1	19.57	DECEASED	2.8	43	11	1	30	0	NA	46	30	8	NA	14	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	5.8	NA	Standard Chemotherapy	Standard Chemotherapy	0.6	No
aml_ohsu_2018	aml_ohsu_2018_953	aml_ohsu_2018_13-00028	24	24	88	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	Negative	1	Yes	0.62	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide	5	Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	5	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Donor Lymphocyte Infusion	Unknown	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Intermediate	White	No	Yes	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	31.7	10.9	NA	NA	Complete Response	Negative	47,XY,+10[18]/46,XY[2]	0	Negative	Negative	419	False	No	No	86.3	0	DLI	No	NA	False	Negative	Negative	AML	39.7	LIVING	2.8	13	14	0	94	0	NA	3	40	3	NA	89	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	5.8	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	21.7	No
aml_ohsu_2018	aml_ohsu_2018_958	aml_ohsu_2018_13-00034	61	61	50	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	0.84	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	No	Yes	NA	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	25.3	8.4	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	102.8	NA	NONE	No	NA	False	Negative	NA	TMN	0.53	DECEASED	2.5	61	NA	1	89	1	NA	0	0	0	NA	24	RNA-seq	No	Follicular lymphoma	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-	4.5	NA	NA	NA	53	No
aml_ohsu_2018	aml_ohsu_2018_1011	aml_ohsu_2018_13-00098	64	64	76	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	2	Yes	0.48	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Favorable	Black	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	32.6	10.9	NA	NA	Complete Response	NA	46,XX[14]	0	NA	NA	184	False	No	No	NA	5	Standard Chemotherapy	No	23	False	Positive	NA	AMLNPM1	NA	NA	3.6	22	20	1.4	0	0.1	NA	94.3	1.5	2.7	NA	32	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	7.5	NA	Standard Chemotherapy	Standard Chemotherapy	1.5	Yes
aml_ohsu_2018	aml_ohsu_2018_231	aml_ohsu_2018_13-00106	31	33	83	NA	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	Dead-Disease	No	NA	1	Yes	0.5	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Et	9	Consolidation | Salvage | Unknown | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	7	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Donor Lymphocyte Infusion	Unknown	t(6;9)(p22;q34)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Adverse	Adverse	HispNative	Yes	Yes	NOS	Negative	NA	DEK-NUP214	Residual Disease|Post-Transplant|Post-DLI	30.5	11.3	NA	NA	Complete Response	NA	46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20]	0	NA	NA	NA	False	No	No	82.6	-1	DLI	No	3	False	Negative	NA	AMLDEKNUP214	27.57	DECEASED	3	81	48	1	NA	0	NA	60	3	36	NA	13	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML with t(6;9)(p23;q34); DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO	6.6	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	0.9	Yes
aml_ohsu_2018	aml_ohsu_2018_685	aml_ohsu_2018_13-00118	54	57	71	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.81	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation | Salvage | Induction | Re-induction | Maintenance	5	Standard Chemotherapy	1	Decitabine	Re-induction	Trisomy 21	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-II	Favorable	White	Yes	Yes	M4	Negative	NA	None	Relapse|Post-Chemotherapy	33.7	11.7	NA	NA	Complete Response	NA	47,XY,+21[15]/46,XY[5]	-349	NA	NA	438	False	No	No	100.6	160	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	45.33	DECEASED	3.9	35	31	3	83	2	NA	5	10	4	NA	119	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	33.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1027	aml_ohsu_2018_13-00123	83	83	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	2.48	NA	0	NA	0	NA	0	NONE	NONE	trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Favorable	White	No	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	17.6	6.2	NA	NA	NA	NA	47,XY,+8[6]/46,XY[13]	-1	NA	NA	2037	False	No	No	94.5	NA	NONE	No	NA	False	Positive	NA	TMN	0.3	DECEASED	1.9	242	341	0	90	0	NA	9	7	4	NA	14	RNA-seq	No	Colon Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	3.6	NA	NA	NA	85.9	No
aml_ohsu_2018	aml_ohsu_2018_1045	aml_ohsu_2018_13-00145	70	71	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	1.12	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine | Induction	2	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	No	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	24.7	8.2	NA	NA	Refractory	NA	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	-22	NA	NA	NA	False	No	No	89.2	-1	Supportive/Palliative Care	No	NA	False	Negative	NA	AMLMRC	6.38	DECEASED	NA	NA	NA	NA	78	NA	NA	12	5	3	NA	18	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	24.4	No
aml_ohsu_2018	aml_ohsu_2018_1046	aml_ohsu_2018_13-00146	7	7	85	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Dead-Other	No	Negative	1	Yes	0.41	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction | Re-induction	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	AML/ETO fusion, t(8;21)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	9	Favorable	Favorable	White	No	Yes	NA	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	27.7	9.4	Negative	NA	Complete Response	Negative	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	0	NA	Negative	747	False	No	No	90.5	-1	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLRUNX1RUNX1T1	5.2	DECEASED	3.9	18	19	0	30	0	NA	42	0	27	NA	71	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	7.3	Negative	Standard Chemotherapy	Standard Chemotherapy	4.8	No
aml_ohsu_2018	aml_ohsu_2018_819	aml_ohsu_2018_13-00147	57	58	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Intermediate	AdmixedAsian	No	Yes	NA	Positive	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XX[20]	-14	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Positive	NA	AMLNPM1	8.45	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	No
aml_ohsu_2018	aml_ohsu_2018_1049	aml_ohsu_2018_13-00149	78	79	87	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	1031?1032 ins AAC; MAF 50%	1	Yes	0.75	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	32.3	10.6	Negative	Negative	Refractory	Negative	45,X,-Y[19]/46,XY[1]	0	Negative	Negative	460	False	No	No	103.6	-1	Standard Chemotherapy	No	3	False	Negative	Negative	AMLCEBPA	8.78	DECEASED	3.4	19	41	0	72	1	NA	17	4	1	NA	15	WES + RNA-seq	No	Bladder Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	6.2	Negative	Standard Chemotherapy	Standard Chemotherapy	8.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1051	aml_ohsu_2018_13-00150	52	53	NA	NA	Leukemia	Mixed Phenotype Acute Leukemia, T/Myeloid, NOS	Dead-Disease	No	NA	1	Yes	0.68	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	6	Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine	Salvage	Deleted 5q	Acute Leukaemias of Ambiguous Lineage	Acute Leukaemias of Ambiguous Lineage	NA	Yes	6	Adverse	Adverse	White	No	Yes	NA	Negative	NA	None	Post-Transplant|Post-Chemotherapy|Residual Disease	34	11.1	NA	NA	Refractory	NA	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	-2	NA	NA	167	False	No	No	102.8	80	Standard Chemotherapy	No	NA	False	Negative	NA	MPALTNOS	13.29	DECEASED	3.7	32	34	0	59	0	NA	9	2	29	NA	152	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Mixed phenotype acute leukaemia, T/myeloid, NOS	Mixed phenotype acute leukaemia, T/myeloid, NOS	NA	6.7	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	14	No
aml_ohsu_2018	aml_ohsu_2018_1054	aml_ohsu_2018_13-00157	60	60	80	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.64	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Q696fs*9; MAF 40%	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	41.1	13.4	p.R132H; MAF 40%	NA	Complete Response	Negative	46,XX[20]	0	Negative	Negative	660	False	No	No	86.1	104	Standard Chemotherapy	No	4	False	Positive	Negative	AMLNPM1	45.36	LIVING	2.9	32	50	0	32	0	NA	11	13	23	NA	228	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	7.4	Negative	Standard Chemotherapy	Standard Chemotherapy	53.9	Yes
aml_ohsu_2018	aml_ohsu_2018_967	aml_ohsu_2018_13-00160	70	73	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Maintenance	2	Standard Chemotherapy	1	Azacitidine	Maintenance	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY[19]	-93	NA	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	AMLMRC	38.32	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1058	aml_ohsu_2018_13-00163	24	24	50	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Unknown | Induction	4	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	inv(16)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	HispNative	Yes	Yes	M4	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	26.3	9.2	Negative	Negative	Complete Response	Negative	47,XY,inv(16)(p13q22),+22[20]	0	NA	Negative	NA	False	No	No	91.5	-1	Bone Marrow Transplant	No	1	False	Negative	Negative	AMLCBFBMYH11	13.16	LIVING	NA	NA	NA	0	6	0	NA	19	52	16	NA	53	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	13.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1060	aml_ohsu_2018_13-00165	33	33	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XX[7]	-2	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	11	False	Positive	NA	AMLNPM1	14.44	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1061	aml_ohsu_2018_13-00166	65	67	NA	NA	Leukemia	AML with Maturation	Dead-Unknown	No	NA	1	Yes	1.01	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	8	Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Unknown | Induction | Re-induction	6	Standard Chemotherapy	1	Cladribine	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	M2	Negative	NA	Unknown	Post-Chemotherapy|Residual Relapse	28.1	9.3	NA	NA	Refractory	NA	NA	0	NA	NA	132	False	No	No	93.5	5	Standard Chemotherapy	No	4	False	Negative	NA	AM	33.55	DECEASED	3.6	18	10	0	77	0	NA	15	1	3	NA	22	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with maturation	AML with maturation	NA	6.3	NA	Standard Chemotherapy	Standard Chemotherapy	19.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1072	aml_ohsu_2018_13-00186	74	74	60	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	1	No	0.59	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-I	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22	7.1	Negative	Negative	NA	Negative	46,XY[20]	0	Negative	Negative	399	False	Yes	No	87.4	NA	NONE	No	3	False	Negative	Negative	AMLMRC	4.14	DECEASED	3.2	250	160	0	29	1	NA	26	18	24	NA	107	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	7	Negative	NA	NA	11.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1078	aml_ohsu_2018_13-00195	66	66	90	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	1.13	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 50%	Yes	6	Favorable	Favorable	White	Yes	Yes	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	23.9	7.9	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	387	False	No	No	103.6	74	Standard Chemotherapy	No	9	False	Positive	Negative	AMLNPM1	31.97	LIVING	2.4	19	14	0	24	0	NA	14	61	1	NA	122	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	6.3	Negative	Standard Chemotherapy	Standard Chemotherapy	28	Yes
aml_ohsu_2018	aml_ohsu_2018_1082	aml_ohsu_2018_13-00201	56	56	90	NA	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	Negative	1	Yes	0.97	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.N879D; MAF 50%	No	7	Intermediate-I	Favorable or Intermediate	White	Yes	No	NOS	Positive	Negative	None	Initial Acute Leukemia Diagnosis	32.2	10.7	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	683	False	No	No	87	-1	Bone Marrow Transplant	No	19	False	Positive	Negative	AMLNPM1	8.13	DECEASED	4.2	70	53	0	64	2	NA	12	17	2	NA	38	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	7.9	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	61.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1086	aml_ohsu_2018_13-00202	53	53	73	NA	Leukemia	AML with Mutated NPM1	Dead-Other	No	Negative	3	No	NA	NA	0	NA	0	NA	0	NONE	NONE	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	46,XY[20]	-1	NA	NA	NA	False	No	No	NA	NA	NONE	No	5	False	Positive	NA	AMLNPM1	24.74	DECEASED	NA	NA	NA	NA	32	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes,	NA	NA	NA	NA	22.79	Yes
aml_ohsu_2018	aml_ohsu_2018_1088	aml_ohsu_2018_13-00204	65	65	72	NA	Leukemia	APL with PML-RARA	Dead-Other	No	Negative	1	Yes	0.6	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	2	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Unusual t(15;17), with the fusion signal on the derivative chromosome 15	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	5	Adverse	Favorable	White	Yes	Yes	M3	Positive	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	20.7	6.8	Negative	Negative	Unknown	Negative	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3]	0	Negative	Negative	398	False	No	No	90.2	3	Standard Chemotherapy	No	16	False	Negative	Negative	APLPMLRARA	0.23	DECEASED	2.9	24	33	0	57	0	NA	36	1	8	NA	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	5.6	Negative	Standard Chemotherapy	Standard Chemotherapy	9.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1094	aml_ohsu_2018_13-00218	41	41	80	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	Negative	1	Yes	0.35	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Favorable	Favorable	White	Yes	No	NOS	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	23.6	8.2	Negative	NA	Complete Response	Negative	46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2]	0	Negative	Negative	389	False	No	No	94.4	-1	Bone Marrow Transplant	No	16	False	Negative	Negative	AMLRUNX1RUNX1T1	45.95	LIVING	2.6	48	30	0	52	0	NA	44	3	1	NA	9	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	CD13, dim CD33, CD34, CD38,     CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO	6.8	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	5.8	Yes
aml_ohsu_2018	aml_ohsu_2018_928	aml_ohsu_2018_13-00226	83	83	75	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.7	ATRA, Arsenic Trioxide|Idarubicin	2	Induction | Symptom Control	2	Standard Chemotherapy	1	Idarubicin	Symptom Control	16q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	253	Adverse	Favorable	White	Yes	Yes	M3	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	23.4	8.1	Negative	NA	Complete Response	NA	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	0	Negative	Negative	367	False	No	No	86.2	0	Standard Chemotherapy	Yes	14	False	Negative	Negative	APLPMLRARA	47.01	LIVING	3.7	14	9	0	2.1	0	NA	17	2	23	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	6.8	Negative	Standard Chemotherapy	Standard Chemotherapy	6	Yes
aml_ohsu_2018	aml_ohsu_2018_1101	aml_ohsu_2018_13-00232	22	22	55	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.D107fs*; MAF ~50%	1	Yes	0.64	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Intermediate	White	Yes	Yes	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	24	8	Negative	Negative	Complete Response	Negative	46,XX[24]	0	Negative	Negative	373	False	No	No	95.2	-1	Bone Marrow Transplant	No	9	False	Negative	Negative	AMLCEBPA	32.93	LIVING	2.2	67	16	0	29	2	NA	7	33	24	NA	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+	6.5	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	29.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1103	aml_ohsu_2018_13-00236	2	5	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	0.49	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 	5	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	153	Adverse	Adverse	White	Yes	Yes	M5	Negative	NA	None	Residual Disease|Post-Transplant|Post-Chemotherapy	27.8	9.4	NA	NA	Complete Response	NA	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	-10	NA	NA	NA	False	No	No	96.9	-1	Bone Marrow Transplant	No	1	False	Negative	NA	AMLMRC	65.56	LIVING	3.3	20	34	0	NA	2	NA	67	6	25	NA	106	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.9	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1104	aml_ohsu_2018_13-00237	72	72	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	1	Yes	0.69	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	12p deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.9	8.7	Negative	Negative	Complete Response	Negative	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	0	Negative	Negative	219	False	Yes	No	92.2	6	Standard Chemotherapy	No	13	False	Negative	Negative	AMLMRC	5.79	DECEASED	3.6	66	26	0	5	2	NA	8	70	20	NA	23	WES	No	NA	No	Yes	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive	7.2	Negative	Standard Chemotherapy	Standard Chemotherapy	22.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1093	aml_ohsu_2018_13-00242	62	62	0.5	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	0.69	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Adverse	Adverse	Black	Yes	No	NOS	Negative	NA	None	Post-Chemotherapy	25	9	NA	NA	Complete Response i	NA	46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14)	0	NA	NA	224	False	No	No	NA	5	Standard Chemotherapy	No	2	False	Negative	NA	AMLMRC	8.36	DECEASED	3	8	16	0	0	0	NA	100	0	0	NA	22	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +).	6	Positive	Standard Chemotherapy	Standard Chemotherapy	0.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1108	aml_ohsu_2018_13-00245	8	8	30	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	1	Yes	0.53	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction | Intensification	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	t(8;21)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	11	Favorable	Favorable	Asian	Yes	Yes	M2	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	29.3	10.3	NA	NA	Complete Response	NA	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]	0	NA	NA	NA	False	No	No	93.5	62	Standard Chemotherapy	No	1	False	Negative	NA	AMLRUNX1RUNX1T1	28.19	LIVING	NA	NA	NA	0	17	0	NA	33	17	20	NA	109	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO	NA	NA	Standard Chemotherapy	Standard Chemotherapy	19.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1105	aml_ohsu_2018_13-00247	53	53	NA	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	Negative	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	RUNX1T1/RUNX1 fusion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	Complete Response	NA	46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2]	-4	NA	Negative	588	False	No	No	NA	109	Standard Chemotherapy	No	14	False	Negative	Negative	AMLRUNX1RUNX1T1	6.55	LIVING	NA	NA	NA	NA	22	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	5.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1111	aml_ohsu_2018_13-00250	78	78	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	NA	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Induction	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	Unknown	NA	NA	0	NA	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	4	False	Negative	NA	AMLMRC	11.71	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1113	aml_ohsu_2018_13-00253	42	42	70	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.V119?M120insV; MAF 30%	1	Yes	0.81	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Not Enough Information	Intermediate	White	Yes	No	M7	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	34.8	12	Negative	Negative	Refractory	Negative	NA	0	Negative	Negative	762	False	No	No	85.2	4	Standard Chemotherapy	No	11	False	Negative	Negative	AMLCEBPA	8.98	DECEASED	3.5	36	28	0	9	0	NA	43	6	38	NA	13	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	6.8	Negative	Standard Chemotherapy	Standard Chemotherapy	7.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1104	aml_ohsu_2018_13-00255	72	72	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	1	Yes	0.61	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	12p deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Adverse	White	No	Yes	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.3	8.7	Negative	Negative	Complete Response	Negative	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	-8	Negative	Negative	324	False	Yes	No	92.8	6	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLMRC	5.79	DECEASED	3.5	57	27	0	5	1	NA	3	77	8	NA	19	RNA-seq	No	NA	No	Yes	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.2	Negative	Standard Chemotherapy	Standard Chemotherapy	56.5	No
aml_ohsu_2018	aml_ohsu_2018_1117	aml_ohsu_2018_13-00260	14	14	62	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	Negative	1	Yes	0.58	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	1	Standard Chemotherapy	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	RUNX1T1/ RUNX1 fusion and t(8;21),	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	133	Adverse	Favorable	White	No	Yes	M2	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	18.5	6.3	Negative	NA	Complete Response	Negative	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	0	Negative	Negative	486	False	No	No	105.8	133	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLRUNX1RUNX1T1	33.26	LIVING	4.1	15	9	0	64	0	NA	28	1	7	NA	63	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	7.9	p.S366A; MAF 50%	Standard Chemotherapy	Standard Chemotherapy	13.3	No
aml_ohsu_2018	aml_ohsu_2018_1118	aml_ohsu_2018_13-00262	64	65	81	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	2	Yes	0.53	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	5	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	21	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	27.2	9.7	NA	NA	Refractory	NA	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	-1	NA	NA	743	False	No	No	NA	124	Targeted Therapy - Kinase Inhibitor(s)	No	4	False	Positive	NA	AMLNPM1	14.97	DECEASED	2.8	87	47	NA	94	NA	NA	6	NA	NA	NA	11	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).	5.2	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	26	Yes
aml_ohsu_2018	aml_ohsu_2018_1119	aml_ohsu_2018_13-00266	77	77	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Monosomy 7	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	7	Adverse	Adverse	White	No	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	Refractory	Negative	46,XY,-7,+13,i(17)(q10)[20]	1	Negative	Negative	NA	False	No	No	NA	7	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLMRC	4.24	DECEASED	NA	NA	NA	NA	47	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	25.3	No
aml_ohsu_2018	aml_ohsu_2018_1121	aml_ohsu_2018_13-00268	56	56	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	0.94	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Intermediate	White	Yes	Yes	NOS	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	27.8	9.1	NA	NA	Refractory	NA	NA	0	NA	NA	808	False	No	Yes	90.4	6	Standard Chemotherapy	No	3	False	Negative	NA	AMLMRC	3.72	DECEASED	3.4	22	24	0	5	0	NA	0	10	84	NA	136	WES	No	NA	Yes	No	No	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	5.8	NA	Standard Chemotherapy	Standard Chemotherapy	40.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1123	aml_ohsu_2018_13-00270	18	18	50	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	0.77	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction | Re-induction	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	CBFB rearrangement and inv(16)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	M4	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	21	7.4	Negative	NA	Refractory	Negative	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	0	Negative	p.G13D; MAF 10%	415	False	No	No	97.8	-1	Standard Chemotherapy	No	1	False	Negative	p.G13D; MAF 30%	AMLCBFBMYH11	4.97	LIVING	3.6	13	15	0	22	0	NA	24	49	20	NA	23	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	7.6	Negative	Standard Chemotherapy	Standard Chemotherapy	8.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1126	aml_ohsu_2018_13-00273	51	51	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	0.95	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 50%	No	6	Intermediate-I	Favorable or Intermediate	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	24.7	8.2	Negative	NA	Complete Response	Negative	46,XX[20]	-2	Negative	Negative	NA	False	No	No	86.2	3	Standard Chemotherapy	No	2	False	Positive	Negative	AMLNPM1	7.27	DECEASED	3.1	31	20	2	NA	0	NA	14	13	68	NA	99	WES	No	NA	No	No	No	Yes	No	1	Peripheral Blood	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	21.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1131	aml_ohsu_2018_13-00281	79	79	73	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	4	Yes	NA	Azacitidine, Lenalidomide	1	Salvage	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	NA	Negative	46,XX,del(16)(p11.2)[3]/46,XX[2]	0	Negative	Negative	NA	False	No	Yes	NA	137	Standard Chemotherapy	No	10	False	Negative	Negative	AMLMRC	6.22	DECEASED	NA	NA	NA	NA	56	NA	NA	NA	1	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR	NA	Negative	Standard Chemotherapy	NA	8.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1137	aml_ohsu_2018_13-00286	53	53	NA	Negative	Leukemia	AML with Mutated NPM1	Alive	No	Negative	4	Yes	NA	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy	1	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	7	Intermediate-I	Favorable or Intermediate	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XY[7]	2	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	7	False	Positive	Negative	AMLNPM1	37.83	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1098	aml_ohsu_2018_13-00294	31	36	18	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	NA	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	9	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Experimental | Re-induction	7	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	nuc ish(DXZ1x2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Relapse|Post-Chemotherapy|Post-Transplant	29.6	10.2	NA	NA	Complete Response	NA	46,XX	-4	NA	NA	NA	False	No	Yes	NA	24	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	NA	AMLMRC	87.53	DECEASED	NA	NA	NA	2	0	0	NA	14	8	68	NA	91	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	Transformation from another heme malignancy and Relapse	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	1.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1153	aml_ohsu_2018_13-00331	35	37	92	Negative	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	M5	Negative	NA	None	Post-Chemotherapy|Relapse	NA	NA	Positive	Negative	Complete Response	NA	46,XX[5]	0	Negative	Negative	NA	False	No	No	NA	53	Standard Chemotherapy	No	11	False	Positive	Negative	AMLNPM1	25.03	DECEASED	NA	NA	NA	NA	97	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Relapse	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	140	Yes
aml_ohsu_2018	aml_ohsu_2018_1157	aml_ohsu_2018_13-00338	53	60	82	Negative	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	5	Induction | Re-induction	2	Standard Chemotherapy	1	Azacitidine, Gemtuzumab	Re-induction	Positive	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Favorable	Favorable	White	Yes	No	M4eo	Negative	NA	CBFB-MYH11	Post-Chemotherapy|Relapse	NA	NA	Negative	Negative	Refractory	NA	47,XX,t(16;16)(p13;q22),+22[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	2	False	Negative	Negative	AMLCBFBMYH11	82.96	LIVING	NA	NA	NA	NA	25	NA	NA	NA	19	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Female	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	4.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1159	aml_ohsu_2018_13-00342	31	32	28	Negative	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	Double mutation	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	7	Allogeneic - Sibling | Consolidation | Salvage | Unknown | Induction | Re-induction	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Decitabine	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	8	Favorable	Favorable	Asian	Yes	No	NA	Negative	Negative	None	Relapse|Post-Chemotherapy	NA	NA	Negative	Negative	Complete Response	NA	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	18	False	Negative	Negative	AMLCEBPA	29.67	LIVING	NA	NA	NA	NA	23	NA	NA	NA	6	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Relapse	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)	NA	Negative	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	4	Yes
aml_ohsu_2018	aml_ohsu_2018_1162	aml_ohsu_2018_13-00346	46	47	41	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	NA	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	7	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	6	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	9	Not Enough Information	Adverse	White	Yes	No	NA	Positive	NA	None	Post-Chemotherapy|Post-Transplant|Residual Relapse	23	7.9	NA	NA	Complete Response i	NA	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	0	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	5	False	Negative	NA	AMLMRC	15.76	DECEASED	3.6	33	38	0	42	0	NA	40	0	10	NA	11	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	6.7	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	0.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1161	aml_ohsu_2018_13-00353	30	30	64	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	0.64	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Disruption of MLL signal and t(9;11)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Intermediate	Asian	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	21.8	7.5	Negative	NA	Complete Response	Negative	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	0	Negative	Negative	NA	False	No	No	111.8	31	Supportive/Palliative Care	No	15	False	Negative	Negative	TMN	8.88	DECEASED	3.6	48	33	0	65	0	NA	28.9	25.4	19.3	1.7	29	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	6.1	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	29.25	Yes
aml_ohsu_2018	aml_ohsu_2018_1163	aml_ohsu_2018_13-00354	73	73	84	Negative	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Other	No	Negative	4	Yes	NA	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Intermediate-I	Intermediate	Asian	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	15	False	Negative	Negative	AMOL	10.86	DECEASED	NA	NA	NA	NA	71	NA	NA	NA	6	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	16.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1171	aml_ohsu_2018_13-00365	72	72	NA	Negative	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	Negative	4	Yes	NA	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction | Re-induction	2	Standard Chemotherapy	1	Temozolomide, Vorinostat	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	-13	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	5	False	Positive	Negative	AMLNPM1	13.82	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Positive	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1181	aml_ohsu_2018_13-00383	71	71	34	Negative	Leukemia	AML, NOS	Dead-Disease	No	Negative	4	Yes	NA	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Cytarabine	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	0	Negative	Negative	NA	False	No	No	NA	9	Standard Chemotherapy	No	1	False	Negative	Negative	AMLNOS	23.65	DECEASED	NA	NA	NA	NA	8	NA	NA	NA	15	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	NA	4.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1181	aml_ohsu_2018_13-00384	71	71	34	Negative	Leukemia	AML, NOS	Dead-Disease	No	Negative	4	Yes	NA	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Cytarabine	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	0	Negative	Negative	NA	False	No	No	NA	9	Standard Chemotherapy	No	1	False	Negative	Negative	AMLNOS	23.65	DECEASED	NA	NA	NA	NA	8	NA	NA	NA	15	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	NA	4.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1184	aml_ohsu_2018_13-00393	52	52	21	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	0.89	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation | Salvage | Induction | Experimental | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	15	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	28.3	8.5	NA	NA	Refractory	NA	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	0	NA	NA	183	False	No	No	NA	-1	Bone Marrow Transplant	No	17	False	Negative	NA	AMLMRC	40.69	DECEASED	3.6	17	23	NA	5	NA	NA	68	4	23	NA	22	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	7.5	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	3.42	Yes
aml_ohsu_2018	aml_ohsu_2018_1187	aml_ohsu_2018_13-00396	63	63	51	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Treatment	No	Negative	1	Yes	1.37	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Decitabine	Consolidation	Extra MLL signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Adverse	White	Yes	Yes	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	33.7	11	Negative	NA	Complete Response	Negative	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]	-2	Negative	Negative	NA	False	No	No	92.6	-1	Standard Chemotherapy	No	9	False	Negative	Negative	AMLMRC	7.5	DECEASED	3.2	20	20	1.8	3.5	0.9	NA	41.2	37.7	11.4	0	24	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	7.1	p.R273S; MAF 40%	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	5.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1190	aml_ohsu_2018_13-00406	62	62	95	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	1	No	1.85	NA	0	NA	0	NA	0	NONE	NONE	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p. R882C; MAF 50%	Yes	NA	Intermediate-I	Adverse	White	Yes	Yes	M5	Positive	Negative	None	Initial Acute Leukemia Diagnosis	26.2	8.5	Negative	NA	NA	Negative	46,XY[20]	0	Negative	Negative	2941	False	No	No	104.8	NA	NONE	No	9	False	Negative	Negative	AMOL	0.07	DECEASED	3.2	93	104	0	66.3	0	NA	9.5	1.9	4.8	0.2	92	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Leukapheresis	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	Negative	NA	NA	250.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1190	aml_ohsu_2018_13-00409	62	62	95	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	1	No	1.85	NA	0	NA	0	NA	0	NONE	NONE	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 50%	No	NA	Intermediate-I	Intermediate or Adverse	White	Yes	No	M5	Positive	Negative	None	Initial Acute Leukemia Diagnosis	26.2	8.5	Negative	NA	NA	Negative	46,XY[20]	0	Negative	Negative	2941	False	No	No	104.8	NA	NONE	No	5	False	Negative	Negative	AMOL	0.07	DECEASED	3.2	93	104	0	95	0	NA	9.5	1.9	4.8	0.2	92	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	Negative	NA	NA	250.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1193	aml_ohsu_2018_13-00417	71	71	84	Negative	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	Negative	4	Yes	NA	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Favorable or Intermediate	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Positive	Negative	AMLNPM1	4.18	DECEASED	NA	NA	NA	NA	44	NA	NA	NA	3	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	2	Yes
aml_ohsu_2018	aml_ohsu_2018_1194	aml_ohsu_2018_13-00420	75	75	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation | Induction | Re-induction | Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]	-98	NA	NA	NA	False	No	No	NA	34	Standard Chemotherapy	No	37	False	Negative	NA	AMLNOS	12.6	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1196	aml_ohsu_2018_13-00424	77	77	NA	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	4	Yes	NA	Azacitidine, Lenalidomide	1	Induction	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XY,del(9)(q13q34)[3]/46,XY[14]	-6	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	20	False	Negative	Negative	AMLMRC	0.76	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	Positive	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1197	aml_ohsu_2018_13-00425	40	40	84	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	NA	2	Yes	0.65	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	HiDAC	Consolidation	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	35	12	NA	NA	Complete Response	NA	46,XX,t(9;11)(p22;q23)[20]	-1	NA	NA	613	False	No	No	NA	5	Standard Chemotherapy	No	1	False	Negative	NA	AMLRGA	15.99	LIVING	3.7	21	23	NA	29	NA	NA	63	3	5	NA	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR	6.5	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	9.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1224	aml_ohsu_2018_13-00450	79	79	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	4	Intermediate-I	Favorable	White	Yes	Yes	NA	Positive	NA	Unknown	Post-Chemotherapy|Relapse	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	14	Targeted Therapy - Kinase Inhibitor(s)	No	17	False	Positive	NA	AMLNPM1	4.08	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1226	aml_ohsu_2018_13-00454	31	31	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	Negative	2	Yes	1.04	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Favorable	Favorable	HispNative	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	22	7.4	NA	NA	Complete Response i	NA	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	0	NA	NA	229	False	No	No	NA	95	Standard Chemotherapy	No	1	False	Negative	NA	AMLCBFBMYH11	NA	NA	NA	NA	NA	NA	45	3	NA	25	20	7	NA	30	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), 	NA	NA	Standard Chemotherapy	Standard Chemotherapy	13.63	Yes
aml_ohsu_2018	aml_ohsu_2018_1566	aml_ohsu_2018_13-00466	71	71	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	0.93	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation | Salvage | Induction | Experimental	4	Standard Chemotherapy | Targeted Therapy - Other	2	Cytarabine	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	33.4	11.2	NA	NA	Complete Response	NA	NA	0	NA	NA	195	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	AMLNOS	32.01	DECEASED	3.9	21	27	0.5	0	2.5	NA	56.8	2.6	37.6	NA	89	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.9	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	2	Yes
aml_ohsu_2018	aml_ohsu_2018_1233	aml_ohsu_2018_13-00468	61	61	17	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Monosomy 21	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	25.8	8.5	Negative	Negative	Refractory	Negative	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]	0	Negative	Negative	NA	False	No	No	86.6	126	Standard Chemotherapy	No	14	False	Negative	Negative	AMLMRC	12.17	DECEASED	3.8	47	22	NA	10	NA	NA	27.7	NA	39.2	NA	40	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).	7.6	Negative	Standard Chemotherapy	Standard Chemotherapy	5.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1243	aml_ohsu_2018_13-00487	35	35	49.4	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	0.88	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Trisomy 22	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	Yes	Yes	M4	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	14.3	4.8	Negative	Negative	Complete Response	Negative	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	0	NA	Negative	505	False	No	No	100.7	94	Standard Chemotherapy	No	1	False	Negative	G13D; MAF 6%	AMLCBFBMYH11	11.78	LIVING	3.1	20	17	0	28.6	1.8	NA	19.6	37.5	7.1	0	36	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.	7.8	Negative	Standard Chemotherapy	Standard Chemotherapy	49.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1246	aml_ohsu_2018_13-00493	62	63	81	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Foundation, R882H; MAF 9%	No	24	Not Enough Information	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Relapse	30.2	10.7	NA	NA	Complete Response	NA	46,XY	0	NA	NA	NA	False	No	No	NA	141	Targeted Therapy - Kinase Inhibitor(s)	No	18	False	Positive	NA	AMLNPM1	18.68	DECEASED	4	34	15	0	59	0	NA	0	0	10	NA	17	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	6	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	1.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1247	aml_ohsu_2018_13-00496	33	33	72	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	25.9	9	NA	NA	Complete Response	NA	47,XX,inv(16)(p13.1q22),+22	0	Negative	NA	NA	False	No	No	NA	103	Standard Chemotherapy	No	1	False	Negative	NA	AMLCBFBMYH11	48.68	LIVING	3.4	85	30	0	18	0	NA	38	26	3	NA	18	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	NA	Standard Chemotherapy	Standard Chemotherapy	26.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1247	aml_ohsu_2018_13-00497	33	33	72	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	25.9	9	NA	NA	Complete Response	NA	47,XX,inv(16)(p13.1q22),+22	0	Negative	NA	NA	False	No	No	NA	103	Standard Chemotherapy	No	7	False	Negative	NA	AMLCBFBMYH11	48.68	LIVING	3.4	85	30	0	18	0	NA	38	26	3	NA	18	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	NA	Standard Chemotherapy	Standard Chemotherapy	26.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1248	aml_ohsu_2018_13-00500	71	71	76	NA	Leukemia	AML, NOS	Dead-Unknown	No	Negative	2	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	25	8.5	NA	NA	NA	NA	46,XY	0	Negative	NA	NA	False	No	No	NA	55	Standard Chemotherapy	No	22	False	Negative	NA	AMLNOS	5.13	DECEASED	3.1	27	25	0	58	2	NA	38	6	14	NA	93	WES + RNA-seq	No	Prostate Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial 	5.8	NA	Standard Chemotherapy	NA	7.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1255	aml_ohsu_2018_13-00513	55	55	75	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	NA	1	Yes	1.44	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	MLL rearrangement and t(9;11)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	M5	Positive	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	38.1	12.2	NA	NA	Complete Response	NA	46,XY,t(9;11)(p22;q23)[20]	-274	Negative	NA	497	False	No	No	87.6	4	Standard Chemotherapy	No	3	False	Positive	NA	AMLRGA	8.09	DECEASED	3.8	62	31	1.4	NA	8.5	NA	11.4	8.5	34	0.2	32	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	NA	7.9	NA	Standard Chemotherapy	Standard Chemotherapy	10.21	Yes
aml_ohsu_2018	aml_ohsu_2018_1257	aml_ohsu_2018_13-00515	73	74	32	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	NA	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine | Salvage | Unknown | Induction | Experimental | Re-induction	6	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	39	Intermediate-II	Adverse	White	Yes	Yes	NA	Positive	Negative	None	Post-Chemotherapy|Residual Disease	32.8	11	NA	NA	Refractory	NA	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	0	NA	NA	NA	False	No	Yes	NA	33	Targeted Therapy - Kinase Inhibitor(s)	No	17	False	Negative	NA	AMLMRC	21.64	DECEASED	4.1	15	30	1	67	2	NA	8	3	14	NA	90	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)	5.8	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	24.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1261	aml_ohsu_2018_13-00522	68	68	29	NA	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	Dead-Other	No	NA	3	Yes	NA	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myeloproliferative Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	Yes	18	False	Negative	NA	MPN	11.15	DECEASED	NA	NA	NA	NA	40	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Not specified	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	Secondary myelofibrosis	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	11.36	Yes
aml_ohsu_2018	aml_ohsu_2018_1281	aml_ohsu_2018_13-00532	21	22	88	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	0.51	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	13	Induction | Experimental | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Not Enough Information	Intermediate	HispNative	Yes	No	NA	Negative	NA	Unknown	Residual Disease|Post-Chemotherapy	25.8	9.1	NA	NA	Refractory	NA	NA	0	NA	NA	208	False	No	No	NA	15	Targeted Therapy - Kinase Inhibitor(s)	No	13	False	Negative	NA	AMLNOS	17.66	DECEASED	3.3	22	20	0	92	0	NA	8	0	0	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.4	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	3.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1355	aml_ohsu_2018_13-00535	51	51	50	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	2	Yes	0.71	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	26.1	8.7	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	335	False	No	No	NA	2197	Standard Chemotherapy	No	11	False	Positive	NA	AMLNPM1	8.52	DECEASED	NA	NA	NA	NA	24	1	NA	28	5	42	NA	108	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD7	NA	NA	Standard Chemotherapy	Standard Chemotherapy	4.06	Yes
aml_ohsu_2018	aml_ohsu_2018_757	aml_ohsu_2018_13-00537	32	38	90	NA	Leukemia	AML with Maturation	Dead-Disease	No	Q305?Q312del RNVETQ; MAF: 50%	1	Yes	0.6	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, 	9	Consolidation | Salvage | Induction | Re-induction | Post-Transplant Relapse | Allogeneic - Matched Unrelated Donor	6	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Decitabine, Sirolimus	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Transplant	30.6	10.2	Negative	Negative	Complete Response	Negative	46,XX[19]/46,XY[1]	-18	Negative	Negative	145	False	No	No	91.3	127	Standard Chemotherapy	No	4	False	Negative	Negative	AM	82.66	DECEASED	3.5	62	39	NA	30	NA	NA	56.8	NA	9.9	NA	17	WES	No	NA	No	No	No	Yes	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML with maturation	AML with maturation	CD7, CD13, CD33, CD34, dim CD45, CD56, CD117, CD123, and HLA-DR positive.	7.1	Negative	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2	Yes
aml_ohsu_2018	aml_ohsu_2018_1283	aml_ohsu_2018_13-00540	55	55	NA	NA	Leukemia	APL with PML-RARA	NA	No	NA	3	Yes	NA	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	PML-RARA+ 0.70743	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Favorable	White	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	19	False	Negative	NA	APLPMLRARA	NA	NA	NA	NA	NA	NA	54	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	1.04	Yes
aml_ohsu_2018	aml_ohsu_2018_1285	aml_ohsu_2018_13-00544	68	68	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Adverse	Intermediate	White	No	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	NA	0	NA	NA	NA	False	No	No	NA	5	Standard Chemotherapy	Yes	NA	False	Negative	NA	AMLNOS	0.95	DECEASED	NA	NA	NA	NA	41	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	9.5	No
aml_ohsu_2018	aml_ohsu_2018_1286	aml_ohsu_2018_13-00545	71	72	NA	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	Negative	4	Yes	NA	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Induction | Experimental | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	GATA2-MECOM	Residual Disease|Post-Chemotherapy	NA	NA	Negative	Negative	Refractory	NA	45,XY,-7,t(3;3)[20]	2	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	15	False	Negative	Negative	AMLRGA	18.26	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Prostate Cancer	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	NA	Negative	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1286	aml_ohsu_2018_13-00546	71	72	NA	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	Negative	4	Yes	NA	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Induction | Experimental | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Adverse	Adverse	White	No	Yes	NA	Negative	NA	GATA2-MECOM	Post-Chemotherapy|Residual Disease	NA	NA	Negative	Negative	Refractory	NA	45,XY,-7,t(3;3)[20]	2	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLRGA	18.26	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	Prostate Cancer	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	NA	Negative	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	NA	No
aml_ohsu_2018	aml_ohsu_2018_1314	aml_ohsu_2018_13-00551	51	51	NA	NA	Leukemia	AML, NOS	Alive	No	Negative	2	Yes	0.8	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Intermediate	Black	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	25	8.7	NA	NA	Refractory	NA	46,XY[20]	-3	NA	NA	NA	False	No	No	83.8	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AMLNOS	48.91	LIVING	3.7	16	14	NA	1	NA	NA	17	35	23	NA	16	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1315	aml_ohsu_2018_13-00552	74	75	NA	NA	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	NA	3	Yes	NA	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine | Salvage | Induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	None	Residual Disease	NA	NA	NA	NA	Refractory	NA	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	-7	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	24	False	Negative	NA	AMLMD	13.65	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1339	aml_ohsu_2018_13-00554	64	64	30	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	No	0.77	NA	0	NA	0	NA	0	NONE	NONE	Loss of ERG1 signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease	28.1	9.1	Negative	NA	NA	Negative	46,XY[21]	0	Negative	Negative	180	False	No	No	117.1	NA	NONE	No	4	False	Negative	Negative	AMLMRC	19.21	DECEASED	3.6	21	17	0.8	NA	1.5	0	71.5	1.5	24.7	0	47	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, dim CD38, CD117, and HLA-DR positive (10/31/13).	7.1	C238R; MAF 5% (not confirmed by Sanger seq)	NA	NA	1.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1233	aml_ohsu_2018_13-00557	61	62	17	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	0.3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Monosomy 21	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	32.4	10.4	NA	NA	Refractory	NA	46~49,XY,-21,+1~4mar[cp20]	0	NA	NA	NA	False	No	No	87.2	126	Standard Chemotherapy	No	18	False	Negative	NA	AMLMRC	12.17	DECEASED	3.7	34	15	NA	2	NA	NA	32.2	NA	34.2	NA	21	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.	7	NA	Standard Chemotherapy	Standard Chemotherapy	7.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1341	aml_ohsu_2018_13-00558	61	61	25	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Treatment	No	NA	1	Yes	0.8	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling | Salvage | Induction | Re-induction | Symptom Control	5	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Monosomy 5	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	31.1	9.8	NA	NA	Refractory	NA	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,	0	NA	NA	NA	False	No	No	88.9	-1	Bone Marrow Transplant	Yes	5	False	Negative	NA	AMLMRC	7.01	DECEASED	3.1	45	34	0	20	13	NA	6	12	55	0.9	243	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD117, and MPO+.	6.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	96.64	Yes
aml_ohsu_2018	aml_ohsu_2018_1343	aml_ohsu_2018_13-00563	64	64	NA	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	4	Yes	NA	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling | Induction	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	249	Not Enough Information	Adverse	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	-2	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	27	False	Negative	Negative	AMLMRC	33.59	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1348	aml_ohsu_2018_13-00572	39	39	59.3	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	3	Yes	NA	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	7	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance | Re-induction	5	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	HispNative	Yes	No	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Negative	NA	TMN	5.56	DECEASED	NA	NA	NA	NA	28	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	1.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1349	aml_ohsu_2018_13-00573	85	86	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	0.9	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Residual Disease|Post-Chemotherapy	25.7	8.2	NA	NA	NA	NA	NA	0	NA	NA	175	False	No	No	88	169	Standard Chemotherapy	No	4	False	Negative	NA	AMLMRC	10.95	DECEASED	3.5	15	9	0	NA	0	NA	17	44	39	0	18	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.9	NA	Standard Chemotherapy	NA	13.22	Yes
aml_ohsu_2018	aml_ohsu_2018_1353	aml_ohsu_2018_13-00578	30	31	NA	NA	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	Dead-Disease	No	NA	2	Yes	0.85	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	DEK-NUP214	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	3	NA	NA	329	False	No	No	NA	52	Targeted Therapy - Kinase Inhibitor(s)	No	14	False	Negative	NA	AMLDEKNUP214	18.68	DECEASED	4.2	49	31	NA	47	NA	NA	NA	NA	NA	NA	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with t(6;9)(p23;q34); DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	NA	6.3	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	20.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1353	aml_ohsu_2018_13-00581	30	31	65	NA	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	Dead-Disease	No	NA	2	Yes	0.87	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	No	Yes	NA	Positive	NA	DEK-NUP214	Residual Disease|Post-Chemotherapy	22.4	7.9	NA	NA	Refractory	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	0	NA	NA	NA	False	No	No	90.9	52	Targeted Therapy - Kinase Inhibitor(s)	No	NA	False	NA	NA	AMLDEKNUP214	18.68	DECEASED	3.9	NA	26	NA	52	0	NA	10	0	28	NA	20	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	AML with t(6;9)(p23;q34); DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	43.3	No
aml_ohsu_2018	aml_ohsu_2018_1257	aml_ohsu_2018_13-00593	73	74	66	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	NA	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine | Salvage | Unknown | Induction | Experimental | Re-induction	6	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	39	Intermediate-I	Adverse	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	34.7	11.6	NA	NA	Refractory	NA	46,XY	0	NA	NA	NA	False	No	Yes	NA	33	Targeted Therapy - Kinase Inhibitor(s)	No	11	False	Negative	NA	AMLMRC	21.64	DECEASED	4.3	22	36	6	40	2	NA	19	20	8	NA	67	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)	6.2	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	13.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1368	aml_ohsu_2018_13-00600	53	53	30	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	0.94	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Monosomy 7	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	25.4	8.6	Negative	NA	Refractory	Negative	NA	0	Negative	Negative	389	False	No	No	99.6	45	Standard Chemotherapy	No	16	False	Negative	Negative	AMLMRC	7.96	LIVING	3.2	45	31	0	35	1.2	NA	16	7.4	30.7	0	24	WES	No	NA	Yes	No	No	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive	6.5	Negative	Standard Chemotherapy	Standard Chemotherapy	3.28	Yes
aml_ohsu_2018	aml_ohsu_2018_1369	aml_ohsu_2018_13-00601	NA	NA	NA	NA	Myelodysplastic Syndromes	MDS with Excess Blasts	Dead-Unknown	No	NA	2	Yes	NA	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	Yes	60	NA	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Unknown	NA	NA	NA	NA	Unknown	NA	46,XY[20]	-3	NA	NA	NA	True	No	No	NA	60	Standard Chemotherapy	No	16	False	Negative	NA	MDSEB	3.82	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Refractory anaemia with excess blasts	Refractory anaemia with excess blasts	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1370	aml_ohsu_2018_13-00602	63	63	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	Yes	NA	2	Yes	0.75	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	-2	NA	NA	682	False	No	No	NA	-1	Bone Marrow Transplant	No	17	False	Negative	NA	AMLMRC	47.14	LIVING	2.9	16	27	NA	85	0	NA	9	3	3	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.6	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	33	Yes
aml_ohsu_2018	aml_ohsu_2018_1374	aml_ohsu_2018_13-00614	67	67	20	NA	Leukemia	Pure Erythroid Leukemia	Dead-Disease	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	PERL	24.77	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	Acute erythroid leukaemia	Acute erythroid leukaemia	Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1375	aml_ohsu_2018_13-00615	62	62	52	Negative	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	Negative	4	Yes	NA	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Favorable	Favorable	HispNative	Yes	Yes	NA	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XY,t(8;21)(q22;q22)[14]	0	NA	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	19	False	Negative	Positive	AMLRUNX1RUNX1T1	7.86	LIVING	NA	NA	NA	NA	57	NA	NA	NA	6	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	12.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1373	aml_ohsu_2018_13-00619	47	47	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	2	Yes	0.56	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Favorable	White	Yes	No	NA	Negative	NA	Unknown	Residual Disease|Post-Chemotherapy	14.5	5.3	NA	NA	NA	NA	NA	0	NA	NA	291	False	No	No	NA	4	Standard Chemotherapy	No	16	False	Positive	NA	AMLNPM1	30.72	DECEASED	2.8	10	17	0	72	0	NA	28	0	0	NA	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	5.1	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	NA	1.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1377	aml_ohsu_2018_13-00622	48	48	36	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Other	No	NA	4	Yes	NA	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	3	Standard Chemotherapy	1	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	M1	Negative	NA	GATA2-MECOM	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	15	False	Negative	NA	AMLRGA	4.05	DECEASED	NA	NA	NA	NA	0	NA	NA	NA	15	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117	NA	NA	Standard Chemotherapy	Standard Chemotherapy	0.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1378	aml_ohsu_2018_13-00625	21	21	66	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	4	Yes	NA	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI	2	Allogeneic - Sibling | Induction	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	177	Adverse	Adverse	White	Yes	No	M1	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	16	False	Negative	Positive	AMLMRC	19.9	LIVING	NA	NA	NA	NA	1	NA	NA	NA	17	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2737	aml_ohsu_2018_13-00650	NA	20	NA	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Unknown	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	3	False	Positive	NA	AMLNPM1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1394	aml_ohsu_2018_13-00654	62	62	93	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	5	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-II	Intermediate	White	Yes	No	M5a	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	-1	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	14	False	Negative	NA	AMLRGA	32.2	DECEASED	NA	NA	NA	NA	58	NA	NA	NA	NA	NA	NA	NA	WES	No	Prostate Cancer	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	14.66	Yes
aml_ohsu_2018	aml_ohsu_2018_1394	aml_ohsu_2018_13-00655	62	62	93	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	5	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	M5a	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	-1	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	16	False	Negative	NA	AMLRGA	32.2	DECEASED	NA	NA	NA	NA	58	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Prostate Cancer	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Male	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	14.66	Yes
aml_ohsu_2018	aml_ohsu_2018_1396	aml_ohsu_2018_13-00658	60	60	30	NA	Leukemia	AML with Mutated NPM1	Alive	No	p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%	1	Yes	1.22	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	30.6	10.6	Negative	Negative	Complete Response	Negative	46,XY[21]	0	Negative	Negative	536	False	No	No	95.6	114	Standard Chemotherapy	No	5	False	Positive	Negative	AMLNPM1	6.61	LIVING	3.5	49	23	0.8	42.4	4.5	NA	19.7	8.3	15.9	0.3	141	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	7.2	Negative	Standard Chemotherapy	Standard Chemotherapy	11.93	Yes
aml_ohsu_2018	aml_ohsu_2018_1397	aml_ohsu_2018_13-00659	55	55	54	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	Negative	1	Yes	1.14	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	5	Intermediate-II	Intermediate	White	Yes	No	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	19.3	6.6	Negative	Negative	Refractory	Negative	47,XY,+8[16]/46,XY[4]	0	Negative	Negative	NA	False	No	No	93.7	-1	Bone Marrow Transplant	No	9	False	Negative	p.G12R, MAF 50%	AML	12.7	DECEASED	2.7	463	477	0	54	0	NA	14	59.6	5.3	0	47	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	5.7	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	16.66	Yes
aml_ohsu_2018	aml_ohsu_2018_1398	aml_ohsu_2018_13-00660	72	72	41	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	1.66	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Adverse	Adverse	Black	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	23.3	7.2	Negative	Negative	NA	NA	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	0	Negative	Negative	398	False	No	No	82	-1	Standard Chemotherapy	Yes	11	False	Negative	Negative	AMLMRC	1.97	LIVING	3.8	36	31	2.6	NA	0	NA	15.3	9.3	28.8	0.6	42	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	6.6	Negative	Standard Chemotherapy	NA	12.44	Yes
aml_ohsu_2018	aml_ohsu_2018_1400	aml_ohsu_2018_14-00001	56	56	95	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.97	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-I	Favorable or Intermediate	HispNative	No	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	11.1	3.7	Negative	NA	Refractory	Negative	46,XY[20]	0	Negative	Negative	314	False	No	No	95.7	111	Standard Chemotherapy	No	NA	False	Positive	Negative	AMLNPM1	7.14	LIVING	3.4	27	16	0.8	95	0	NA	25.6	0	0	0.7	20	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	Negative	Standard Chemotherapy	Standard Chemotherapy	13.26	No
aml_ohsu_2018	aml_ohsu_2018_1400	aml_ohsu_2018_14-00004	56	56	95	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.97	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-I	Favorable or Intermediate	HispNative	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	11.1	3.7	Negative	NA	Refractory	Negative	46,XY[20]	0	Negative	Negative	314	False	No	No	95.7	111	Standard Chemotherapy	No	15	False	Positive	Negative	AMLNPM1	7.14	LIVING	3.4	27	16	0.8	95	0	NA	25.6	0	0	0.7	20	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	Negative	Standard Chemotherapy	Standard Chemotherapy	13.26	Yes
aml_ohsu_2018	aml_ohsu_2018_1406	aml_ohsu_2018_14-00012	72	72	94	Negative	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	4	No	NA	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Not Enough Information	Favorable	White	Yes	No	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	NA	48,XYY,+8[21]	0	Negative	Negative	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	11	False	Positive	Negative	AMLNPM1	1.09	DECEASED	NA	NA	NA	NA	71	NA	NA	NA	0	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	NA	Negative	Supportive/Palliative Care	NA	24.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1161	aml_ohsu_2018_14-00015	30	31	75	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	0.56	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	MLL disruption and t(9;11)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	Asian	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Relapse|Post-Chemotherapy	22.1	7.7	NA	NA	Complete Response	Negative	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	0	Negative	NA	NA	False	No	No	89.8	31	Supportive/Palliative Care	No	16	False	Negative	NA	TMN	8.88	DECEASED	3.1	37	39	0	35	0	NA	9.9	9.9	37.2	0.8	39	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Relapse	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	6	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	43.72	Yes
aml_ohsu_2018	aml_ohsu_2018_1408	aml_ohsu_2018_14-00021	74	74	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	4	Yes	NA	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage | Induction | Re-induction | Symptom Control	4	Standard Chemotherapy	1	Decitabine	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY	-49	NA	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	6	False	Negative	NA	AMLMRC	11.74	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1409	aml_ohsu_2018_14-00023	74	74	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.79	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	No	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	28.1	9.4	NA	NA	Complete Response	NA	NA	0	NA	NA	645	False	No	No	98.3	6	Standard Chemotherapy	No	NA	False	Positive	NA	AMLNPM1	0.92	LIVING	2.6	17	28	0.9	NA	0	NA	11.4	44.7	35.1	7.1	71	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.2	NA	Standard Chemotherapy	Standard Chemotherapy	35.91	No
aml_ohsu_2018	aml_ohsu_2018_1410	aml_ohsu_2018_14-00026	38	39	NA	NA	Leukemia	AML with Recurrent Genetic Abnormalities	NA	No	NA	2	Yes	0.77	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage | Unknown | Induction | Maintenance	4	Standard Chemotherapy | Supportive/Palliative Care	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Adverse	Intermediate	HispNative	Yes	No	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	30.5	10.6	NA	NA	Refractory	NA	NA	0	NA	NA	340	False	No	Yes	NA	6	Standard Chemotherapy	No	11	False	Negative	NA	AMLRGA	NA	NA	4.3	152	49	NA	16	NA	NA	20	10	54	NA	215	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	7	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	4.01	Yes
aml_ohsu_2018	aml_ohsu_2018_1431	aml_ohsu_2018_14-00034	55	55	50	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%	1	Yes	1.01	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	30.6	10.1	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	NA	NA	False	No	No	98.4	-1	Bone Marrow Transplant	No	22	False	Negative	NA	AMLCEBPA	29.8	LIVING	3.7	27	20	0	25	0	NA	45.3	19.6	9.3	6	15	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	6.3	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.85	Yes
aml_ohsu_2018	aml_ohsu_2018_1434	aml_ohsu_2018_14-00041	71	71	22	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	4	Yes	NA	AG-221	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	AG-221	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Adverse	Adverse	White	Yes	Yes	M4	Negative	Negative	GATA2-MECOM	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	NA	NA	46,XX,inv(3)?(q21q25)[21]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	7	False	Negative	Negative	AMLRGA	31.32	LIVING	NA	NA	NA	NA	8	NA	NA	NA	10	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR	NA	Negative	Standard Chemotherapy	NA	2.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1153	aml_ohsu_2018_14-00044	35	37	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	NA	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Favorable	White	No	Yes	NA	Negative	NA	None	Residual Relapse|Post-Chemotherapy|Post-Transplant	NA	NA	NA	NA	Complete Response	NA	46,XX[5]	-159	NA	NA	NA	False	No	No	NA	53	Standard Chemotherapy	No	NA	False	Positive	NA	AMLNPM1	25.03	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	No
aml_ohsu_2018	aml_ohsu_2018_1435	aml_ohsu_2018_14-00045	47	48	62	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Salvage | Induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Adverse	HispNative	Yes	Yes	NA	Positive	Negative	None	Post-Chemotherapy|Post-Transplant|Relapse	35.5	12.1	Negative	Negative	Refractory	NA	46,XX	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	1	False	Negative	NA	AMLMRC	19.14	DECEASED	3.4	24	40	0	66	0	NA	7	0	13	NA	29	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	5.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	58.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1438	aml_ohsu_2018_14-00052	71	71	NA	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Unknown	No	Negative	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	23	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	GATA2-MECOM	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	45,XY,inv(3)(q21q26),-7[20]	-14	Negative	Negative	NA	False	No	No	NA	4	Standard Chemotherapy	No	22	False	Negative	Negative	AMLRGA	8.62	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1438	aml_ohsu_2018_14-00053	71	71	NA	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Unknown	No	Negative	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	23	Adverse	Adverse	White	No	No	NA	Negative	Negative	GATA2-MECOM	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	45,XY,inv(3)(q21q26),-7[20]	-14	Negative	Negative	NA	False	No	No	NA	4	Standard Chemotherapy	No	NA	False	Negative	Negative	AMLRGA	8.62	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	No
aml_ohsu_2018	aml_ohsu_2018_1441	aml_ohsu_2018_14-00060	68	68	NA	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	Dead-Unknown	No	NA	1	Yes	1.18	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	6	NA	Adverse	White	Yes	No	NA	Negative	NA	None	Unknown	21	7	NA	NA	Unknown	NA	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	-13	NA	NA	1138	True	No	No	88.6	6	Standard Chemotherapy	No	17	False	Negative	NA	MDSU	9.84	DECEASED	3	27	23	0	15	1.7	NA	38.7	3.4	30.3	0	26	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	5.7	NA	Standard Chemotherapy	Standard Chemotherapy	2.42	Yes
aml_ohsu_2018	aml_ohsu_2018_202	aml_ohsu_2018_14-00061	68	72	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation | Induction | Supportive/Palliative Care	3	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Missing ABL and ASS signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	7	Adverse	Adverse	White	No	Yes	NA	Negative	Negative	None	Relapse	22.7	7.6	Negative	Negative	Complete Response	Negative	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	-2	Negative	Negative	556	False	No	No	93.8	9	Standard Chemotherapy	No	NA	False	Negative	Negative	TMN	40.72	DECEASED	NA	NA	NA	0	NA	0	NA	14.9	0.8	2.5	0	32	RNA-seq	Yes	Lung Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	47.2	No
aml_ohsu_2018	aml_ohsu_2018_1443	aml_ohsu_2018_14-00063	80	80	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	3	No	NA	Bevacizumab	1	Unknown	1	Unknown	1	Bevacizumab	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]	-4	NA	NA	NA	False	No	No	NA	-1	Unknown	No	2	False	Negative	NA	AMLMRC	0.33	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Unknown	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1444	aml_ohsu_2018_14-00064	58	59	10	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	2	Yes	0.69	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	8	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Other	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	26.8	9.4	Negative	Negative	Refractory	NA	46,XY[20]	0	NA	NA	88	False	No	No	NA	-1	Standard Chemotherapy	No	7	False	Negative	NA	AMLMRC	11.74	DECEASED	3.7	45	19	1	6	0	NA	32.7	12.6	53.7	NA	75	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	5.8	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1446	aml_ohsu_2018_14-00066	51	51	10	NA	Leukemia	Pure Erythroid Leukemia	Alive	No	Negative	1	Yes	1.12	Fludarabine, Melphalan|Azacitidine	2	Induction | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	20q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	32.8	11	Negative	NA	Complete Response	Negative	46,XY,del(20)(q12)[14]/46,XY[6]	0	Negative	Negative	284	False	No	No	100.9	-1	Bone Marrow Transplant	No	9	False	Negative	Negative	PERL	18.65	LIVING	3.8	83	52	0.9	NA	3.5	0.4	54.5	3	37.7	0	99	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute erythroid leukaemia	Acute erythroid leukaemia	The analysis shows CD34+ blasts comprise approximately 4.2% of total CD45+ events and show variable expression of CD13, CD33, CD117, and dim partial CD123.  Please see below for antibodies tested.  B-cells (2% of lymphocyte gate) show polytypic surface li	8.2	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.31	Yes
aml_ohsu_2018	aml_ohsu_2018_1448	aml_ohsu_2018_14-00067	62	62	12	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	Dead-Unknown	No	Negative	2	Yes	NA	Fludarabine, Melphalan|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	61	NA	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	24.7	8.3	NA	NA	Refractory	NA	44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2]	0	NA	NA	NA	True	No	No	NA	-1	Bone Marrow Transplant	No	15	False	Negative	NA	MDSU	22.66	DECEASED	4.3	80	54	NA	1	NA	NA	NA	NA	NA	NA	91	WES	No	Breast Cancer	Yes	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-)	7.9	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	5.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1450	aml_ohsu_2018_14-00078	17	17	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	1	Yes	0.7	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	3	Induction | Re-induction	2	Standard Chemotherapy	1	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	74	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	25.6	9.1	Negative	NA	Refractory	Negative	NA	0	Negative	Negative	NA	False	No	No	87.4	5	Standard Chemotherapy	No	5	False	Negative	Negative	AMLNOS	23.45	DECEASED	3.5	18	11	0	NA	0	NA	48.5	0.6	1.2	1.6	25	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.9	Negative	Standard Chemotherapy	Standard Chemotherapy	4.34	Yes
aml_ohsu_2018	aml_ohsu_2018_1453	aml_ohsu_2018_14-00081	71	71	46	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	Negative	1	Yes	0.73	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Re-induction	5q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Adverse	Adverse	White	Yes	No	M2	Negative	Negative	None	Initial Acute Leukemia Diagnosis	20.7	6.4	Negative	Negative	Complete Response	Negative	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	0	Negative	Negative	685	False	No	No	79	28	Standard Chemotherapy	No	11	False	Negative	Negative	AMLMRC	NA	NA	3.3	32	39	0	49.1	0	NA	20.5	8	17	0.9	11	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	6.6	V173M; MAF 80%	Standard Chemotherapy	Standard Chemotherapy	12.87	Yes
aml_ohsu_2018	aml_ohsu_2018_1989	aml_ohsu_2018_14-00083	46	46	NA	Negative	Leukemia	AML with Mutated NPM1	NA	No	Negative	4	Yes	NA	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	5	Consolidation | Salvage | Induction | Re-induction	4	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Positive	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease	NA	NA	Positive	Negative	Complete Response	NA	46,XY[20]	-2	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	17	False	Positive	Positive	AMLNPM1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1461	aml_ohsu_2018_14-00092	63	63	13	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.74	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.T138I; MAF 50%	Yes	6	Favorable	Favorable	White	Yes	Yes	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	21.2	7.3	Negative	Negative	Complete Response	NA	46,XX[20]	0	NA	Negative	514	False	No	No	101.4	-1	Bone Marrow Transplant	No	10	False	Positive	p.Q61H; MAF 40%	AMLNPM1	18.62	LIVING	2.8	18	26	1.7	14	0.8	NA	9.4	28.2	49.6	1.6	57	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive	6.1	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	63.75	Yes
aml_ohsu_2018	aml_ohsu_2018_1464	aml_ohsu_2018_14-00096	56	56	72	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	27	Not Enough Information	Adverse	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	11	False	Negative	Negative	AMLMRC	6.51	DECEASED	NA	NA	NA	NA	88	NA	NA	NA	1	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	12.9	Yes
aml_ohsu_2018	aml_ohsu_2018_584	aml_ohsu_2018_14-00111	60	62	20	NA	Leukemia	AML with Maturation	Dead-Disease	No	Negative	1	Yes	0.75	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI	3	Allogeneic - Sibling | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	20/200 cells (10%) were missing a signal for D20S108 (20q12)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	7	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	Negative	None	Relapse|Post-Chemotherapy	31.1	11.2	Negative	NA	Complete Response	NA	46,XY,del(20)(q11.2)[2]/46,XY[18]	0	NA	Negative	177	False	No	No	99	-1	Bone Marrow Transplant	No	3	False	Negative	Negative	AM	42.04	DECEASED	4.3	114	45	1.4	NA	1.4	0.5	33.8	4.5	58.4	0	83	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Male	Unmatched	AML with maturation	AML with maturation	CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive	7.1	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.22	Yes
aml_ohsu_2018	aml_ohsu_2018_1466	aml_ohsu_2018_14-00113	41	44	NA	NA	Leukemia	APL with PML-RARA	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	7	Allogeneic - Sibling | Consolidation | Induction | Maintenance | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	Etoposide, TBI	Allogeneic - Sibling	48% PML/RARA translocation	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Favorable	White	Yes	No	NA	Negative	NA	PML-RARA	Post-Chemotherapy|Post-Transplant	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	NA	False	Negative	NA	APLPMLRARA	64.74	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1477	aml_ohsu_2018_14-00125	10	10	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	NA	1	Yes	0.41	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction | Intensification | Re-induction	3	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	CBFB rearrangement and inverted 16	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	10	Favorable	Favorable	White	No	Yes	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	24.7	8.3	NA	NA	Complete Response	NA	46,XX,inv(16)(p13q22)[17]/46,XX[3]	-2	NA	NA	702	False	No	No	88.5	29	Standard Chemotherapy	No	NA	False	Negative	NA	AMLCBFBMYH11	4.67	LIVING	2.1	NA	NA	0.8	NA	0	NA	10.5	21	7.3	0.5	31	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	55.35	No
aml_ohsu_2018	aml_ohsu_2018_1451	aml_ohsu_2018_14-00126	46	46	NA	NA	Leukemia	Mixed Phenotype Acute Leukemia, T/Myeloid, NOS	Alive	No	NA	3	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Leukaemias of Ambiguous Lineage	Acute Leukaemias of Ambiguous Lineage	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	6	False	Negative	NA	MPALTNOS	NA	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Mixed phenotype acute leukaemia, T/myeloid, NOS	Mixed phenotype acute leukaemia, T/myeloid, NOS	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1481	aml_ohsu_2018_14-00127	37	38	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.6	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Maintenance	2	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Maintenance	Extra chromosome 5	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	23	7.9	Negative	Negative	Refractory	Negative	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl	-1	Negative	Negative	NA	False	No	No	86.8	-1	Supportive/Palliative Care	No	4	False	Negative	p.G13D, MAF 46%	AMLMRC	6.81	DECEASED	1.8	17	56	0	95	0	NA	0.9	0	0	0.1	20	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	5.3	p.R273H, MAF 96%	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	38.47	Yes
aml_ohsu_2018	aml_ohsu_2018_1484	aml_ohsu_2018_14-00134	63	63	30	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	0.8	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling | Salvage | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Decitabine	Supportive/Palliative Care	Trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 30%	No	NA	Adverse	Intermediate	White	Yes	No	NA	Positive	Negative	None	Post-Transplant|Relapse	34.4	11.3	Negative	Negative	NA	Negative	49,XX,+X,+8,+10[13]/46,XY[7]	0	Negative	Negative	245	False	Yes	No	95.3	-1	Supportive/Palliative Care	No	4	False	Positive	Negative	AMLNPM1	5.53	DECEASED	3.7	27	21	0	14	0.9	NA	3.6	21.2	69	1	299	WES	No	NA	No	Yes	No	No	No	1	Bone Marrow Aspirate	Transformation from another heme malignancy and Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	7.3	Negative	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	NA	6.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1485	aml_ohsu_2018_14-00135	72	72	55	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	1.37	Azacitidine|Decitabine	2	Consolidation | Induction | Maintenance	3	Standard Chemotherapy	1	Azacitidine	Maintenance	Previous FISH results were consistent with the deleted 5q and trisomy 9	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	38	Adverse	Adverse	White	Yes	Yes	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	20.6	6.6	Negative	Negative	Unknown	Negative	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	0	Negative	Negative	435	False	No	No	85.8	36	Standard Chemotherapy	No	7	False	Negative	Negative	AMLMRC	8.29	DECEASED	2.2	32	31	0	46	0	NA	27.8	27	20.6	0	33	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	5.9	p.H193R; MAF 92%	Standard Chemotherapy	Standard Chemotherapy	20.82	Yes
aml_ohsu_2018	aml_ohsu_2018_1488	aml_ohsu_2018_14-00141	85	85	NA	Negative	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	Negative	4	Yes	NA	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Not Enough Information	Intermediate	Asian	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XY[14]	-15	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	10	False	Negative	Negative	AML	11.74	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1494	aml_ohsu_2018_14-00150	77	78	67	Negative	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Treatment	No	Double positive	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Not Enough Information	Intermediate	White	Yes	No	M4	Negative	Negative	None	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	45,X,-Y,del(7)(p15)[4]/46,XY[16]	0	Negative	Negative	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	5	False	Negative	Negative	AMLCEBPA	2.34	DECEASED	NA	NA	NA	NA	67	NA	NA	NA	0	NA	NA	NA	WES	No	NA	Yes	No	No	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1495	aml_ohsu_2018_14-00152	75	75	64	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation | Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	21	Intermediate-II	Intermediate	White	Yes	No	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	2	False	Negative	NA	AML	11.02	DECEASED	NA	NA	NA	NA	7	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Bone Marrow Aspirate	Denovo	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	NA	NA	Standard Chemotherapy	Standard Chemotherapy	4.67	Yes
aml_ohsu_2018	aml_ohsu_2018_1505	aml_ohsu_2018_14-00171	62	62	39	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	1.13	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Unknown | Induction	4	Standard Chemotherapy | Unknown | Bone Marrow Transplant	3	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	4	Favorable	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	30.8	10.6	Negative	Negative	Refractory	Negative	46,XY[20]	0	Negative	Negative	168	False	No	Yes	107.7	182	Standard Chemotherapy	No	16	False	Negative	Negative	AMLMRC	14.18	LIVING	3.2	35	15	0	5	0.9	NA	84.1	8.8	2.7	0	131	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive	5.8	Negative	Standard Chemotherapy|Unknown|Bone Marrow Transplant	Standard Chemotherapy	2.51	Yes
aml_ohsu_2018	aml_ohsu_2018_1495	aml_ohsu_2018_14-00173	75	75	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation | Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	21	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	-6	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Negative	NA	AML	11.02	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	3	Peripheral Blood	Denovo	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1508	aml_ohsu_2018_14-00175	46	46	25.9	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin)	8	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Post-Transplant Relapse	6	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Donor Lymphocyte Infusion	Post-Transplant Relapse	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	M5	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	NA	0	Negative	NA	NA	False	No	No	NA	-1	DLI	No	1	False	Negative	NA	AMOL	33.06	DECEASED	NA	NA	NA	NA	0.5	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes	NA	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.6	Yes
aml_ohsu_2018	aml_ohsu_2018_924	aml_ohsu_2018_14-00180	72	73	45	Negative	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	1	3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction	3	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	None	Relapse	22.7	7.4	p.R132S; MAF 20%	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	166	False	No	No	103.7	-1	Standard Chemotherapy	No	21	False	Positive	Negative	AMLNPM1	20.46	DECEASED	3.9	28	25	0	NA	1	1	48	5.1	44.9	2	68	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.6	Negative	Standard Chemotherapy	Standard Chemotherapy	0.98	Yes
aml_ohsu_2018	aml_ohsu_2018_1513	aml_ohsu_2018_14-00184	5	5	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	1	Yes	0.44	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	MLL rearrangement	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	9	Not Enough Information	Intermediate	White	Yes	No	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis|Post-Transplant	17.1	5.7	NA	NA	Complete Response	NA	46,XY[25]	0	NA	NA	1072	False	No	No	98.8	-1	Bone Marrow Transplant	No	1	False	Negative	NA	TMN	22.7	LIVING	3	12	32	0	80	0	NA	33	0	0	0	34	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	95.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1519	aml_ohsu_2018_14-00193	56	57	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Disease	No	NA	2	Yes	1.3	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	3	Adverse	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Unknown	NA	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	0	NA	NA	409	False	No	No	NA	3	Standard Chemotherapy	No	3	False	Negative	Q61H; MAF 5%	AMLCBFBMYH11	13.85	DECEASED	3	15	23	0	54	0	NA	38	8	0	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	6.6	NA	Standard Chemotherapy	Standard Chemotherapy	8.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1527	aml_ohsu_2018_14-00212	47	47	10	NA	Myelodysplastic/Myeloproliferative Neoplasms	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	Alive	No	Negative	1	No	NA	NA	0	NA	0	NA	0	NONE	NONE	Missing MLL signal	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	NA	NA	Intermediate	HispNative	Yes	Yes	NA	Negative	Negative	None	Residual Disease	NA	NA	NA	NA	NA	Negative	47,XX,+8,del(11)(q23)[18]	0	Negative	NA	283	True	No	No	NA	NA	NONE	No	12	False	Negative	NA	ACML	NA	LIVING	NA	NA	NA	NA	17	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	Yes	No	No	No	1	Peripheral Blood	NA	Female	Matched	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR	NA	NA	NA	NA	31.85	Yes
aml_ohsu_2018	aml_ohsu_2018_1532	aml_ohsu_2018_14-00228	46	46	80	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.77	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	4	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 46%	Yes	7	Favorable	Favorable	White	Yes	Yes	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	25.2	8.4	Negative	Negative	Complete Response	Negative	46,XX[20]	0	Negative	Negative	550	False	No	No	88.1	339	Standard Chemotherapy	No	6	False	Positive	Negative	AMLNPM1	25.92	LIVING	2.5	52	28	0	45	1.6	NA	9.9	14.9	10.7	0	107	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	6.3	Negative	Standard Chemotherapy	Standard Chemotherapy	57.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1533	aml_ohsu_2018_14-00231	57	57	76	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation | Induction | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine, Hydroxyurea	Supportive/Palliative Care	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Adverse	Adverse	White	No	Yes	NA	Negative	Negative	Complex	Initial Acute Leukemia Diagnosis	28.6	9.6	Negative	Negative	Refractory	NA	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	0	NA	NA	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	NA	False	Negative	NA	TMN	4.54	DECEASED	3.2	45	41	0	79	0	NA	9	5	4	NA	64	RNA-seq	No	Ovarian cancer	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	6.3	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	19.5	No
aml_ohsu_2018	aml_ohsu_2018_1540	aml_ohsu_2018_14-00240	78	78	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	2	No	1.09	Azacitidine	1	Supportive/Palliative Care	1	Other	1	Azacitidine	Supportive/Palliative Care	nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	Black	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	26.1	8.3	NA	NA	NA	NA	45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]	-17	NA	NA	342	False	No	No	NA	-1	Other	No	4	False	Negative	NA	AMLMRC	1.22	DECEASED	2.9	9	15	NA	1	NA	NA	6	49	35	NA	50	WES	No	NA	No	No	No	Yes	No	1	Peripheral Blood	Denovo	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.7	NA	Other	NA	51.64	Yes
aml_ohsu_2018	aml_ohsu_2018_1536	aml_ohsu_2018_14-00242	63	63	22	NA	Myelodysplastic Syndromes	MDS with Excess Blasts	Dead-Disease	No	NA	2	Yes	0.95	Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental	4	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	3	Decitabine	Hypomethylating/Low Dose Cytarabine	nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	33.3	11.7	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	195	True	No	Yes	104.3	-1	Supportive/Palliative Care	No	2	False	Negative	NA	MDSEB	32.89	DECEASED	4.3	38	29	NA	1	3	NA	54	3	37	NA	115	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Refractory anaemia with excess blasts	Refractory anaemia with excess blasts	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+)	7	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	Standard Chemotherapy	1.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1410	aml_ohsu_2018_14-00244	38	39	37	NA	Leukemia	AML with Recurrent Genetic Abnormalities	NA	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage | Unknown | Induction | Maintenance	4	Standard Chemotherapy | Supportive/Palliative Care	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	Negative	GATA2-MECOM	Post-Chemotherapy|Residual Disease	23.9	8.3	Negative	Negative	Refractory	NA	46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6]	0	NA	NA	NA	False	No	Yes	NA	6	Standard Chemotherapy	No	17	False	Negative	NA	AMLRGA	NA	NA	NA	NA	NA	0	26	0	NA	17	12	44	NA	55	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable).	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	4.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1528	aml_ohsu_2018_14-00245	62	62	20	NA	Leukemia	AML, NOS	Alive	No	Negative	1	Yes	0.78	5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Missing D7S486 signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R309G; MAF 31%	No	6	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	30.3	10.7	p.R132C; MAF 33%	NA	Refractory	Negative	46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6]	-19	Negative	Negative	136	False	No	No	81.9	-1	Bone Marrow Transplant	No	6	False	Negative	Negative	AMLNOS	23.72	LIVING	2.6	27	14	NA	NA	NA	NA	NA	NA	NA	0	31	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive	6.6	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.49	Yes
aml_ohsu_2018	aml_ohsu_2018_1545	aml_ohsu_2018_14-00253	72	72	78	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	4	Yes	NA	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction | Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Positive	Negative	Refractory	NA	50,XY,+8,+9,+13,+22[17]/46,XY[3]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	13	False	Negative	Negative	AMLMRC	9.31	DECEASED	NA	NA	NA	NA	15	NA	NA	NA	1	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	1.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1546	aml_ohsu_2018_14-00259	65	65	70	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	0.87	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	5	Consolidation | Salvage | Induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 50%	Yes	6	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	M4	Positive	NA	None	Initial Acute Leukemia Diagnosis	30.4	9.6	Negative	NA	Complete Response	Negative	46,XX[20]	0	Negative	Negative	506	False	No	No	101.7	4	Standard Chemotherapy	No	6	False	Positive	Negative	AMLNPM1	14.44	DECEASED	2.7	16	13	0.1	NA	0.1	1.7	8.3	85.2	4.6	0.2	112	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	7.4	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	58.86	Yes
aml_ohsu_2018	aml_ohsu_2018_1552	aml_ohsu_2018_14-00268	74	74	45	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	2	Yes	0.65	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	24.5	8.3	NA	NA	NA	NA	46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10]	0	NA	NA	266	False	No	No	99.9	-1	Standard Chemotherapy	No	19	False	Negative	NA	AMLMRC	26.15	DECEASED	2.7	21	33	0	25	4	NA	57	4	35	NA	68	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-)	5.6	NA	Standard Chemotherapy	NA	1.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1553	aml_ohsu_2018_14-00270	40	39	8	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	NA	No	NA	2	Yes	0.65	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Induction	4	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	Yes	5	Intermediate-I	Intermediate	HispNative	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy	22.7	7.7	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	249	True	No	Yes	NA	5	Standard Chemotherapy	No	14	False	Negative	NA	MDSU	NA	NA	NA	73	53	NA	2	NA	NA	27	6	65	NA	13	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	3.42	Yes
aml_ohsu_2018	aml_ohsu_2018_1554	aml_ohsu_2018_14-00272	34	34	87	Negative	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	Double positive: p.Ser17Profs*99 and p.Lys313dup	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	24	Favorable	Favorable	HispNative	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX[20]	-1	Negative	Positive	NA	False	No	No	NA	105	Standard Chemotherapy	No	11	False	Negative	Negative	AMLCEBPA	27.4	LIVING	NA	NA	NA	NA	87	NA	NA	NA	0	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	99.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1554	aml_ohsu_2018_14-00273	34	34	87	Negative	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	Double positive: p.Ser17Profs*99 and p.Lys313dup	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	24	Not Enough Information	Intermediate	HispNative	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX[20]	-1	Negative	Positive	NA	False	No	No	NA	105	Standard Chemotherapy	No	12	False	Negative	Negative	AMLCEBPA	27.4	LIVING	NA	NA	NA	NA	87	NA	NA	NA	0	NA	NA	NA	WES	No	NA	No	No	No	Yes	No	2	Peripheral Blood	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	99.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1558	aml_ohsu_2018_14-00279	52	52	91	Negative	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	4	Yes	NA	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Favorable	Favorable	HispNative	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX,inv(16)(p13.1q22)[cp20]	0	Negative	Negative	NA	False	No	No	NA	8	Standard Chemotherapy	No	5	False	Negative	Negative	AMLCBFBMYH11	1.18	LIVING	NA	NA	NA	NA	79	NA	NA	NA	0	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	28.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1561	aml_ohsu_2018_14-00289	23	23	3	Negative	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	0.91	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	2	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib	Experimental	Low-level tetraploidy or near-tetraploidy	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	8	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	17.9	5.7	Negative	Negative	Complete Response	Negative	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	0	Negative	Negative	16499	False	No	No	95.2	197	Targeted Therapy - Kinase Inhibitor(s)	No	12	False	Negative	p.G12C; MAF 86%	TMN	10.46	DECEASED	3	32	131	3.2	20.4	2.1	NA	25.8	1.1	36.6	43.4	24	WES + RNA-seq	No	mediastinum mass	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	5.6	p.G245S; MAF 87%	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	40.76	Yes
aml_ohsu_2018	aml_ohsu_2018_1569	aml_ohsu_2018_14-00311	73	73	54.8	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	3	Yes	NA	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Negative	NA	TMN	0.56	DECEASED	NA	NA	NA	NA	25	NA	NA	NA	NA	NA	NA	NA	WES	No	Breast Cancer	No	No	No	No	No	1	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia	NA	NA	Standard Chemotherapy	NA	0.92	Yes
aml_ohsu_2018	aml_ohsu_2018_1585	aml_ohsu_2018_14-00329	72	72	59.3	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	NA	3	Yes	NA	MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	SGN-CD33A	Experimental	3q21.3q26.2 (RPN1/MECOM): rearrangement present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	24	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	GATA2-MECOM	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX,inv(3)(q21;q26.2)[20]	0	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	26	False	Negative	NA	AMLRGA	10.63	LIVING	NA	NA	NA	NA	40	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	44.76	Yes
aml_ohsu_2018	aml_ohsu_2018_1586	aml_ohsu_2018_14-00331	61	61	81	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	2	Yes	0.85	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Not Enough Information	Favorable	HispNative	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	28.8	10.1	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	1205	False	No	No	NA	5	Standard Chemotherapy	No	15	False	Positive	NA	AMLNPM1	NA	NA	3.1	85	52	1	68	NA	NA	5	2	2	NA	20	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +)	6.2	NA	Standard Chemotherapy	Standard Chemotherapy	152.75	Yes
aml_ohsu_2018	aml_ohsu_2018_17	aml_ohsu_2018_14-00334	27	31	93	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.8	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	2	Intermediate-II	Intermediate	White	Yes	No	NA	Positive	NA	None	Post-Transplant|Post-Chemotherapy|Relapse	31.6	10.9	NA	NA	Unknown	NA	46,XX,del(6)(q13q23)[18]/46,XY[2]	0	NA	NA	527	False	No	No	93.5	105	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	48.13	DECEASED	3.4	13	20	0	48	0	NA	59.4	1.9	12.3	3.2	33	WES	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	5	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	6.7	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	5.3	Yes
aml_ohsu_2018	aml_ohsu_2018_1598	aml_ohsu_2018_14-00335	79	79	NA	Negative	Leukemia	AML with Maturation	Dead-Unknown	No	Negative	4	Yes	NA	Hydroxyurea|Azacitidine, MLN4924	2	Induction | Supportive/Palliative Care	2	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine, MLN4924	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	63	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3]	-33	Negative	Negative	NA	False	No	No	NA	63	Standard Chemotherapy	Yes	22	False	Negative	Negative	AM	8.65	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	Yes	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with maturation	AML with maturation	NA	NA	Positive	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1602	aml_ohsu_2018_14-00355	78	78	NA	Negative	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	4	Yes	NA	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction | Experimental | Re-induction	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	317	Not Enough Information	Adverse	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XY[25]	-14	Negative	Negative	NA	False	No	No	NA	8	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	Negative	AMOL	23.19	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	NA	NA	Negative	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1604	aml_ohsu_2018_14-00359	58	58	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]	-2	Negative	NA	NA	False	No	No	NA	210	Standard Chemotherapy	No	19	False	Negative	NA	AMLCBFBMYH11	25.03	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1612	aml_ohsu_2018_14-00369	72	72	78	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	Positive	Negative	Refractory	NA	47,XY,+8[17]/46,XY[3]	0	Negative	Negative	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	21	False	Negative	Negative	AMLMRC	1.28	DECEASED	NA	NA	NA	NA	1	NA	NA	NA	1.8	NA	NA	NA	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1614	aml_ohsu_2018_14-00376	48	48	17	NA	Myelodysplastic Syndromes	MDS with Excess Blasts	Alive	No	Negative	1	Yes	0.82	Decitabine|Busulfan, Cyclophosphamide	2	Induction | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Trisomy 8	Myelodysplastic Syndromes	Myelodysplastic Syndromes	p.R882C; MAF 45%	Yes	116	NA	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Unknown	32.5	10.2	p.R132C; MAF 44%	Negative	Complete Response	Negative	47,XY,+8[18]/46,XY[2]	0	Negative	Negative	155	True	No	No	83.5	-1	Bone Marrow Transplant	No	20	False	Negative	NA	MDSEB	23.49	LIVING	3.5	36	20	0	5.3	0	NA	67.3	22.1	5.3	0	105	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Refractory anaemia with excess blasts	Refractory anaemia with excess blasts	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	7.9	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.94	Yes
aml_ohsu_2018	aml_ohsu_2018_1616	aml_ohsu_2018_14-00380	67	67	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Treatment	No	NA	3	Yes	NA	Azacitidine|Decitabine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine | Induction	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	43% del 5q31, 56% del 7q31, 58% del20q	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	UNKNOWN	NA	42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]	-10	NA	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	NA	False	Negative	NA	AMLMRC	0.99	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_17	aml_ohsu_2018_14-00395	27	31	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.66	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	2	Intermediate-II	Intermediate	White	Yes	No	NA	Positive	NA	None	Post-Transplant|Residual Disease	21.6	7.5	NA	NA	Unknown	NA	46,XX,del(6)(q13q23)[18]/46,XY[2]	-15	NA	NA	512	False	No	No	91.5	105	Targeted Therapy - Kinase Inhibitor(s)	No	4	False	Positive	NA	AMLNPM1	48.13	DECEASED	3.6	13	22	0	NA	0.8	0.4	75.6	18.9	4.3	5.1	28	WES	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	5	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	6.9	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	2.54	Yes
aml_ohsu_2018	aml_ohsu_2018_1630	aml_ohsu_2018_14-00401	78	79	10	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	0.57	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	F609fs*3; MAF 42%	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	27.6	8.9	Negative	NA	NA	NA	46,XX[20]	0	NA	NA	230	False	No	Yes	97.5	-1	Targeted Therapy - Other	No	17	False	Negative	NA	AMLMRC	31.91	DECEASED	4.3	17	21	0	0	4	NA	50	8	38	NA	221	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-).	6.9	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	2.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1631	aml_ohsu_2018_14-00404	54	54	29	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	1.02	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Salvage | Induction	2	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Salvage	21q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Adverse	Adverse	White	Yes	No	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.4	8.3	Negative	Negative	Refractory	Negative	46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21]	0	Negative	NA	NA	False	No	No	90.3	196	Supportive/Palliative Care	No	10	False	Negative	NA	AMLMRC	10.43	DECEASED	3.4	16	17	0	0	0.9	NA	75.2	17.9	6	0	30	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD117, MPO and HLA-DR	6.7	p.T312fs*25 (one nucleotide insertion); MAF 30%	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	2.12	Yes
aml_ohsu_2018	aml_ohsu_2018_1644	aml_ohsu_2018_14-00423	51	51	74	Negative	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Favorable	Favorable	White	Yes	Yes	M4eo	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX,inv(16)(p13q22)[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	14	False	Negative	Negative	AMLCBFBMYH11	26.15	LIVING	NA	NA	NA	NA	61	NA	NA	NA	1	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	34.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1646	aml_ohsu_2018_14-00425	47	47	NA	Negative	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.6	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	26	Intermediate-II	Favorable	White	Yes	No	M3	Positive	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	19.5	6.5	Negative	Negative	Complete Response	Negative	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	0	Negative	Negative	819	False	No	No	70.8	31	Standard Chemotherapy	No	5	False	Negative	Negative	APLPMLRARA	15.16	LIVING	3.3	19	37	0	NA	0	NA	14.8	13.1	13.9	0.9	9	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	NA	7.1	Negative	Standard Chemotherapy	Standard Chemotherapy	25.11	Yes
aml_ohsu_2018	aml_ohsu_2018_1651	aml_ohsu_2018_14-00430	75	75	62	NA	Leukemia	AML with Maturation	Dead-Disease	No	Negative	1	Yes	0.88	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Trisomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Intermediate-II	Adverse	White	Yes	No	M2	Negative	Negative	None	Initial Acute Leukemia Diagnosis	33.7	10.5	Negative	NA	NA	Negative	47,XX,+8[20]	0	Negative	Negative	216	False	No	No	93.9	-1	Standard Chemotherapy	No	28	False	Negative	Negative	AM	2.63	DECEASED	3.2	11	9	0	17	0.9	NA	64.3	11.3	5.2	0	38	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with maturation	AML with maturation	CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO.	7	Negative	Standard Chemotherapy	NA	2.37	Yes
aml_ohsu_2018	aml_ohsu_2018_1648	aml_ohsu_2018_14-00434	69	69	94	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	4	Yes	NA	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	365	Intermediate-II	Intermediate	White	Yes	Yes	M5a	Negative	Negative	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Unknown	NA	46,XX[1]	0	Negative	Negative	NA	False	No	No	NA	365	Standard Chemotherapy	No	12	False	Negative	Negative	AMLRGA	NA	LIVING	NA	NA	NA	NA	83	NA	NA	NA	0	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	137.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1655	aml_ohsu_2018_14-00447	48	48	NA	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	1	Yes	0.85	Fludarabine, Melphalan|Idarubicin and Cytarabine	2	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	MLL rearrangement	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	5	Intermediate-II	Intermediate	HispNative	No	Yes	M5	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	30.4	9.7	Negative	Negative	Complete Response	Negative	47,XX,+8,t(9;11)(p22;q23)[20]	0	Negative	Negative	4484	False	No	No	80.4	-1	Bone Marrow Transplant	No	NA	False	Negative	Negative	AMLRGA	15.07	LIVING	3.1	51	152	0	NA	0	NA	9.5	0	6	0	87	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	NA	6	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	49.29	No
aml_ohsu_2018	aml_ohsu_2018_1656	aml_ohsu_2018_14-00448	78	78	78	Negative	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	4	Yes	NA	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	111	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Positive	Negative	Refractory	NA	46,XX[20]	0	Negative	Negative	NA	False	No	No	NA	111	Standard Chemotherapy	No	24	False	Negative	Negative	TMN	5.3	DECEASED	NA	NA	NA	NA	77	NA	NA	NA	1	NA	NA	NA	WES + RNA-seq	No	Uterine Sarcoma	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	5.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1656	aml_ohsu_2018_14-00449	78	78	78	Negative	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	4	Yes	NA	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	111	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Positive	Negative	Refractory	NA	46,XX[20]	0	Negative	Negative	NA	False	No	No	NA	111	Standard Chemotherapy	No	16	False	Negative	Negative	TMN	5.3	DECEASED	NA	NA	NA	NA	77	NA	NA	NA	1	NA	NA	NA	WES	No	Uterine Sarcoma	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	5.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1657	aml_ohsu_2018_14-00451	69	70	55	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	NA	3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	3	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	5q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease	26.6	9.1	Negative	Negative	Refractory	Negative	46,XY,del(5)(q22q33),del(21)(q22q22)[cp20]	0	Negative	Negative	NA	False	No	Yes	85.2	4	Standard Chemotherapy	No	9	False	Negative	Negative	AMLMRC	5.99	DECEASED	NA	NA	NA	1.7	NA	0.6	NA	70	21.1	6.6	NA	3	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR.	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	1.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1665	aml_ohsu_2018_14-00454	65	66	96	Negative	Leukemia	AML, NOS	Dead-Disease	No	Negative	4	Yes	NA	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	8	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	5	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	3	AG-221	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Relapse	NA	NA	Negative	NA	Complete Response	NA	46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]	0	Negative	Negative	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	13	False	Negative	Negative	AMLNOS	12.99	DECEASED	NA	NA	NA	NA	85	NA	NA	NA	5	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117	NA	Negative	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	Standard Chemotherapy	0.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1662	aml_ohsu_2018_14-00458	51	51	4	NA	Myelodysplastic Syndromes	MDS with Excess Blasts	Dead-Treatment	No	Negative	1	Yes	0.87	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction | Allogeneic - Mismatched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Trisomy 8	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Negative	No	117	NA	Intermediate	White	Yes	No	NA	Negative	Negative	None	Unknown	22.4	7.5	Negative	Negative	Complete Response	Negative	47,XY,+8[2]/46,XY[18]	0	Negative	Negative	438	True	No	No	93.7	-1	Bone Marrow Transplant	No	18	False	Negative	Negative	MDSEB	9.41	DECEASED	3.5	58	51	0	6	0	NA	38.9	1.1	56.7	NA	20	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Refractory anaemia with excess blasts	Refractory anaemia with excess blasts	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	5.9	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.23	Yes
aml_ohsu_2018	aml_ohsu_2018_1664	aml_ohsu_2018_14-00464	22	22	65	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	4	Yes	NA	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-II	Intermediate	White	Yes	Yes	M1	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XX,t(9;11)(p22;q23)[22]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	3	False	Negative	Negative	AMLRGA	14.9	LIVING	NA	NA	NA	NA	90	NA	NA	NA	0.1	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	40.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1666	aml_ohsu_2018_14-00473	62	62	22	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	1	Yes	0.78	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage | Induction	2	Standard Chemotherapy	1	HAM (Cytarabine, Mitoxantrone)	Salvage	Trisomy 9	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	29.5	9.5	Negative	Negative	Complete Response	Negative	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	0	Negative	Negative	444	False	No	No	101.4	7	Standard Chemotherapy	No	17	False	Negative	p.G12D; MAF:11%	AMLMRC	5.49	DECEASED	3.2	13	11	6.1	17.4	5.2	16.5	31.3	1.7	21.8	0.2	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD34, CD58 and CD117	7	p.R280T;  MAF 36%	Standard Chemotherapy	Standard Chemotherapy	10.75	Yes
aml_ohsu_2018	aml_ohsu_2018_1670	aml_ohsu_2018_14-00476	47	47	70	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	NA	4	Yes	NA	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation | Induction | CNS | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Intermediate-II	Intermediate	HispNative	Yes	No	M5	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,t(11;19)(q23;p13.1)[20]	0	NA	NA	NA	False	No	No	NA	9	Supportive/Palliative Care	No	8	False	Negative	NA	AMOL	7.5	DECEASED	NA	NA	NA	NA	79	NA	NA	NA	2	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	NA	NA	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	Standard Chemotherapy	261.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1670	aml_ohsu_2018_14-00477	47	47	70	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	NA	4	Yes	NA	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation | Induction | CNS | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Supportive/Palliative Care | Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Adverse	HispNative	Yes	Yes	M5	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,t(11;19)(q23;p13.1)[20]	0	NA	NA	NA	False	No	No	NA	9	Supportive/Palliative Care	No	7	False	Negative	NA	AMOL	7.5	DECEASED	NA	NA	NA	NA	79	NA	NA	NA	2	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	NA	NA	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	Standard Chemotherapy	261.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1672	aml_ohsu_2018_14-00484	62	63	NA	Negative	Leukemia	AML, NOS	Alive	No	Negative	1	Yes	NA	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease	24.6	8.5	Negative	Negative	Refractory	Negative	46,XY[19]	0	Negative	Negative	NA	False	No	No	89.5	4	Standard Chemotherapy	No	12	False	Negative	Negative	AMLNOS	3.98	LIVING	NA	NA	NA	0	NA	0	0.9	59.3	31.9	3.5	0	46	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	2.78	Yes
aml_ohsu_2018	aml_ohsu_2018_1675	aml_ohsu_2018_14-00487	44	44	86.1	NA	Leukemia	AML, NOS	Dead-Unknown	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	5	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Intermediate or Adverse	White	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Unknown	NA	46,XX[20]	-1	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	11	False	Negative	NA	AMLNOS	11.25	DECEASED	NA	NA	NA	NA	65	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	11.38	Yes
aml_ohsu_2018	aml_ohsu_2018_1675	aml_ohsu_2018_14-00488	44	44	86.1	NA	Leukemia	AML, NOS	Dead-Unknown	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	5	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Unknown	NA	46,XX[20]	-1	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	18	False	Negative	NA	AMLNOS	11.25	DECEASED	NA	NA	NA	NA	65	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	11.38	Yes
aml_ohsu_2018	aml_ohsu_2018_1246	aml_ohsu_2018_14-00495	62	64	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	R882H; MAF unlisted	Yes	24	Intermediate-II	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Post-Transplant|Residual Disease	27.9	9.6	NA	NA	Complete Response	NA	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	-28	NA	NA	NA	False	No	No	NA	141	Targeted Therapy - Kinase Inhibitor(s)	No	43	False	Positive	NA	AMLNPM1	18.68	DECEASED	2.9	23	26	NA	NA	NA	NA	NA	NA	NA	NA	30	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	5	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	27.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1683	aml_ohsu_2018_14-00496	55	55	37	NA	Leukemia	AML with Mutated NPM1	NA	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-1	Negative	NA	NA	False	No	No	NA	129	Standard Chemotherapy	No	20	False	Positive	NA	AMLNPM1	NA	NA	NA	NA	NA	NA	20	NA	NA	NA	NA	NA	NA	283	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm	NA	NA	Standard Chemotherapy	Standard Chemotherapy	16.11	Yes
aml_ohsu_2018	aml_ohsu_2018_1684	aml_ohsu_2018_14-00498	62	62	50	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	1	Yes	0.46	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Induction | Re-induction	2	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	Tetrasomy 8	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Not Enough Information	Adverse	White	Yes	No	NA	Positive	NA	Unknown	Initial Acute Leukemia Diagnosis	22.2	7.4	NA	NA	Refractory	NA	NA	0	NA	NA	184	False	No	No	87.4	4	Standard Chemotherapy	Yes	19	False	Negative	NA	AMLNOS	2.66	DECEASED	2	16	9	0	57.4	0	0	38.4	1	3.2	0	6	WES	No	NA	No	No	Yes	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	6	NA	Standard Chemotherapy	Standard Chemotherapy	0.81	Yes
aml_ohsu_2018	aml_ohsu_2018_1689	aml_ohsu_2018_14-00499	68	68	42	NA	Leukemia	Acute Undifferentiated Leukemia	Dead-Other	No	Negative	1	Yes	1.27	HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine)	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Bu/Cy/TBI	Allogeneic - Matched Unrelated Donor	c/w karyotype	Acute Leukaemias of Ambiguous Lineage	Acute Leukaemias of Ambiguous Lineage	Negative	No	3	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	32.5	11.2	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	170	False	No	No	100.9	-1	Bone Marrow Transplant	No	20	False	Negative	p.G12S; MAF: 15%	AUL	12.66	DECEASED	3.5	23	20	1	43.8	0.9	0	26.7	5.7	20.9	0	57	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute undifferentiated leukaemia	Acute undifferentiated leukaemia	partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive	6.3	Negative	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	2.22	Yes
aml_ohsu_2018	aml_ohsu_2018_1691	aml_ohsu_2018_14-00502	NA	NA	NA	NA	Blastic Plasmacytoid Dendritic Cell Neoplasm	Blastic Plasmacytoid Dendritic Cell Neoplasm	NA	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	6	False	Negative	NA	BPDCN	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	Blastic plasmacytoid dendritic cell neoplasm	Blastic plasmacytoid dendritic cell neoplasm	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1693	aml_ohsu_2018_14-00504	35	35	NA	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	-2	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	22	False	Positive	NA	AMLRGA	40.33	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1696	aml_ohsu_2018_14-00514	71	71	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	1.83	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	23.7	7.7	Negative	Negative	NA	NA	NA	0	NA	NA	766	False	No	Yes	92.2	107	Standard Chemotherapy	No	19	False	Negative	NA	AMLMRC	1.74	DECEASED	3.2	19	42	0	50	1	NA	17	1	13	NA	11	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.1	NA	Standard Chemotherapy	NA	45.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1700	aml_ohsu_2018_14-00521	60	60	56	Negative	Leukemia	AML without Maturation	Alive	No	Negative	4	Yes	NA	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Not Enough Information	Intermediate	White	Yes	No	M1	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	46,XX[21]	0	Negative	Negative	NA	False	No	No	NA	7	Standard Chemotherapy	No	1	False	Negative	Negative	AWM	1.15	LIVING	NA	NA	NA	NA	1	NA	NA	NA	1.4	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML without maturation	AML without maturation	CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	1	Yes
aml_ohsu_2018	aml_ohsu_2018_1702	aml_ohsu_2018_14-00527	62	63	82	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	2	Yes	0.95	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	4	Standard Chemotherapy	1	HiDAC	Maintenance	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	Black	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Relapse	36.8	12.1	NA	Negative	Refractory	NA	46,XY[20]	0	NA	NA	932	False	No	No	87.4	5	Standard Chemotherapy	No	47	False	Negative	NA	AMLMRC	17.57	LIVING	3.8	11	28	0	47	2	NA	34	9	9	NA	127	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Relapse	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +).	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	11.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1533	aml_ohsu_2018_14-00528	57	58	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation | Induction | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine, Hydroxyurea	Supportive/Palliative Care	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Not Enough Information	Adverse	White	No	Yes	NA	Negative	NA	Complex	Post-Chemotherapy|Relapse	21.4	7.7	NA	NA	Refractory	NA	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	-111	NA	NA	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	NA	False	Negative	NA	TMN	4.54	DECEASED	3.7	24	116	0	58	0	NA	14	3	19	NA	10	RNA-seq	No	Ovarian cancer	No	No	No	Yes	Yes	2	Peripheral Blood	Relapse	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	6	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	11.2	No
aml_ohsu_2018	aml_ohsu_2018_1707	aml_ohsu_2018_14-00536	69	70	78	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	0.5	7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine	3	Unknown | Induction	2	Standard Chemotherapy | Unknown	2	7+3 (Cytarabine, Idarubicin)	Induction	5q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 37%	No	75	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease	24.9	8.5	p.R132C; MAF 37%	Negative	Unknown	Negative	47,XX,del(5)(q22q35),+8[20]	0	Negative	NA	158	False	No	No	86.5	8	Standard Chemotherapy	No	16	False	Negative	NA	TMN	11.32	DECEASED	2.5	9	8	0	15	0	0	75	0.9	10.7	0	26	WES	No	Breast Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive.	5.9	p.I251M; MAF 34%	Standard Chemotherapy|Unknown	Standard Chemotherapy	1.75	Yes
aml_ohsu_2018	aml_ohsu_2018_1708	aml_ohsu_2018_14-00537	17	17	NA	NA	Leukemia	AML, NOS	Alive	No	NA	2	Yes	NA	Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Unknown	NA	46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	1	False	Negative	NA	AMLNOS	2.43	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	Yes	No	1	Peripheral Blood	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1710	aml_ohsu_2018_14-00542	27	27	69	Negative	Leukemia	AML with Mutated NPM1	Alive	No	Negative	4	Yes	NA	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	8	Not Enough Information	Favorable	HispNative	Yes	No	M2	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	48,XX,+3,+10[2]/46,XX[18]	0	Negative	Negative	NA	False	No	No	NA	137	Standard Chemotherapy	No	30	False	Positive	Negative	AMLNPM1	8.22	LIVING	NA	NA	NA	NA	68	NA	NA	NA	1	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	5.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1710	aml_ohsu_2018_14-00543	27	27	69	Negative	Leukemia	AML with Mutated NPM1	Alive	No	Negative	4	Yes	NA	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	8	Intermediate-II	Favorable	HispNative	Yes	No	M2	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	NA	48,XX,+3,+10[2]/46,XX[18]	0	Negative	Negative	NA	False	No	No	NA	137	Standard Chemotherapy	No	36	False	Positive	Negative	AMLNPM1	8.22	LIVING	NA	NA	NA	NA	68	NA	NA	NA	1	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	5.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1711	aml_ohsu_2018_14-00546	69	69	83	NA	Leukemia	APL with PML-RARA	NA	No	NA	1	Yes	1.05	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	PML/RARA fusion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Favorable	White	No	Yes	M3	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	22.7	8.1	NA	NA	Complete Response	NA	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	0	NA	NA	1816	False	No	No	92.3	-1	Standard Chemotherapy	No	NA	False	Negative	NA	APLPMLRARA	NA	NA	3.2	31	51	0	77	0	0	16.1	5.3	4.5	1.2	33	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	5.7	NA	Standard Chemotherapy	Standard Chemotherapy	16.03	No
aml_ohsu_2018	aml_ohsu_2018_1717	aml_ohsu_2018_14-00555	53	54	68	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	0.51	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Adverse	Intermediate	Black	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Relapse	28.4	9.7	Negative	Negative	Complete Response	NA	46,XX,del(17)(p11.2p13)[19]/46,XX[1]	0	NA	NA	183	False	No	No	86.1	-1	Standard Chemotherapy	No	16	False	Negative	NA	AMLNOS	12.83	DECEASED	2.2	33	27	0	54	0	NA	60	2	0	NA	10	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+).	6.1	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1721	aml_ohsu_2018_14-00559	68	68	79	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Re-induction | Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	R882C; MAF 50%	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	20.8	6.8	Negative	Negative	Complete Response	NA	46,XY	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	12	False	Positive	G13D; MAF 44%	AMLNPM1	32.11	LIVING	4	8	26	0	54	NA	NA	10	42	30	NA	61	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	41.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1719	aml_ohsu_2018_14-00564	57	57	45	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	1	Yes	0.83	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	10	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	26.9	9.1	Negative	Negative	Unknown	Negative	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]	0	Negative	Negative	NA	False	No	No	97.1	10	Standard Chemotherapy	No	18	False	Negative	Negative	AMLMRC	1.15	DECEASED	2	32	19	0	NA	0.9	27.8	18.2	12.2	40.9	0	77	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	6.7	p.R248Q; MAF 80%	Standard Chemotherapy	Standard Chemotherapy	5.92	Yes
aml_ohsu_2018	aml_ohsu_2018_1723	aml_ohsu_2018_14-00567	71	71	NA	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Treatment	No	Negative	1	Yes	0.62	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.4	7	p.R132C; MAF 50%	Negative	Complete Response	Negative	46,XX,idic(7)(q11.2)[20]	-3	Negative	Negative	373	False	No	No	93.9	-1	Bone Marrow Transplant	No	10	False	Negative	Negative	AMOL	15.2	DECEASED	2.6	20	20	0	NA	0	0	6.7	5.1	0	0.1	19	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	5.8	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	78.71	Yes
aml_ohsu_2018	aml_ohsu_2018_1727	aml_ohsu_2018_14-00573	45	45	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.78	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	4	Standard Chemotherapy | Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-II	Adverse	HispNative	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	24.2	8.3	Negative	Negative	Refractory	Negative	47,XY,der(7)t(1;7)(q10;p10),+8[20]	0	Negative	Negative	NA	False	No	Yes	89	4	Standard Chemotherapy	No	17	False	Negative	Negative	AMLMRC	8.52	DECEASED	3.5	50	32	0	NA	0	7	14.8	25.2	19.1	0	59	WES	No	NA	Yes	No	No	No	No	3	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive	7.1	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	22.95	Yes
aml_ohsu_2018	aml_ohsu_2018_1730	aml_ohsu_2018_14-00578	75	75	90	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	1	Yes	0.94	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.P777L; MAF 50%	Yes	6	Intermediate-I	Intermediate or Adverse	White	Yes	Yes	M5	Positive	Negative	None	Initial Acute Leukemia Diagnosis	26.8	9.1	Negative	NA	Complete Response	Negative	46,XY[20]	0	Negative	Negative	1173	False	No	No	105.5	-1	Bone Marrow Transplant	No	5	False	Negative	Negative	AMOL	10.76	DECEASED	2.6	18	49	0	NA	0	0	6	2.6	0	0.1	45	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	6.8	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	98.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1731	aml_ohsu_2018_14-00581	68	68	33	Negative	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	Triple positive	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	Black	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	Refractory	NA	42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]	-1	Negative	Negative	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	14	False	Negative	Negative	AMLCEBPA	2.3	DECEASED	NA	NA	NA	NA	37	NA	NA	NA	8	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	29.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1737	aml_ohsu_2018_14-00588	53	53	9	NA	Leukemia	Pure Erythroid Leukemia	Dead-Treatment	No	NA	2	Yes	0.65	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	R882C; MAF 43%	No	6	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	22.1	7.4	Negative	Negative	Complete Response	NA	46,XX,del(9)(q22q34)[20].	-1	NA	NA	NA	False	No	No	93.4	-1	Bone Marrow Transplant	No	8	False	Negative	NA	PERL	4.51	DECEASED	3.3	14	40	0	4	0	NA	61	10	22	NA	38	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	Acute erythroid leukaemia	Acute erythroid leukaemia	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	5.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1604	aml_ohsu_2018_14-00597	58	58	0.4	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Favorable	Intermediate	White	Yes	No	NA	Negative	NA	CBFB-MYH11	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	210	Standard Chemotherapy	No	5	False	Negative	NA	AMLCBFBMYH11	25.03	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	29.18	Yes
aml_ohsu_2018	aml_ohsu_2018_1739	aml_ohsu_2018_14-00599	69	69	NA	NA	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	Negative	1	Yes	1.01	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Consistent with karyotype	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-II	Adverse	White	Yes	No	M0	Negative	Negative	None	Initial Acute Leukemia Diagnosis	23.5	7.5	Negative	Negative	Refractory	Negative	47,XY,+8[2]/46,XY[18]	0	Negative	Negative	NA	False	No	No	101.7	63	Standard Chemotherapy	No	6	False	Negative	Negative	AMLMD	15.46	DECEASED	3.1	21	15	0	NA	0	0	78.5	15.1	6.4	2.9	47	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with minimal differentiation	AML with minimal differentiation	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	6.7	Negative	Standard Chemotherapy	Standard Chemotherapy	2.05	Yes
aml_ohsu_2018	aml_ohsu_2018_1746	aml_ohsu_2018_14-00602	69	69	NA	Negative	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	79	Intermediate-I	Intermediate or Adverse	White	Yes	No	NA	Positive	Negative	None	Post-Chemotherapy|Residual Disease	NA	NA	Positive	Negative	Refractory	NA	46,XY[22]	-8	Negative	Negative	NA	False	No	No	NA	5	Standard Chemotherapy	No	10	False	Negative	Negative	AMLNPM1	10	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1746	aml_ohsu_2018_14-00603	69	69	NA	Negative	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	79	Not Enough Information	Favorable	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	Positive	Negative	Refractory	NA	46,XY[22]	-8	Negative	Negative	NA	False	No	No	NA	5	Standard Chemotherapy	No	16	False	Positive	Negative	AMLNPM1	10	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1749	aml_ohsu_2018_14-00608	75	77	NA	NA	Leukemia	AML with Maturation	Dead-Other	No	NA	4	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	NA	NA	46,XX[8]	-710	NA	NA	NA	False	No	No	NA	1131	Standard Chemotherapy	No	14	False	Negative	NA	AM	37.3	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	AML with maturation	AML with maturation	NA	NA	NA	Standard Chemotherapy	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1752	aml_ohsu_2018_14-00613	31	31	80	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	NA	2	Yes	0.91	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Adverse	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	28.8	10.2	NA	NA	Complete Response	NA	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	-1	NA	NA	434	False	No	No	NA	5	Standard Chemotherapy	No	2	False	Negative	NA	AMLCBFBMYH11	NA	NA	3.9	63	39	NA	56	2	NA	17	21	3	NA	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variab	8.2	NA	Standard Chemotherapy	Standard Chemotherapy	41.35	Yes
aml_ohsu_2018	aml_ohsu_2018_1754	aml_ohsu_2018_14-00618	77	78	73	NA	Leukemia	AML with Biallelic Mutations of CEBPA	NA	No	L81fs*72; MAF 92%	2	Yes	0.82	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental	4	Standard Chemotherapy | Targeted Therapy - Other	2	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	Negative	Negative	Refractory	NA	46,XY[20]	0	NA	NA	165	False	No	No	NA	-1	Standard Chemotherapy	No	5	False	Negative	NA	AMLCEBPA	NA	NA	4.2	9	13	NA	84	NA	NA	10	NA	6	NA	NA	WES + RNA-seq	No	Lung Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	NA	6.5	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	13.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1761	aml_ohsu_2018_14-00632	64	64	90	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	Negative	1	Yes	0.52	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab,	6	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-II	Adverse	White	Yes	No	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	23.5	7.7	Negative	Negative	Refractory	Negative	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	0	Negative	p.G12V; MAF 30%	452	False	No	No	94.4	3	Standard Chemotherapy	No	18	False	Negative	p.G12D; MAF 7%	AML	18.72	LIVING	1.8	37	31	0	30	0	0	37.5	27.7	0	2.6	56	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	6.2	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	6.44	Yes
aml_ohsu_2018	aml_ohsu_2018_17	aml_ohsu_2018_14-00639	27	31	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	6q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	2	Not Enough Information	Intermediate	White	Yes	No	NA	Positive	NA	None	Residual Disease|Post-Transplant	22.2	7.7	NA	NA	Unknown	NA	46,XX,del(6)(q13q23)[15]/46,XY[5]	-81	NA	NA	1065	False	No	No	81	105	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	48.13	DECEASED	1.9	80	180	0	NA	0	0	21.6	4.5	0	0.6	17	WES	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	5	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	17.79	Yes
aml_ohsu_2018	aml_ohsu_2018_17	aml_ohsu_2018_14-00640	27	31	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	6q deletion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	2	Not Enough Information	Unknown	White	No	Yes	NA	NA	NA	None	Post-Transplant|Residual Disease	22.2	7.7	NA	NA	Unknown	NA	46,XX,del(6)(q13q23)[15]/46,XY[5]	-81	NA	NA	1065	False	No	No	81	105	Targeted Therapy - Kinase Inhibitor(s)	No	NA	False	Positive	NA	AMLNPM1	48.13	DECEASED	1.9	80	180	0	NA	0	0	21.6	4.5	0	0.6	17	WES + RNA-seq	No	Juvenile pilocytic astrocytoma	No	No	No	Yes	No	5	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	17.79	No
aml_ohsu_2018	aml_ohsu_2018_1763	aml_ohsu_2018_14-00643	37	37	NA	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	Negative	1	Yes	0.89	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage | Consolidation | Induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	Asian	Yes	Yes	M2	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	15.8	5.5	Negative	Negative	Refractory	Negative	45,X,-Y,t(8;21)(q22;q22)[20]	0	NA	Negative	411	False	No	No	100.6	0	Bone Marrow Transplant	No	10	False	Negative	Negative	AMLRUNX1RUNX1T1	18.62	LIVING	3	22	13	0.8	NA	0	7.5	17.5	0	37.5	0.4	42	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	7	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	8.15	Yes
aml_ohsu_2018	aml_ohsu_2018_1775	aml_ohsu_2018_14-00658	59	59	51.5	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	3	Yes	NA	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	-1	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	8.36	DECEASED	NA	NA	NA	NA	72	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	89.17	Yes
aml_ohsu_2018	aml_ohsu_2018_1782	aml_ohsu_2018_14-00664	75	75	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	1	Yes	1.1	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	27.9	9.3	Negative	Negative	Complete Response i	Negative	46,XY[20]	0	Negative	Negative	241	False	No	No	99.6	6	Standard Chemotherapy	No	20	False	Negative	Negative	AMLMRC	0.92	DECEASED	3.3	21	11	0	NA	0	0.8	75.6	4.6	19	3.8	31	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	6.5	Negative	Standard Chemotherapy	Standard Chemotherapy	1.31	Yes
aml_ohsu_2018	aml_ohsu_2018_1783	aml_ohsu_2018_14-00667	57	57	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Treatment	No	Negative	1	Yes	0.78	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	371	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	29.6	10.1	Negative	Negative	Complete Response	Negative	46,XY[20]	-1	Negative	Negative	160	False	No	No	93.7	-1	Bone Marrow Transplant	No	23	False	Negative	Negative	AMLMRC	8.06	DECEASED	3.4	82	52	0.3	NA	0	0.6	32.6	14.7	51.8	0	91	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	7.5	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.53	Yes
aml_ohsu_2018	aml_ohsu_2018_1787	aml_ohsu_2018_14-00670	63	63	20	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	2	Yes	1.24	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine | Experimental | Allogeneic - Child	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Adverse	Black	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	24.9	8.3	Negative	NA	NA	NA	46,XY[20]	0	NA	NA	148	False	No	Yes	100.4	-1	Bone Marrow Transplant	No	12	False	Negative	NA	AMLMRC	34.84	LIVING	4.1	18	16	0	0	0	NA	76	0	24	NA	72	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	NA	1.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1786	aml_ohsu_2018_14-00672	64	77	15	NA	Myeloproliferative Neoplasms	Essential Thrombocythemia	Alive	No	NA	7	Yes	NA	Ruxolitinib|Imatinib|Hydroxyurea	3	Induction | Re-induction	2	Standard Chemotherapy	1	Ruxolitinib	Re-induction	Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome.	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	NA	Yes	4626	NA	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]	0	NA	NA	NA	True	No	No	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	ET	174.51	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	Essential thrombocythaemia	Essential thrombocythaemia	dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1561	aml_ohsu_2018_14-00676	23	24	5	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	0.82	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	2	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib	Experimental	Low-level tetraploidy or near-tetraploidy	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	25.5	7.9	NA	NA	Complete Response	NA	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]	0	NA	NA	NA	False	No	No	98.5	197	Targeted Therapy - Kinase Inhibitor(s)	No	71	False	Negative	p.G12C; MAF 97%	TMN	10.46	DECEASED	3.4	30	146	0	10	0	2.9	36.2	1.5	47.8	NA	48	WES + RNA-seq	No	mediastinum mass	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.	6.1	p.G245S; MAF 96%	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	11.28	Yes
aml_ohsu_2018	aml_ohsu_2018_1797	aml_ohsu_2018_14-00681	65	65	NA	NA	Leukemia	AML without Maturation	Alive	No	Negative	1	Yes	0.78	7+3 (Cytarabine, Idarubicin)|Cytarabine	2	Consolidation | Induction	2	Standard Chemotherapy	1	Cytarabine	Consolidation	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 44%	No	6	Intermediate-II	Intermediate	White	Yes	No	M1	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.4	7.4	Negative	NA	Complete Response	Negative	46,XY,del(13)(q12q2?1)[14]	0	Negative	Negative	509	False	No	No	103.4	133	Standard Chemotherapy	No	14	False	Negative	Negative	AWM	10.63	LIVING	3.3	19	25	0	NA	0	0	31.2	0.9	0	0	17	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML without maturation	AML without maturation	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	6.6	Negative	Standard Chemotherapy	Standard Chemotherapy	5.39	Yes
aml_ohsu_2018	aml_ohsu_2018_1800	aml_ohsu_2018_14-00690	49	49	54	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	consistent with karyotype (68% del 17p13)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Favorable	White	Yes	No	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX,del(17)(p11.2)[15]/46,XX[5]	-1	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	14	False	Positive	NA	AMLNPM1	15.2	LIVING	NA	NA	NA	NA	3	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1810	aml_ohsu_2018_14-00712	65	65	18	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	Negative	1	Yes	1.65	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage | Induction | Re-induction	3	Standard Chemotherapy | Other	2	Decitabine	Salvage	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	20.1	6.7	Negative	Negative	Refractory	Negative	46,XY,i(17)(q10)[20]	0	Negative	Negative	3923	False	No	No	81	9	Standard Chemotherapy	No	8	False	Negative	p.G12D; MAF 46%	TMN	5.2	DECEASED	2.9	44	165	0	12	0.9	32	7.4	35.2	18.5	4.8	40	WES + RNA-seq	No	Pancreatic adenocarcinoma	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD13, CD33, CD34, CD117, and HLA-DR positive	5.7	Negative	Standard Chemotherapy|Other	Standard Chemotherapy	161.89	Yes
aml_ohsu_2018	aml_ohsu_2018_1811	aml_ohsu_2018_14-00714	50	55	72	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Not Enough Information	Adverse	White	No	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	Negative	Negative	Complete Response	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	0	Negative	Negative	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	NA	False	Negative	Negative	AMLMRC	63.75	DECEASED	NA	NA	NA	NA	81	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	NA	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	3.8	No
aml_ohsu_2018	aml_ohsu_2018_1811	aml_ohsu_2018_14-00715	50	55	72	Negative	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	Negative	Negative	Complete Response	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	0	Negative	Negative	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	30	False	Negative	Negative	AMLMRC	63.75	DECEASED	NA	NA	NA	NA	81	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	NA	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	3.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1813	aml_ohsu_2018_14-00720	74	74	17	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	0.64	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	3	Induction | Maintenance	2	Standard Chemotherapy | Targeted Therapy - Other	2	Crenolanib	Maintenance	DEK-NUP214 fusion; MAF unavailable	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	F827fs*4; MAF 35%	No	-1	Adverse	Adverse	White	Yes	No	NA	Positive	NA	DEK-NUP214	Initial Acute Leukemia Diagnosis	25.4	8.8	Negative	Negative	Complete Response	NA	46,XY,t(6;9)(p23;q34)[18]/46,XY[2].	0	NA	NA	162	False	No	No	119.8	433	Targeted Therapy - Other	No	15	False	Negative	NA	TMN	32.99	DECEASED	4.2	19	18	NA	0	NA	NA	40	NA	60	NA	60	WES	Yes	Prostate Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	6.5	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	2	Yes
aml_ohsu_2018	aml_ohsu_2018_1814	aml_ohsu_2018_14-00725	32	32	24	NA	Leukemia	AML, NOS	Alive	No	NA	2	Yes	0.49	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.9	9	Negative	Negative	Refractory	NA	47,XX,+8[13]/46,XX[7].	0	NA	NA	125	False	No	No	97.1	-1	Bone Marrow Transplant	No	9	False	Negative	NA	AMLNOS	27.4	LIVING	4.4	10	22	0	2	2	NA	54	0	44	NA	67	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and vari	7.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.4	Yes
aml_ohsu_2018	aml_ohsu_2018_1817	aml_ohsu_2018_14-00730	40	40	90	Negative	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.68	ATRA, Arsenic Trioxide	1	Consolidation | Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	58% PML-RARA  (c/w karyotype)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	33	Intermediate-II	Favorable	HispNative	Yes	No	M3	Negative	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	20.3	7.1	Negative	Negative	Complete Response	Negative	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	0	Negative	Negative	259	False	No	No	85.3	193	Standard Chemotherapy	No	12	False	Negative	Negative	APLPMLRARA	19.31	LIVING	3.2	24	15	0	20	0	0.8	75.9	0	2.6	2.6	53	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	7.3	Negative	Standard Chemotherapy	Standard Chemotherapy	1.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1818	aml_ohsu_2018_14-00735	83	83	NA	Negative	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	4	Yes	NA	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine | Induction	2	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Intermediate-I	Intermediate	Asian	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XY[13]	-6	Negative	Negative	NA	False	Yes	No	NA	-1	Standard Chemotherapy	No	16	False	Positive	Negative	AMLNPM1	1.55	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1819	aml_ohsu_2018_14-00738	65	65	30	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.77	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	9	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	20.1	6.2	Negative	Negative	Refractory	NA	45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1]	0	Negative	Negative	NA	False	No	No	77	9	Standard Chemotherapy	Yes	17	False	Negative	Negative	AMLMRC	2.2	DECEASED	2.3	33	50	8	7	7.1	2.7	17	12.5	47.3	1.4	9	WES	No	NA	No	No	Yes	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive	6.4	p.V272M; MAF 88%	Standard Chemotherapy	Standard Chemotherapy	19.99	Yes
aml_ohsu_2018	aml_ohsu_2018_1820	aml_ohsu_2018_14-00739	39	39	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	1	Yes	0.97	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	4	Induction | CNS | Re-induction	3	Standard Chemotherapy | Intrathecal	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	31.1	10.7	Negative	Negative	Refractory	Negative	46,XY,t(6;11)(q27;q23)[20]	0	Negative	Negative	NA	False	No	No	98.4	4	Standard Chemotherapy	No	2	False	Negative	Negative	AMLNOS	7.11	DECEASED	3	19	14	0	NA	0	0	28.3	17.7	3.5	0	31	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.2	Negative	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	21.12	Yes
aml_ohsu_2018	aml_ohsu_2018_1821	aml_ohsu_2018_14-00742	51	51	9	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	NA	No	Negative	2	Yes	0.7	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	Complex	Unknown	27.2	9.1	Negative	Negative	NA	NA	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+	0	NA	NA	517	True	No	No	92.4	4	Standard Chemotherapy	No	7	False	Negative	NA	MDSU	NA	NA	2.6	19	28	0	11	0.8	NA	28.2	13.7	43.6	NA	74	WES + RNA-seq	No	Breast Cancer	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	6.2	NA	Standard Chemotherapy	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1827	aml_ohsu_2018_14-00756	40	40	3	NA	Leukemia	AML, NOS	Alive	No	Negative	1	Yes	0.71	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Intermediate-II	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	27.2	9.4	Negative	Negative	Refractory	Negative	47,XX,+8[11]/46,XX[10]	0	Negative	Negative	NA	False	No	No	84.2	-1	Bone Marrow Transplant	No	2	False	Negative	Negative	AMLNOS	16.74	LIVING	3	81	45	0	NA	0	0	57.7	2.7	39.6	5.5	58	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	population of CD117+ progenitors (~3.5% of total      CD45+ events) that expresses CD13, dim CD33, CD38, CD58, CD117, dim CD123 and HLA-DR, without the expression of CD64.	7	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.09	Yes
aml_ohsu_2018	aml_ohsu_2018_1495	aml_ohsu_2018_14-00757	75	75	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation | Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	21	Not Enough Information	Intermediate	White	No	No	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-77	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Negative	NA	AML	11.02	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	9.7	No
aml_ohsu_2018	aml_ohsu_2018_1833	aml_ohsu_2018_14-00761	72	72	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	3	Induction | Re-induction	2	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	186	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Residual Disease	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	-22	NA	NA	NA	False	No	Yes	NA	62	Standard Chemotherapy	No	17	False	Negative	NA	AMLMRC	13.72	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1843	aml_ohsu_2018_14-00774	84	84	85	Negative	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	Negative	4	Yes	NA	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Intermediate-I	Adverse	White	Yes	Yes	M0	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	15	False	Negative	Negative	AMLMD	2.2	DECEASED	NA	NA	NA	NA	88	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	30	Yes
aml_ohsu_2018	aml_ohsu_2018_1845	aml_ohsu_2018_14-00777	69	69	60	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	p.P23fs*81; MAF 41%	1	Yes	0.87	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	FISH normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	5	Favorable	Favorable	Asian	Yes	No	M4	Negative	Negative	None	Initial Acute Leukemia Diagnosis	30.5	9.9	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	99	5	Standard Chemotherapy	No	13	False	Negative	Negative	AMLCEBPA	2.96	LIVING	2.3	19	22	0	NA	2.6	2.6	33.6	14.7	18.1	0.7	118	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive	7.3	Negative	Standard Chemotherapy	Standard Chemotherapy	7.62	Yes
aml_ohsu_2018	aml_ohsu_2018_1098	aml_ohsu_2018_14-00780	31	38	7	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	NA	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	9	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Experimental | Re-induction	7	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	nuc ish(DXZ1x2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Post-Transplant|Residual Disease	31.9	11	NA	NA	Complete Response	NA	46,XX	-480	NA	NA	NA	False	No	Yes	NA	24	Targeted Therapy - Kinase Inhibitor(s)	No	5	False	Negative	NA	AMLMRC	87.53	DECEASED	4.2	15	21	NA	1	NA	NA	NA	NA	NA	NA	45	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.2	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_1847	aml_ohsu_2018_14-00781	71	71	95	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Disease	No	Negative	1	Yes	1.61	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	c/w karyotype	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	5	Adverse	Adverse	White	Yes	Yes	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	31.8	10	NA	NA	Complete Response	NA	47,XY,t(1;11)(p32;q23),+8[cp20]	0	Negative	p.G13D; MAF 27%	7759	False	No	No	102.3	5	Standard Chemotherapy	No	7	False	Negative	Negative	AMOL	5.33	DECEASED	3.2	29	282	0	80	0	2	21	4	1	0.8	59	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	6.1	Negative	Standard Chemotherapy	Standard Chemotherapy	71.19	Yes
aml_ohsu_2018	aml_ohsu_2018_1848	aml_ohsu_2018_14-00787	61	61	90	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.N307_V308ins; MAF 50%	1	Yes	1.21	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Intermediate	White	Yes	Yes	M1	Negative	NA	None	Initial Acute Leukemia Diagnosis	17.3	5.2	Negative	Negative	Complete Response	NA	46,XY[20]	0	Negative	Negative	1873	False	No	No	96.1	-1	Bone Marrow Transplant	No	9	False	Negative	Negative	AMLCEBPA	14.54	LIVING	3.1	22	43	0	90.5	0	0	8.2	2.2	0.9	0.8	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	6.9	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	427.46	Yes
aml_ohsu_2018	aml_ohsu_2018_1863	aml_ohsu_2018_14-00793	NA	NA	NA	NA	Leukemia	Acute Myeloid Leukemia	NA	No	NA	1	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	HispNative	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	1	True	Negative	NA	AML	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Unmatched	unknown	unknown	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1852	aml_ohsu_2018_14-00798	36	36	74	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Other	No	Negative	1	Yes	0.68	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	M4	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	20.4	7.1	Negative	Negative	Unknown	Negative	46,XX,inv(16)(p13.1q22)[20]	0	Negative	p.G12D; MAF 9%	NA	False	No	No	87.6	6	Standard Chemotherapy	No	6	False	Negative	p.G12D; MAF 10%	AMLCBFBMYH11	0.49	DECEASED	2.7	45	36	0	82	1.7	1.7	6.7	82.3	3.4	0	12	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	5.8	Negative	Standard Chemotherapy	Standard Chemotherapy	117.53	Yes
aml_ohsu_2018	aml_ohsu_2018_1854	aml_ohsu_2018_14-00800	68	69	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	Negative	1	Yes	1.07	CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	4	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	20.9	7.2	Negative	Negative	Refractory	NA	46,XY[20]	-30	Negative	Negative	1004	False	Yes	No	90.1	4	Standard Chemotherapy	No	4	False	Negative	Negative	AML	3.75	DECEASED	3.1	26	65	NA	NA	NA	NA	NA	NA	NA	3.6	17	WES	No	NA	No	Yes	No	Yes	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	5.4	Negative	Standard Chemotherapy	Standard Chemotherapy	53.76	Yes
aml_ohsu_2018	aml_ohsu_2018_1855	aml_ohsu_2018_14-00801	61	61	3	NA	Leukemia	Myeloid Sarcoma	Alive	No	Negative	1	Yes	0.94	Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	5	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	5	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease|Post-Transplant	42.5	14	NA	NA	Complete Response	NA	46,XY[23]	1	Negative	Negative	753	False	Yes	Yes	87.6	269	Standard Chemotherapy	No	NA	False	Negative	Negative	MS	19.61	LIVING	3.3	51	76	0.6	0	7.2	0.4	31.8	13	47	0	188	WES	No	NA	Yes	Yes	No	Yes	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Myeloid sarcoma	Myeloid sarcoma	maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polycl	6.9	Negative	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	5.16	Yes
aml_ohsu_2018	aml_ohsu_2018_1727	aml_ohsu_2018_14-00803	45	46	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.57	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	4	Standard Chemotherapy | Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Adverse	HispNative	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	25.1	8.5	Negative	Negative	Refractory	Negative	47,XY,der(7)t(1;7)(q10;p10)+8[20]	-2	Negative	Negative	295	False	No	Yes	93	4	Standard Chemotherapy	No	19	False	Negative	Negative	AMLMRC	8.52	DECEASED	3.4	25	12	0	NA	0	0	7.9	76.3	11.4	0	27	WES	No	NA	Yes	No	No	No	No	3	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.5	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	12.25	Yes
aml_ohsu_2018	aml_ohsu_2018_1814	aml_ohsu_2018_14-00815	32	32	2	NA	Leukemia	AML, NOS	Alive	No	NA	2	Yes	NA	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	nuc ish(D8Z2x3,D20S108x2)[27/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	White	No	Yes	NA	Negative	NA	None	Post-Chemotherapy	23.2	7.7	NA	NA	Refractory	NA	47,XX,+8[3]/46,XX[17].	-7	NA	NA	130	False	No	No	89.9	-1	Bone Marrow Transplant	No	NA	False	Negative	NA	AMLNOS	27.4	LIVING	NA	NA	NA	0	0	0	NA	NA	44	56	NA	113	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.9	No
aml_ohsu_2018	aml_ohsu_2018_1865	aml_ohsu_2018_14-00817	53	53	66	NA	Leukemia	Acute Myeloid Leukemia	NA	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	No	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-1	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Negative	NA	AML	NA	NA	NA	NA	NA	NA	56	NA	NA	NA	NA	NA	NA	123	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Leukapheresis	Denovo	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leuk	NA	NA	Standard Chemotherapy	Standard Chemotherapy	180	No
aml_ohsu_2018	aml_ohsu_2018_1866	aml_ohsu_2018_14-00831	26	26	81	NA	Leukemia	APL with PML-RARA	NA	No	NA	2	Yes	0.8	ATRA, Arsenic Trioxide	1	Consolidation | Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Intermediate-II	Favorable	HispNative	Yes	Yes	NA	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	18.6	6.3	NA	NA	Complete Response	NA	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	0	NA	NA	484	False	No	No	NA	5	Standard Chemotherapy	No	17	False	Negative	NA	APLPMLRARA	NA	NA	4.4	47	44	NA	37	3	NA	33	1	15	NA	105	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appea	6.7	NA	Standard Chemotherapy	Standard Chemotherapy	4.95	Yes
aml_ohsu_2018	aml_ohsu_2018_1868	aml_ohsu_2018_14-00832	65	65	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	0.78	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-II	Intermediate or Adverse	White	Yes	Yes	NA	Positive	Negative	Unknown	Initial Acute Leukemia Diagnosis	22.4	7.4	Negative	Negative	Complete Response	Negative	NA	0	Negative	Negative	561	False	No	No	107.2	0	Bone Marrow Transplant	No	15	False	Negative	Negative	AMLMRC	14.8	LIVING	3	23	29	0.8	30	0	12.5	24.2	28.3	18.4	0	60	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	6.6	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	31.66	Yes
aml_ohsu_2018	aml_ohsu_2018_1870	aml_ohsu_2018_14-00901	61	61	NA	NA	Leukemia	AML, NOS	Dead-Unknown	No	Negative	1	Yes	0.73	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.3	6.9	Negative	Negative	Refractory	Negative	46,XY,t(1;4)(q21;p14)[20]	-2	Negative	Negative	178	False	No	No	103.4	44	Standard Chemotherapy	No	7	False	Negative	Negative	AMLNOS	3.42	DECEASED	2.4	14	18	0	NA	0	0	45.5	0.8	0	0.3	57	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	7	NA	Standard Chemotherapy	Standard Chemotherapy	13.68	Yes
aml_ohsu_2018	aml_ohsu_2018_1876	aml_ohsu_2018_15-00009	71	71	40	NA	Leukemia	AML without Maturation	Alive	No	Negative	5	Yes	NA	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine | Experimental | Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	M0	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	46,XY[12]	1	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	NA	False	Negative	NA	AWM	15.76	LIVING	NA	6	9	NA	NA	NA	NA	NA	NA	NA	NA	31	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	Denovo	Male	Matched	AML without maturation	AML without maturation	CD34, dim CD45, CD117	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	NA	0.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1877	aml_ohsu_2018_15-00014	77	77	95	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	Negative	1	Yes	1.02	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Adverse	Intermediate	White	Yes	No	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.8	8.6	Negative	Negative	NA	Negative	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	1	Negative	Negative	601	False	No	Yes	97	6	Standard Chemotherapy	No	25	False	Positive	Negative	AMLNPM1	0.53	DECEASED	4	10	16	0	9	0	0.9	53	0	28.7	0.8	8	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	8.2	Negative	Standard Chemotherapy	NA	3.65	Yes
aml_ohsu_2018	aml_ohsu_2018_1889	aml_ohsu_2018_15-00018	57	58	70	Negative	Leukemia	AML, NOS	Dead-Disease	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	Binimetinib (MEK162)	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	NA	NA	Negative	Negative	Refractory	NA	46,XY[14]	0	Negative	Negative	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	9	False	Negative	Negative	AMLNOS	3.65	DECEASED	NA	NA	NA	NA	8	NA	NA	NA	10	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	Negative	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	7.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1916	aml_ohsu_2018_15-00024	75	75	NA	Negative	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	Negative	4	Yes	NA	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	206	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	NA	46,XX,t(5;16)(q31;p13)[3]/46,XX[14]	-6	Negative	Negative	NA	False	No	No	NA	206	Standard Chemotherapy	No	29	False	Negative	Negative	AML	10.53	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1919	aml_ohsu_2018_15-00029	80	80	21	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	1.26	Decitabine, ABT-199|Hydroxyurea	2	Unknown | Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine, ABT-199	Unknown	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	35	11.1	Negative	Negative	NA	NA	46,XY[20]	0	NA	NA	639	False	No	No	90.4	-1	Standard Chemotherapy	No	21	False	Negative	NA	AMLNOS	11.97	DECEASED	4.1	25	52	0	47	0	NA	5	10	41	NA	110	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim 	7.5	NA	Standard Chemotherapy	NA	64.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1924	aml_ohsu_2018_15-00043	43	44	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Positive for an EVI1 rearrangement	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	12	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]	-46	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	4	False	Negative	NA	AMLMRC	13.82	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1925	aml_ohsu_2018_15-00045	30	30	36	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	NA	2	Yes	0.59	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	40	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	31.8	11	Negative	Negative	Complete Response	NA	46,XX,inv(16)(p13q22)[20]	0	NA	NA	441	False	No	No	NA	-1	Standard Chemotherapy	No	9	False	Negative	NA	AMLCBFBMYH11	28.09	LIVING	4.2	61	44	0	22	0	NA	12	44	5	NA	33	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO	7	NA	Standard Chemotherapy	Standard Chemotherapy	55	Yes
aml_ohsu_2018	aml_ohsu_2018_1929	aml_ohsu_2018_15-00051	66	66	95	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	Negative	1	Yes	0.5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	18.9	6.1	Negative	NA	Complete Response	Negative	NA	0	Negative	Negative	501	False	No	No	100.5	2	Bone Marrow Transplant	No	9	False	Positive	Negative	TMN	17.57	LIVING	3	19	23	0	90.2	0	2.5	4.9	0.8	1.6	0.6	10	WES + RNA-seq	Yes	Breast Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD13, CD33, dim CD71, CD117, CD123, and MPO	6.4	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	66.67	Yes
aml_ohsu_2018	aml_ohsu_2018_1184	aml_ohsu_2018_15-00053	52	54	6	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	1.03	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation | Salvage | Induction | Experimental | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	15	Not Enough Information	Adverse	HispNative	Yes	No	NA	Positive	NA	None	Relapse	37.2	12.1	NA	NA	Refractory	NA	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	-506	NA	NA	166	False	No	No	NA	-1	Bone Marrow Transplant	No	15	False	Negative	NA	AMLMRC	40.69	DECEASED	NA	18	25	NA	2	NA	NA	54	23	19	NA	77	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Relapse	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	8.2	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	5.94	Yes
aml_ohsu_2018	aml_ohsu_2018_1933	aml_ohsu_2018_15-00056	76	76	70	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	5	Yes	NA	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Residual Disease	NA	NA	Negative	NA	NA	Negative	46,XY[20]	0	NA	NA	NA	False	No	Yes	NA	-1	Targeted Therapy - Other	No	71	False	Negative	NA	AMLMRC	22.37	DECEASED	NA	NA	NA	NA	55	NA	NA	NA	NA	NA	NA	46	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	4.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1933	aml_ohsu_2018_15-00057	76	76	70	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	5	Yes	NA	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease	NA	NA	Negative	NA	NA	Negative	46,XY[20]	0	NA	NA	NA	False	No	Yes	NA	-1	Targeted Therapy - Other	No	65	False	Negative	NA	AMLMRC	22.37	DECEASED	NA	NA	NA	NA	55	NA	NA	NA	NA	NA	NA	46	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	4.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1962	aml_ohsu_2018_15-00071	53	56	1	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	1.14	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Post-Transplant	31.3	10.2	Negative	Negative	Complete Response	NA	45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]	0	NA	NA	NA	False	No	No	97.2	4	Standard Chemotherapy	No	1	False	Negative	NA	AMLMRC	30.2	DECEASED	2.7	9	16	0.9	0	3.5	NA	7.8	5.2	82.6	NA	365	WES	No	NA	No	No	No	Yes	No	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).	4.9	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	7.5	Yes
aml_ohsu_2018	aml_ohsu_2018_1963	aml_ohsu_2018_15-00073	81	81	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	No	0.76	AG-221|Hydroxyurea	2	Experimental | Supportive/Palliative Care	2	Supportive/Palliative Care | Targeted Therapy - Other	2	AG-221	Experimental	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	30.3	10.5	NA	NA	NA	NA	46,XY[20]	-8	NA	NA	227	False	No	No	85.6	14	Targeted Therapy - Other	No	25	False	Negative	NA	AMLNOS	2.37	DECEASED	3.3	30	41	0	12	0	NA	69	5	12	NA	117	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	8.8	NA	Supportive/Palliative Care|Targeted Therapy - Other	NA	33.1	Yes
aml_ohsu_2018	aml_ohsu_2018_1964	aml_ohsu_2018_15-00075	80	80	90	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	5	No	NA	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	C.G395A; p.R132H; MAF unknown	NA	NA	NA	46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]	1	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	Yes	12	False	Negative	NA	AMLMRC	1.12	DECEASED	NA	NA	NA	NA	48	NA	NA	NA	NA	NA	NA	65	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT	NA	NA	Targeted Therapy - Other	NA	6.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1757	aml_ohsu_2018_15-00081	48	49	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Disease	No	NA	3	Yes	NA	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	6	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | CNS | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Intermediate	White	Yes	No	NA	Negative	NA	CBFB-MYH11	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-2	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	1	False	Negative	NA	AMLCBFBMYH11	14.57	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1953	aml_ohsu_2018_15-00084	82	82	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	0.96	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease	31.5	11	NA	NA	NA	NA	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	-21	NA	NA	1304	False	No	Yes	86.8	122	Standard Chemotherapy	No	2	False	Negative	NA	AMLMRC	1.15	DECEASED	3.1	24	22	7.6	NA	4.2	8.5	28	6.8	12.7	0.1	21	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.3	NA	Standard Chemotherapy	NA	17.63	Yes
aml_ohsu_2018	aml_ohsu_2018_1969	aml_ohsu_2018_15-00123	42	42	81	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	2	Yes	0.94	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	Negative	Unknown	Initial Acute Leukemia Diagnosis	27.8	9.5	NA	NA	Complete Response	NA	NA	0	NA	NA	945	False	No	No	95.5	-1	Bone Marrow Transplant	No	6	False	Positive	NA	AMLNPM1	27.37	LIVING	3	89	50	NA	85	NA	NA	4	7	4	NA	39	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	5.7	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	48.03	Yes
aml_ohsu_2018	aml_ohsu_2018_1972	aml_ohsu_2018_15-00129	68	68	15	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	Negative	5	No	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Unknown	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	NA	NA	Negative	Negative	NA	Negative	46,XY[19]	0	NA	NA	NA	False	No	No	NA	-1	Unknown	No	NA	False	Negative	NA	AMLMRC	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	51	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD34, CD117,  CD13, CD33 and HLA-DR	NA	NA	Unknown	NA	2.9	Yes
aml_ohsu_2018	aml_ohsu_2018_1721	aml_ohsu_2018_15-00140	68	68	1	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Re-induction | Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	35.4	12	Negative	Negative	Complete Response	NA	46,XY	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	AMLNPM1	32.11	LIVING	4.6	23	24	NA	0	NA	NA	NA	NA	NA	NA	61	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	7.5	NA	Standard Chemotherapy	Standard Chemotherapy	2.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1876	aml_ohsu_2018_15-00143	71	71	4	NA	Leukemia	AML without Maturation	Alive	No	Negative	5	Yes	NA	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine | Experimental | Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	Negative	Negative	NA	Negative	46,XY[12]	-29	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	NA	False	Negative	NA	AWM	15.76	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Male	Matched	AML without maturation	AML without maturation	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	NA	0.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1981	aml_ohsu_2018_15-00147	28	30	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	NA	1	Yes	0.3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Re-induction	5	Standard Chemotherapy	1	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	HispNative	Yes	Yes	NOS	Negative	NA	None	Post-Chemotherapy|Residual Disease	27.3	9.2	NA	NA	Complete Response	NA	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]	-27	NA	NA	NA	False	No	No	91.3	5	Standard Chemotherapy	No	5	False	Negative	NA	AMLCEBPA	27.73	DECEASED	3.7	54	37	0	NA	0	0	4.1	0	2.1	32.3	8	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	NA	6.3	NA	Standard Chemotherapy	Standard Chemotherapy	20.18	Yes
aml_ohsu_2018	aml_ohsu_2018_1988	aml_ohsu_2018_15-00148	61	61	25	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.92	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	19.4	6.7	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	1146	False	No	No	97.5	113	Standard Chemotherapy	No	25	False	Positive	p.G13D; MAF 17%	AMLNPM1	6.58	LIVING	2.9	16	42	0	39	0	2	58.4	2	12.9	24.7	21	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive	5.6	Negative	Standard Chemotherapy	Standard Chemotherapy	3.28	Yes
aml_ohsu_2018	aml_ohsu_2018_1989	aml_ohsu_2018_15-00150	46	47	NA	NA	Leukemia	AML with Mutated NPM1	NA	No	Negative	4	Yes	0.82	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	5	Consolidation | Salvage | Induction | Re-induction	4	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 47%	Yes	6	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	NA	Positive	Negative	None	Residual Disease|Post-Chemotherapy	24.5	8.2	p.R132C; MAF 47%	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	87.5	-1	Standard Chemotherapy	No	25	False	Positive	p.G13D; MAF 17%	AMLNPM1	NA	NA	2.9	38	22	0	NA	0	0	7.2	0	8.9	1.5	18	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	5.4	Negative	Standard Chemotherapy	Standard Chemotherapy	5.98	Yes
aml_ohsu_2018	aml_ohsu_2018_1993	aml_ohsu_2018_15-00159	75	75	58	NA	Leukemia	AML, NOS	NA	No	NA	2	No	1.72	NA	0	NA	0	NA	0	NONE	NONE	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	37.6	12.1	Negative	Negative	NA	NA	46,XY[20]	0	NA	NA	379	False	No	No	94	NA	NONE	No	3	False	Negative	NA	AMLNOS	NA	NA	3.9	11	23	0	31	0	NA	24	9	31	NA	36	WES	No	Prostate Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(sma	6.7	NA	NA	NA	12.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1998	aml_ohsu_2018_15-00167	42	42	50	NA	Leukemia	AML with Mutated NPM1	Dead-Other	No	Negative	1	Yes	0.91	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	3	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	23.2	7.3	Negative	NA	Complete Response	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	90.6	3	Standard Chemotherapy	No	2	False	Positive	Negative	AMLNPM1	1.15	DECEASED	2.1	22	30	1.7	55	0.9	4.4	13.2	23.7	14	0	176	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+	6.3	Negative	Standard Chemotherapy	Standard Chemotherapy	93.94	Yes
aml_ohsu_2018	aml_ohsu_2018_2001	aml_ohsu_2018_15-00169	67	67	24	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	0.89	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	4	Salvage | Experimental | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	4	Sorafenib	Experimental	nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Intermediate	Black	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	30.1	9.9	NA	Negative	NA	NA	46,XX[20]	0	NA	NA	511	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Negative	NA	TMN	14.77	DECEASED	4.1	29	37	0	6	0	NA	77	10	7	NA	288	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	8	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	NA	3.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2002	aml_ohsu_2018_15-00171	80	80	80	NA	Leukemia	AML with Minimal Differentiation	Dead-Disease	No	Negative	5	Yes	NA	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation | Salvage | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine	Salvage	Positive for deletion of 20q12 in 11.5% of 200 cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]	1	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	20	False	Negative	NA	AMLMD	10.16	DECEASED	NA	NA	NA	NA	86	NA	NA	NA	NA	NA	NA	4	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5	NA	Negative	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_1999	aml_ohsu_2018_15-00175	50	50	76	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.44	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage | Induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	18.8	6.3	Negative	Negative	Refractory	Negative	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]	0	NA	Negative	NA	False	No	Yes	85.8	4	Standard Chemotherapy	No	12	False	Negative	p.Q61K; MAF 37%	AMLMRC	3.26	DECEASED	2.2	7	10	0	93	0	0	6.1	1.7	1.8	0	14	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	5.9	p.R273H; MAF 44%	Standard Chemotherapy	Standard Chemotherapy	50.74	Yes
aml_ohsu_2018	aml_ohsu_2018_2005	aml_ohsu_2018_15-00180	73	73	55	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	Negative	5	Yes	NA	FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)	3	Salvage | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine, Lenalidomide	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic Syndromes	NA	No	NA	Intermediate-I	Adverse	White	Yes	No	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.G105G; MAF 50%	Negative	NA	Negative	46,XY[20]	0	Negative	NA	NA	False	No	Yes	NA	76	Standard Chemotherapy	No	10	False	Negative	NA	AML	14.47	DECEASED	NA	NA	NA	NA	39	NA	NA	NA	NA	NA	NA	25	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	Unknown	positive for CD34, CD117, CD13, CD33, and HLA-DR	NA	NA	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	NA	46.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1973	aml_ohsu_2018_15-00194	70	70	NA	NA	Leukemia	AML with Minimal Differentiation	Alive	No	Negative	1	Yes	0.74	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Intermediate-II	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	24.4	8.1	Negative	Negative	Refractory	Negative	47,XY,+4[9]/46,XY[11]	1	Negative	Negative	NA	False	No	No	103.8	-1	Supportive/Palliative Care	No	6	False	Negative	Negative	AMLMD	17.2	LIVING	2	46	27	0	NA	0	0	78.1	0.9	1.7	0	23	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Bone Marrow Aspirate	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	NA	4.7	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	4.85	Yes
aml_ohsu_2018	aml_ohsu_2018_2013	aml_ohsu_2018_15-00196	83	83	85	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	5	No	NA	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Monosomy 7	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	NA	Negative	45,XX,-7[20]	1	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	14	False	Negative	NA	AMLNOS	0.79	DECEASED	NA	NA	NA	NA	92	NA	NA	NA	NA	NA	NA	77	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7	NA	NA	Targeted Therapy - Other	NA	20.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2016	aml_ohsu_2018_15-00200	71	71	65	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	5	Yes	NA	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	Venetoclax (ABT-199), Azacitidine	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.A1312V; MAF 32.1%	Negative	Complete Response	Negative	46,XX[20]	0	Negative	NA	NA	False	No	No	NA	115	Targeted Therapy - Other	No	17	False	Positive	NA	AMLNPM1	28.55	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	96	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2016	aml_ohsu_2018_15-00201	71	71	65	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	5	Yes	NA	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	Venetoclax (ABT-199), Azacitidine	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Favorable	White	No	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.A1312V; MAF 32.1%	Negative	Complete Response	Negative	46,XX[20]	0	Negative	NA	NA	False	No	No	NA	115	Targeted Therapy - Other	No	NA	False	Positive	NA	AMLNPM1	28.55	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	96	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	1.6	No
aml_ohsu_2018	aml_ohsu_2018_2018	aml_ohsu_2018_15-00208	65	65	35	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	3	Standard Chemotherapy	1	Clofarabine, Cytarabine	Re-induction	FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Relapse	NA	NA	p.G105G; MAF 52.8%	Negative	Complete Response	Negative	46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3]	0	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	10	False	Negative	NA	AMLMRC	7.83	DECEASED	NA	NA	NA	NA	44	NA	NA	NA	NA	NA	NA	51	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56.	NA	loss exons 10-11	Standard Chemotherapy	Standard Chemotherapy	4.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2024	aml_ohsu_2018_15-00229	25	25	NA	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.9	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	FISH c/w PML/RARA fusion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	28	Adverse	Favorable	White	No	No	M3	Positive	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	21.3	7.7	Negative	Negative	Complete Response	Negative	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	0	Negative	Negative	921	False	No	No	92.2	28	Standard Chemotherapy	No	NA	False	Negative	Negative	APLPMLRARA	0.92	LIVING	3.2	25	50	0	NA	0	0	22.3	0	0.9	0.7	16	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	NA	6.8	Negative	Standard Chemotherapy	Standard Chemotherapy	18.25	No
aml_ohsu_2018	aml_ohsu_2018_1727	aml_ohsu_2018_15-00231	45	46	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	0.52	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	4	Standard Chemotherapy | Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Intermediate-II	Intermediate	HispNative	Yes	No	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	20.6	7	NA	NA	Refractory	NA	47,XY,der(7)t(1;7)(q10;p10)+8[20]	-86	NA	NA	NA	False	No	Yes	87.3	4	Standard Chemotherapy	No	21	False	Negative	NA	AMLMRC	8.52	DECEASED	3	29	19	0	NA	0	1.7	7.8	51.3	18.3	0	5	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	3	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	5.8	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	11.13	Yes
aml_ohsu_2018	aml_ohsu_2018_2028	aml_ohsu_2018_15-00237	29	29	95	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.54	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant	4	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Transplant	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	24	Not Enough Information	Intermediate or Adverse	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	23	7.9	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	1119	False	No	No	95.8	-1	Bone Marrow Transplant	No	12	False	Negative	NA	AMLNOS	15.66	LIVING	3	20	25	0	78	0.9	0	11.7	0	13.5	1.8	12	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	6.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	68.79	Yes
aml_ohsu_2018	aml_ohsu_2018_2032	aml_ohsu_2018_15-00246	65	65	10	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	2	Yes	1.48	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	W297*; MAF 44%	No	NA	Not Enough Information	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	20.4	7.2	Negative	Negative	NA	NA	46,XY[20]	0	NA	NA	275	False	No	No	93.3	214	Standard Chemotherapy	No	14	False	Positive	NA	AMLNPM1	8.85	DECEASED	4.3	24	27	NA	1	0	NA	80	2	17	NA	23	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	6.9	NA	Standard Chemotherapy	NA	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2033	aml_ohsu_2018_15-00248	61	61	64	NA	Leukemia	AML with Biallelic Mutations of CEBPA	NA	No	A111FS*56; MAF 48%	2	Yes	1.01	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Adverse	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	32.9	10.3	Negative	Negative	Complete Response	NA	46,XY[20]	0	NA	NA	578	False	No	No	99.7	-1	Standard Chemotherapy	No	62	False	Negative	G13V; MAF 37%	AMLCEBPA	NA	NA	3.7	29	26	0	47.4	1.7	NA	23.3	27.6	0	NA	20	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-D	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	20.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2052	aml_ohsu_2018_15-00261	43	43	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	No	Negative	1	Yes	0.77	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	Cytarabine	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Intermediate-I	Adverse	White	Yes	Yes	M4	Positive	Negative	None	Initial Acute Leukemia Diagnosis	22.1	7.5	NA	NA	Refractory	NA	46,XY[20]	0	NA	Negative	297	False	No	No	95.7	125	Supportive/Palliative Care	No	11	False	Negative	Negative	AML	8.06	DECEASED	3	26	16	0	NA	0	0	31.9	12.4	2.6	0.1	59	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	6.5	Negative	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	22.95	Yes
aml_ohsu_2018	aml_ohsu_2018_2053	aml_ohsu_2018_15-00269	59	59	35	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	Y181*; MAF 15%	2	Yes	1.4	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	23.6	7.6	NA	NA	Complete Response	NA	46,XY[20]	-1	NA	NA	383	False	No	No	NA	107	Standard Chemotherapy	No	15	False	Positive	NA	AMLNPM1	14.14	DECEASED	2.9	13	25	0	27.4	0	NA	36.8	6.6	29.2	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6	NA	Standard Chemotherapy	Standard Chemotherapy	3.6	Yes
aml_ohsu_2018	aml_ohsu_2018_1992	aml_ohsu_2018_15-00275	53	53	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction | Re-induction	2	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	29	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	Complete Response	NA	53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]	-33	NA	NA	NA	False	No	No	NA	17	Standard Chemotherapy	No	7	False	Negative	NA	TMN	2.37	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Ovarian cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2059	aml_ohsu_2018_15-00276	60	60	90	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	1.17	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage | Induction | Re-induction	3	Standard Chemotherapy | Other	2	Azacitidine	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	167	Favorable	Favorable	White	Yes	Yes	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	14	4.6	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	612	False	No	No	104.5	6	Standard Chemotherapy	No	16	False	Positive	NA	AMLNPM1	28.62	DECEASED	2.4	30	26	0	39.6	1	4	47	10	1	0.1	80	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	5.8	NA	Standard Chemotherapy|Other	Other	70.84	Yes
aml_ohsu_2018	aml_ohsu_2018_2087	aml_ohsu_2018_15-00279	48	48	86	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation | Induction | CNS | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	TBI, VP-16	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Arg882Cys; MAF 47.1%	Yes	-1	Intermediate-I	Intermediate	White	Yes	Yes	M5b	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	46,XX	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	3	False	Positive	Negative	AMLNPM1	14.31	LIVING	NA	NA	NA	NA	77	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	81	Yes
aml_ohsu_2018	aml_ohsu_2018_2061	aml_ohsu_2018_15-00281	60	60	15	NA	Leukemia	AML, NOS	Dead-Unknown	No	Negative	1	Yes	0.56	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	8	Intermediate-I	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.6	7.1	p.R132C; MAF 34%	NA	Unknown	Negative	46,XY[20]	0	NA	Negative	293	False	No	No	89.3	8	Standard Chemotherapy	No	14	False	Negative	Negative	AMLNOS	2.04	DECEASED	1.8	46	35	0	3.5	3.5	0	92.2	0	0.8	0	417	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO	6.5	NA	Standard Chemotherapy	Standard Chemotherapy	0.94	Yes
aml_ohsu_2018	aml_ohsu_2018_2073	aml_ohsu_2018_15-00287	85	85	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.K313_V314insK; MAF 50%	1	Yes	0.98	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Favorable	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	33.2	10.7	NA	NA	NA	NA	46,XY[20]	2	Negative	Negative	289	False	No	No	89.5	105	Standard Chemotherapy	No	1	False	Negative	Negative	AMLCEBPA	5.49	DECEASED	3.5	14	15	0	NA	2.5	0	14.6	2.4	0	0.5	8	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	NA	7.4	Negative	Standard Chemotherapy	NA	25.63	Yes
aml_ohsu_2018	aml_ohsu_2018_2010	aml_ohsu_2018_15-00294	68	68	60	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	5	Yes	NA	AG-221|Azacitidine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine | Unknown | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	loss of 7q31 sequences in 85% of assayed cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	NA	NA	46,XY,r(7)(p1?3q2?2)[12]/46,XY[5]	-34	NA	NA	NA	False	No	Yes	NA	-1	Targeted Therapy - Other	No	18	False	Negative	NA	AMLNOS	11.02	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	Yes	No	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2079	aml_ohsu_2018_15-00296	16	16	93	Negative	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	Negative	1	Yes	0.72	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Induction	MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	10	Adverse	Adverse	White	Yes	Yes	M5	Negative	Negative	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	18.2	6.1	Negative	Negative	Complete Response	Negative	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	0	Negative	p.G13D; MAF 6%	934	False	No	No	100	10	Standard Chemotherapy	No	1	False	Negative	p.Q61H; MAF 19%	AMLRGA	10.46	LIVING	NA	NA	NA	0	0	0	0	33	67	0	0	39	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	24.72	Yes
aml_ohsu_2018	aml_ohsu_2018_2067	aml_ohsu_2018_15-00300	76	76	20	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	Negative	5	No	NA	NA	0	NA	0	NA	0	NONE	NONE	Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.F543C; MAF 35.7%	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]	0	Negative	NA	NA	False	No	No	NA	NA	NONE	No	35	False	Negative	NA	AMLMRC	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	91	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	Negative	NA	NA	5.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2068	aml_ohsu_2018_15-00302	65	65	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Other	No	Negative	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	Negative	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	UNKNOWN	Negative	NA	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Positive	Negative	AMLNPM1	0.69	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2069	aml_ohsu_2018_15-00303	64	64	NA	Negative	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	1.33	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction | Re-induction	2	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	c/w karyotype	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	23.2	7.7	Negative	Negative	Refractory	Negative	46,XY,inv(16)(p13q22)[17]/46,XY[3]	-8	Negative	p.G12D; MAF 27%	NA	False	No	No	87.2	5	Standard Chemotherapy	No	2	False	Negative	Negative	AMLCBFBMYH11	2.24	LIVING	2.6	10	7	0	NA	0	0.9	48.7	30.1	5.3	0	53	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	5.9	Negative	Standard Chemotherapy	Standard Chemotherapy	8.69	Yes
aml_ohsu_2018	aml_ohsu_2018_2075	aml_ohsu_2018_15-00309	63	64	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy|Post-Transplant	NA	NA	NA	NA	Complete Response	NA	46,XY[6]	-11	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	12.99	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	Yes	No	1	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	25.7	Yes
aml_ohsu_2018	aml_ohsu_2018_1967	aml_ohsu_2018_15-00312	69	70	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	NA	No	NA	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	3	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	Rituximab	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Positive	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XY[18]	-54	NA	NA	NA	False	No	Yes	NA	-1	Targeted Therapy - Other	No	11	False	Negative	NA	TMN	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	Yes	Squamous cell carcinoma	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2084	aml_ohsu_2018_15-00320	57	57	55	NA	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	F290fs*24; MAF 40%	No	-1	Intermediate-I	Favorable or Intermediate	White	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response i	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	13	False	Positive	NA	AMLNPM1	2.66	DECEASED	NA	NA	NA	NA	47	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +).	NA	NA	Standard Chemotherapy	Standard Chemotherapy	26.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2091	aml_ohsu_2018_15-00331	60	60	33	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Disease	No	Negative	5	Yes	NA	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	FISH positive for CBFB rearrangement in 49% of cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]	0	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	23	False	Negative	p.Q61K; MAF 24.1%	AMLCBFBMYH11	19.11	DECEASED	NA	NA	NA	NA	23	NA	NA	NA	NA	NA	NA	42	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with d	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	29	Yes
aml_ohsu_2018	aml_ohsu_2018_2094	aml_ohsu_2018_15-00338	42	42	92	NA	Leukemia	APL with PML-RARA	Alive	No	NA	2	Yes	0.66	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction | Experimental | Maintenance	3	Standard Chemotherapy | Targeted Therapy - Other | Intrathecal	3	ATRA, 6-MP, Methotrexate	Maintenance	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	22	Intermediate-II	Favorable	White	Yes	Yes	NA	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	22.2	7.6	Negative	Negative	Unknown	NA	46,XX,t(15;17)(q24;q21.1)[1]	0	NA	NA	475	False	No	No	88.4	-1	Standard Chemotherapy	No	8	False	Negative	NA	APLPMLRARA	5.1	LIVING	3.9	35	35	0	83	0	NA	11	4	0	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	5.8	NA	Standard Chemotherapy|Targeted Therapy - Other|Intrathecal	Intrathecal	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2102	aml_ohsu_2018_15-00351	48	56	62	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	1	Yes	0.8	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction	5	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 15%	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant	24.1	8.3	NA	NA	Refractory	NA	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	0	NA	NA	290	False	No	No	94.5	5	Standard Chemotherapy	No	35	False	Negative	NA	AMLNOS	100.95	DECEASED	2.5	28	21	0	5	0	0	83.2	1.8	0	0	53	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	6.5	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.46	Yes
aml_ohsu_2018	aml_ohsu_2018_2104	aml_ohsu_2018_15-00353	60	60	13	NA	Leukemia	Acute Megakaryoblastic Leukemia	Dead-Disease	No	Negative	5	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	NA	46,XY,del(13)(q12q14)[3]/46,XY[17]	-6	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	15	False	Negative	NA	AMKL	6.71	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	136	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	Acute megakaryoblastic leukaemia	Acute megakaryoblastic leukaemia	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature c	NA	NA	Standard Chemotherapy	NA	3.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2106	aml_ohsu_2018_15-00357	50	53	30	NA	Leukemia	AML, NOS	NA	No	Negative	5	Yes	NA	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	4	AG-221	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Transplant|Post-Chemotherapy|Residual Relapse	NA	NA	Negative	NA	Refractory	Negative	46,XY[20]	1	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	2	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	0.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2106	aml_ohsu_2018_15-00358	50	53	30	NA	Leukemia	AML, NOS	NA	No	Negative	5	Yes	NA	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	4	AG-221	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Residual Relapse|Post-Transplant|Post-Chemotherapy	NA	NA	Negative	NA	Refractory	Negative	46,XY[20]	1	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	2	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	0.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2108	aml_ohsu_2018_15-00361	77	77	86	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	No	0.62	Vincristine, Dexamethasone	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Vincristine, Dexamethasone	Supportive/Palliative Care	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	17.9	6.1	Negative	Negative	NA	NA	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	0	NA	NA	599	False	No	No	93.7	13	Supportive/Palliative Care	No	14	False	Negative	NA	AMLMRC	0.95	DECEASED	2.9	10	24	0	12.9	0.9	NA	71.6	1.7	8.6	NA	5	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), 	4.8	NA	Supportive/Palliative Care	NA	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2113	aml_ohsu_2018_15-00371	74	75	32	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Unknown	No	NA	2	Yes	1.21	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	32.9	11.1	Negative	Negative	Refractory	NA	46,XY[18]	0	NA	NA	199	False	No	No	NA	48	Standard Chemotherapy	No	19	False	Negative	NA	AMLCEBPA	10.66	DECEASED	4.3	23	22	0	5	0	NA	69	8	18	NA	178	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	2.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2116	aml_ohsu_2018_15-00377	10	10	80	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.G96fs*12; MAF ~50%	1	Yes	0.51	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Induction | Re-induction	2	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	33	Favorable	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	30.3	9.1	Negative	Negative	Complete Response	Negative	46,XX[20]	0	Negative	Negative	688	False	No	No	83.7	-1	Standard Chemotherapy	No	3	False	Negative	p.G12D; MAF 5%	AMLCEBPA	18.72	LIVING	3.7	24	22	0	75	1.7	6.1	17.4	7.8	11.3	0.7	74	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	7.3	Negative	Standard Chemotherapy	Standard Chemotherapy	39.69	Yes
aml_ohsu_2018	aml_ohsu_2018_2127	aml_ohsu_2018_15-00383	63	63	9	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	2	No	0.6	Ruxolitinib|Hydroxyurea	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Intermediate	Black	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	22.7	7	Negative	Negative	NA	NA	46,XY[20]	0	NA	Foundation; A59T mutation; MAF 47%	1086	False	No	No	NA	103	Supportive/Palliative Care	Yes	9	False	Positive	NA	AMLNPM1	0.26	DECEASED	NA	NA	NA	1	15.4	2.9	NA	20.2	16.3	42.3	NA	126	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	NA	NA	Supportive/Palliative Care	NA	73.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2129	aml_ohsu_2018_15-00392	56	58	10	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	5	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	AG-221	Experimental	Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0%	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Intermediate-II	Adverse	HispNative	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Post-Transplant|Residual Relapse	NA	NA	Negative	NA	Complete Response	Negative	48,XY,+8,+8[14]/46,XY[6]	1	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	6	False	Negative	NA	AMLNOS	44.67	DECEASED	NA	NA	NA	NA	9.5	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase.	NA	Negative	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2119	aml_ohsu_2018_15-00395	76	76	50	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	Negative	1	Yes	1.45	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation | Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	5% trisomy 8 (c/w karyotype)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	35	Intermediate-II	Adverse	White	Yes	No	M0	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.3	7.6	Negative	Negative	Complete Response	Negative	47,XY,+8[3]/46,XY[17]	0	Negative	Negative	NA	False	No	No	118.6	77	Standard Chemotherapy	No	11	False	Negative	Negative	AMLMRC	17.11	DECEASED	3.7	18	16	0	5	2	0.2	52.2	37.1	8.5	0	104	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive	7.7	Negative	Standard Chemotherapy	Standard Chemotherapy	4.48	Yes
aml_ohsu_2018	aml_ohsu_2018_2120	aml_ohsu_2018_15-00396	1	3	35	NA	Leukemia	Acute Megakaryoblastic Leukemia	Dead-Disease	No	NA	1	Yes	0.21	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin	5	Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction | Maintenance	4	Standard Chemotherapy | Bone Marrow Transplant	2	Etoposide	Maintenance	37% trisomy 21, 38.5% XX, 61.5% XY (donor)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	NA	None	Relapse|Post-Transplant|Post-Chemotherapy	29.6	9.3	NA	NA	Complete Response	NA	48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10]	0	NA	NA	NA	False	No	No	86.5	-1	Standard Chemotherapy	No	2	False	Negative	NA	AMKL	25.69	DECEASED	NA	NA	NA	0	7	0	0	16.1	9.8	68.7	0	247	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Female	Unmatched	Acute megakaryoblastic leukaemia	Acute megakaryoblastic leukaemia	partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.87	Yes
aml_ohsu_2018	aml_ohsu_2018_2130	aml_ohsu_2018_15-00406	59	59	2	NA	Myelodysplastic Syndromes	MDS with Multilineage Dysplasia	NA	No	p.E10K; MAF 26.7%	5	No	NA	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	NA	Adverse	White	No	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	Negative	Negative	NA	Negative	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	0	Negative	NA	NA	True	No	No	NA	-1	Unknown	No	NA	False	Negative	NA	MDSMD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	No	2	Peripheral Blood	NA	Female	Unmatched	Refractory cytopenia with multilineage dysplasia	Refractory cytopenia with multilineage dysplasia	NA	NA	NA	Unknown	NA	2.8	No
aml_ohsu_2018	aml_ohsu_2018_2130	aml_ohsu_2018_15-00407	59	59	2	NA	Myelodysplastic Syndromes	MDS with Multilineage Dysplasia	NA	No	p.E10K; MAF 26.7%	5	No	NA	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	NA	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	Negative	Negative	NA	Negative	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	0	Negative	NA	NA	True	No	No	NA	-1	Unknown	No	4	False	Negative	NA	MDSMD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Unmatched	Refractory cytopenia with multilineage dysplasia	Refractory cytopenia with multilineage dysplasia	NA	NA	NA	Unknown	NA	2.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2133	aml_ohsu_2018_15-00416	33	33	80	NA	Leukemia	AML, NOS	NA	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine	2	Induction | Re-induction	2	Standard Chemotherapy	1	Clofarabine, Cytarabine	Re-induction	90.5% monosomy 17, 6% trisomy 11q23	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.V468M; MAF 51.2%	No	-1	Intermediate-II	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	Negative	NA	Refractory	Negative	45,XX,-17[15]/46,XX[2]	1	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	13	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	21	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO	NA	p.R43H; MAF 76.7%	Standard Chemotherapy	Standard Chemotherapy	0.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2135	aml_ohsu_2018_15-00417	44	44	62	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	NA	2	No	0.73	NA	0	NA	0	NA	0	NONE	NONE	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	22.4	7.2	NA	NA	NA	NA	47,XY,+21[19]/46,XY[1]	0	NA	NA	NA	False	No	Yes	NA	NA	NONE	No	9	False	Negative	NA	AMLMRC	NA	NA	1.8	24	90	0	19	1	NA	18	35	25	NA	18	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +)	7.1	NA	NA	NA	8	Yes
aml_ohsu_2018	aml_ohsu_2018_2147	aml_ohsu_2018_15-00464	71	71	NA	NA	Leukemia	AML, NOS	Dead-Unknown	No	NA	2	No	1.18	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Supportive/Palliative Care	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	29.3	9.8	Negative	Negative	NA	NA	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	-3	NA	NA	194	False	No	No	NA	-1	Supportive/Palliative Care	No	33	False	Negative	NA	AMLNOS	9.47	DECEASED	4.2	28	27	0.9	NA	2.8	NA	NA	NA	NA	NA	73	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	7.1	NA	Supportive/Palliative Care	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2144	aml_ohsu_2018_15-00470	32	32	NA	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.84	ATRA, Arsenic Trioxide	1	Consolidation | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Consolidation	70% PML/RARA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-II	Favorable	HispNative	Yes	Yes	NA	Positive	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	19.1	6.3	Negative	Negative	NA	Negative	46,XY,t(15;17)(q22;q21)[20]	-2	Negative	Negative	NA	False	No	No	96.5	232	Standard Chemotherapy	No	1	False	Negative	Negative	APLPMLRARA	9.61	LIVING	3	31	20	0	NA	0	19.6	56.3	0.9	3.6	0.1	49	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	NA	6.9	Negative	Standard Chemotherapy|Targeted Therapy - Other	NA	7.19	Yes
aml_ohsu_2018	aml_ohsu_2018_2142	aml_ohsu_2018_15-00471	69	69	60	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	Yes	c.117delC; MAF 27.2%	3	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	19	False	Negative	NA	AMLCEBPA	8.22	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.	NA	NA	Standard Chemotherapy	NA	33	Yes
aml_ohsu_2018	aml_ohsu_2018_2167	aml_ohsu_2018_15-00479	65	65	95	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199)	4	Hypomethylating/Low Dose Cytarabine | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Gain of 8q22 and 21q22 (88%)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]	-1	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	3	False	Negative	NA	AMLMRC	6.91	DECEASED	NA	NA	NA	NA	62	NA	NA	NA	NA	NA	NA	33	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	NA	19.8	Yes
aml_ohsu_2018	aml_ohsu_2018_1532	aml_ohsu_2018_15-00482	46	47	70	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.72	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	4	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 39%	Yes	7	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Relapse	37	12.6	Negative	Negative	Complete Response	Negative	46,XX[20]	0	Negative	Negative	NA	False	No	No	94.4	339	Standard Chemotherapy	No	16	False	Positive	Negative	AMLNPM1	25.92	LIVING	2.8	184	77	0	64.6	3.5	0.9	17.7	0	13.3	0	138	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Relapse	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	5.7	Negative	Standard Chemotherapy	Standard Chemotherapy	16.95	Yes
aml_ohsu_2018	aml_ohsu_2018_2172	aml_ohsu_2018_15-00491	83	83	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	NA	1	Yes	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	2	False	Negative	NA	TMN	1.64	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	Yes	Prostate Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2140	aml_ohsu_2018_15-00492	29	29	NA	NA	Leukemia	AML with Minimal Differentiation	Alive	No	Negative	1	Yes	0.59	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Mismatched Unrelated Donor	MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.4	7.6	Negative	Negative	Refractory	Negative	46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7]	-15	Negative	NA	NA	False	No	No	88.5	30	Bone Marrow Transplant	No	19	False	Negative	p.G12D; MAF 15%	AMLMD	11.41	LIVING	2.7	42	17	0	27.8	0	0	72.2	0	0	0	193	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	NA	6	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.23	Yes
aml_ohsu_2018	aml_ohsu_2018_2188	aml_ohsu_2018_15-00514	81	81	50	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	Negative	5	Yes	NA	Azacitidine|Venetoclax (ABT-199)	2	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	Venetoclax (ABT-199)	Experimental	44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8,	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.R132C; MAF 16.3%	Negative	NA	Negative	46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6]	1	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	28	False	Negative	NA	TMN	21.41	LIVING	NA	NA	NA	NA	11	NA	NA	NA	NA	NA	NA	104	WES	No	Bladder Cancer|Ovarian cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	1	Yes
aml_ohsu_2018	aml_ohsu_2018_2192	aml_ohsu_2018_15-00525	36	36	90	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.76	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Experimental	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	27	Intermediate-II	Favorable	Black	Yes	No	M3	Positive	NA	PML-RARA	Initial Acute Leukemia Diagnosis	26.3	8.2	Negative	Negative	Complete Response	Negative	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	2	Negative	Negative	605	False	No	No	89.2	-1	Targeted Therapy - Other	No	12	False	Negative	Negative	APLPMLRARA	9.31	LIVING	3.9	37	27	0	69.14	0	28.8	1.8	1.8	0.9	0.4	25	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	7.5	Negative	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	103.66	Yes
aml_ohsu_2018	aml_ohsu_2018_2195	aml_ohsu_2018_15-00534	87	87	60	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.A66fs; MAF 37.3%	5	Yes	NA	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-120	Experimental	9.5% gain 21q22	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	p.R132C; MAF 48.7%	NA	NA	NA	47,XY,+21[3]/46,XY[9]	1	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	Yes	6	False	Negative	NA	AMLCEBPA	8.19	DECEASED	NA	NA	NA	NA	39	NA	NA	NA	2	NA	NA	43	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR	NA	p.N107D; MAF 97.6%	Standard Chemotherapy|Targeted Therapy - Other	NA	139.9	Yes
aml_ohsu_2018	aml_ohsu_2018_2196	aml_ohsu_2018_15-00539	72	73	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	0.58	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Maintenance	2	Standard Chemotherapy | Other	2	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	27.5	8.8	NA	NA	NA	NA	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	-79	NA	NA	NA	False	No	Yes	NA	-1	Other	No	7	False	Negative	NA	AMLMRC	15.3	DECEASED	3.6	41	34	0	25	0	NA	2	54	18	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.2	NA	Standard Chemotherapy|Other	NA	58.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2202	aml_ohsu_2018_15-00556	10	10	75	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.R142fs*19; MAF 52%	1	Yes	0.47	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC	3	Induction | Re-induction	2	Standard Chemotherapy | Intrathecal | Other	3	MiDAC	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	10	Not Enough Information	Intermediate or Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	21.6	6.9	Negative	Negative	Refractory	Negative	46,XY[20]	1	Negative	Negative	970	False	No	No	96	31	Standard Chemotherapy	No	2	False	Negative	Negative	AMLCEBPA	2.47	LIVING	3.6	13	23	0	86	0	0	7.5	1.8	4.7	0.1	42	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	7.8	Negative	Standard Chemotherapy|Intrathecal|Other	Intrathecal	133.63	Yes
aml_ohsu_2018	aml_ohsu_2018_2205	aml_ohsu_2018_15-00559	42	42	50	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.S307fs; MAF 45.6%	Yes	-1	Not Enough Information	Adverse	HispNative	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	NA	NA	c.C315T; p.G105G; MAF 46.6%	NA	Refractory	Negative	46,XX[20]	0	Negative	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	15	False	Negative	NA	AML	14.74	DECEASED	NA	NA	NA	NA	51	NA	NA	NA	NA	NA	NA	256	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	10.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2204	aml_ohsu_2018_15-00563	2	2	80	NA	Leukemia	AML without Maturation	Alive	No	NA	1	Yes	0.24	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	136	Adverse	Adverse	White	Yes	Yes	M1	Negative	NA	None	Initial Acute Leukemia Diagnosis	22	6.9	NA	NA	Complete Response	NA	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	0	NA	NA	NA	False	No	No	92.8	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AWM	14.08	LIVING	NA	22	53	0	52.2	0	1.8	46	0	0	0.2	40	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML without maturation	AML without maturation	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	57.08	Yes
aml_ohsu_2018	aml_ohsu_2018_2213	aml_ohsu_2018_15-00571	61	61	84	NA	Leukemia	AML with Maturation	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	M2	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	28	False	Negative	NA	AM	1.18	LIVING	NA	NA	NA	NA	91	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	Denovo	Male	Matched	AML with maturation	AML with maturation	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	NA	NA	Standard Chemotherapy	Standard Chemotherapy	25	Yes
aml_ohsu_2018	aml_ohsu_2018_2213	aml_ohsu_2018_15-00572	61	61	84	NA	Leukemia	AML with Maturation	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Adverse	White	Yes	No	M2	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	27	False	Negative	NA	AM	1.18	LIVING	NA	NA	NA	NA	91	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with maturation	AML with maturation	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	NA	NA	Standard Chemotherapy	Standard Chemotherapy	25	Yes
aml_ohsu_2018	aml_ohsu_2018_2214	aml_ohsu_2018_15-00578	62	62	95	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	0.78	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Child	4	Standard Chemotherapy | Bone Marrow Transplant | Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	7	Adverse	Adverse	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	27.4	9.1	Negative	Negative	Complete Response	Negative	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	0	Negative	Negative	861	False	No	No	93.2	-1	Bone Marrow Transplant	No	4	False	Negative	p.G12S; MAF 19%	AMLMRC	0.89	LIVING	3.3	54	57	0	67.25	0	0	9.5	23.3	0	0.1	26	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	6.8	Negative	Standard Chemotherapy|Bone Marrow Transplant|Other	Standard Chemotherapy	87.72	Yes
aml_ohsu_2018	aml_ohsu_2018_2222	aml_ohsu_2018_15-00581	74	74	4	NA	Myelodysplastic Syndromes	MDS with Isolated Del(5q)	Dead-Unknown	No	NA	2	Yes	0.68	Lenalidomide|Azacitidine	2	Hypomethylating/Low Dose Cytarabine | Maintenance	2	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	NA	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	22.4	7.4	Negative	Negative	NA	NA	42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del(	0	NA	NA	NA	True	No	No	NA	6	Supportive/Palliative Care	No	19	False	Negative	NA	MDSID5Q	6.15	DECEASED	3.6	42	42	NA	2	1	NA	37	7	50	NA	18	WES	No	Uterine Sarcoma|Breast Cancer	Yes	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic syndrome associated with isolated del(5q)	Myelodysplastic syndrome associated with isolated del(5q)	CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-).	6.6	Foundation; R337L	Standard Chemotherapy|Supportive/Palliative Care	NA	2.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2225	aml_ohsu_2018_15-00593	71	71	82	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	5	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XX,del(7)(q22q36)[20]	-1	NA	NA	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	25	False	Negative	NA	TMN	9.21	DECEASED	NA	NA	NA	NA	66	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Follicular lymphoma	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD7, CD13, weak CD33, CD34, CD117, and HLA-DR	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	133.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2226	aml_ohsu_2018_15-00595	55	55	91	NA	Leukemia	AML without Maturation	NA	No	Negative	2	Yes	0.74	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5CBFB con 3C	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	8	Adverse	Intermediate	White	Yes	No	M1	Positive	NA	None	Initial Acute Leukemia Diagnosis	22.8	7.1	p.R132C; MAF unlisted	Negative	Unknown	NA	92<4n>,XXYY[13]/46,XY[7]	0	NA	NA	NA	False	No	No	NA	8	Standard Chemotherapy	No	18	False	Negative	NA	AWM	NA	NA	2.8	391	343	0	61	0	NA	46.1	1.7	9.4	NA	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML without maturation	AML without maturation	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably	5.8	NA	Standard Chemotherapy	Standard Chemotherapy	9.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2232	aml_ohsu_2018_15-00608	61	61	40	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	5	Yes	NA	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]	1	Negative	NA	NA	False	No	Yes	NA	-1	Bone Marrow Transplant	No	21	False	Negative	p.G12D; MAF 10%	AMLMRC	15.26	LIVING	NA	NA	NA	NA	28	NA	NA	NA	NA	NA	NA	26	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive CD13, CD34, dim CD45, CD117 and HLA-DR	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	4.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2233	aml_ohsu_2018_15-00610	42	42	35	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Alive	No	Negative	5	Yes	NA	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	4	Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Refractory	Negative	46,XX[20]	0	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	5	False	Negative	NA	AMOL	16.61	LIVING	NA	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (incl	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	49.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2234	aml_ohsu_2018_15-00614	51	51	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	0.93	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Cy/TBI	Allogeneic - Mismatched Unrelated Donor	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second c	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Adverse	Adverse	White	Yes	Yes	M0	Negative	Negative	None	Initial Acute Leukemia Diagnosis	25.1	8.2	Negative	Negative	Refractory	Negative	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	0	Negative	Negative	634	False	No	No	81.8	-1	Bone Marrow Transplant	No	17	False	Negative	p.G13D; MAF ~40%	AMLMRC	9.74	LIVING	3	25	25	0	NA	0	0	85.8	1.9	8.5	0	77	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.5	Splice site (5' splice site mutation in intron 4); MAF 44%	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2235	aml_ohsu_2018_15-00615	24	24	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.Gln41fs; MAF 4%	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	6	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-I	Adverse	Asian	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XX[20]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	13	False	Negative	NA	AMLCEBPA	20.82	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Leukapheresis	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2236	aml_ohsu_2018_15-00616	68	68	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.67	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.9	7.5	Negative	Negative	Complete Response	Negative	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	-14	Negative	NA	821	False	No	No	88.7	-1	Bone Marrow Transplant	No	1	False	Negative	NA	AMLMRC	10.33	DECEASED	2.8	18	16	2.6	49	5.1	6.8	36.8	0.9	14.5	0.2	8	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive	7.2	p.I254N; MAF 40%	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	11.01	Yes
aml_ohsu_2018	aml_ohsu_2018_2239	aml_ohsu_2018_15-00626	77	77	70	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.K90fs; MAF 39.1%	5	Yes	NA	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	35% gain of 11q23	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	212	Intermediate-II	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	NA	Refractory	Negative	47,XY,+11[8]/46,XY[12]	0	Negative	NA	NA	False	No	Yes	NA	-1	Targeted Therapy - Other	No	12	False	Negative	NA	AMLCEBPA	1.25	DECEASED	NA	NA	NA	NA	72	NA	NA	NA	NA	NA	NA	174	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	33.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2241	aml_ohsu_2018_15-00633	52	52	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	11q23 (MLL): rearrangement present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX,t(9;11)(p22;q23)[5]	-3	NA	p.Gly13Asp; MAF 38.9%	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	1	False	Negative	NA	TMN	17.89	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Breast Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2251	aml_ohsu_2018_15-00650	85	85	36	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	No	NA	1	Yes	0.88	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	232	Intermediate-II	Intermediate	White	Yes	Yes	M4	Negative	NA	None	Initial Acute Leukemia Diagnosis	31.5	9.6	NA	NA	Refractory	NA	46,XY,del(12)(p11.2p13)[20]	0	NA	NA	200	False	Yes	No	95.7	232	Standard Chemotherapy	No	2	False	Negative	p.Q61R; MAF 30%	AML	2.63	DECEASED	3.4	24	23	0	23.7	0	8.7	20.2	27.2	20.2	1.6	46	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.	7	NA	Standard Chemotherapy	Standard Chemotherapy	40.53	Yes
aml_ohsu_2018	aml_ohsu_2018_2254	aml_ohsu_2018_15-00653	52	52	83	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	2	Yes	0.55	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Favorable	Favorable	White	Yes	Yes	M1	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.3	8.3	Negative	Negative	Complete Response	NA	46,XX[20]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	5	False	Positive	NA	AMLNOS	20.82	DECEASED	3.3	21	47	0	48.6	0	NA	9.4	0.9	40.2	NA	48	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(	6.6	NA	Standard Chemotherapy	Standard Chemotherapy	22.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2260	aml_ohsu_2018_15-00655	70	70	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2645G>A; MAF 41.8%	No	-1	Intermediate-II	Adverse	White	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	c.394C>T; MAF 46.7%	NA	Complete Response	NA	46,XX,del(7)(q22q36)[11]/46,XX[2]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	17	False	Negative	NA	AMLMRC	17.86	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2265	aml_ohsu_2018_15-00670	61	61	92	NA	Leukemia	AML, NOS	Alive	No	Negative	1	Yes	0.86	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea	4	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF ~50%	Yes	6	Intermediate-I	Intermediate or Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	19.9	6.8	p.R132S; MAF ~50%	Negative	Complete Response	Negative	46,XY[7]	-1	Negative	Negative	330	False	No	No	106.4	-1	Bone Marrow Transplant	No	4	False	Negative	Negative	AMLNOS	9.08	LIVING	3.2	35	23	0	98	0	0.8	2.6	0	0	0.1	49	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	8	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	84.96	Yes
aml_ohsu_2018	aml_ohsu_2018_2269	aml_ohsu_2018_15-00674	54	54	75	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	19	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	50,XX,+8,+10,+12,+21[20]	0	Negative	NA	NA	False	No	No	NA	19	Standard Chemotherapy	No	6	False	Negative	NA	AMLMRC	1.18	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	39	NA	NA	9	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO	NA	NA	Standard Chemotherapy	Standard Chemotherapy	37.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2272	aml_ohsu_2018_15-00680	68	68	86	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.49	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	23	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	M5	Positive	NA	None	Initial Acute Leukemia Diagnosis	33	10.8	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	1211	False	No	No	95.9	-1	Bone Marrow Transplant	No	10	False	Positive	NA	AMLNPM1	14.7	LIVING	2.9	20	28	0.9	74.8	0	0	2.6	20.8	0.9	0.2	83	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	7.2	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	134.36	Yes
aml_ohsu_2018	aml_ohsu_2018_2273	aml_ohsu_2018_15-00682	83	83	45	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	Negative	5	No	NA	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.G105G; MAF 50%	NA	NA	Negative	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	0	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	13	False	Negative	NA	AMLMRC	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	133	WES	No	Squamous cell carcinoma|Lung Cancer	No	No	No	No	No	2	Peripheral Blood	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	NA	NA	Targeted Therapy - Other	NA	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2273	aml_ohsu_2018_15-00683	83	83	45	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	Negative	5	No	NA	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Adverse	Adverse	White	No	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.G105G; MAF 50%	NA	NA	Negative	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	0	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	NA	False	Negative	NA	AMLMRC	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	133	RNA-seq	No	Squamous cell carcinoma|Lung Cancer	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	NA	NA	Targeted Therapy - Other	NA	2.2	No
aml_ohsu_2018	aml_ohsu_2018_2276	aml_ohsu_2018_15-00688	63	63	41	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	Negative	1	Yes	0.98	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUN	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	9	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	27.7	9.4	Negative	Negative	Unknown	Negative	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	0	Negative	Negative	404	False	No	No	88.5	9	Standard Chemotherapy	No	11	False	Negative	Negative	AMLMRC	0.82	DECEASED	2.7	21	19	1.8	2.6	0.9	0	79.6	0.9	14.2	0	6	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	7.6	p.R248Q; MAF 56%	Standard Chemotherapy	Standard Chemotherapy	1.61	Yes
aml_ohsu_2018	aml_ohsu_2018_2277	aml_ohsu_2018_15-00692	72	73	81	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	Foundation; M1fs*60; MAF 34%	2	Yes	0.99	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction	4	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Adverse	White	Yes	Yes	M0	Negative	Negative	None	Post-Chemotherapy|Relapse	28.2	9.6	Negative	Negative	Complete Response	NA	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]	0	NA	NA	NA	False	No	No	NA	112	Supportive/Palliative Care	No	22	False	Negative	NA	AMLCEBPA	18.59	DECEASED	4.5	11	16	0	43	0	NA	51	3	2	NA	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Relapse	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD12	6.9	Foundation; splice site 560-2insA; MAF 44%	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	35	Yes
aml_ohsu_2018	aml_ohsu_2018_2279	aml_ohsu_2018_15-00693	66	66	60	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.84	Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine	4	Allogeneic - Sibling | Consolidation | Induction | Experimental	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Fludarabine, Cytarabine	Allogeneic - Sibling	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH re	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	24.2	7.7	NA	NA	Refractory	NA	47,XX,+6[6]/46,XX[19]	0	NA	NA	453	False	No	No	104.8	-1	Bone Marrow Transplant	No	21	False	Negative	p.Q61R MAF ~5%	AMLNOS	27.57	LIVING	2.5	23	19	0	NA	0	0.9	29.8	54.4	1.8	0.5	92	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	Standard Chemotherapy	14.94	Yes
aml_ohsu_2018	aml_ohsu_2018_2280	aml_ohsu_2018_15-00701	50	50	NA	NA	Leukemia	AML with Minimal Differentiation	Dead-Unknown	No	NA	1	Yes	NA	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Re-induction	5	Standard Chemotherapy | Other	2	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	M0	Negative	NA	None	Residual Disease	19.8	6.4	NA	NA	Refractory	NA	48,XX,+11,+13[19]	-111	NA	NA	NA	False	No	No	93.4	365	Other	No	5	False	Negative	NA	AMLMD	9.93	DECEASED	NA	NA	NA	0	NA	0	2.6	8.8	17.6	2.6	0	31	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with minimal differentiation	AML with minimal differentiation	NA	NA	NA	Standard Chemotherapy|Other	Standard Chemotherapy	206.64	Yes
aml_ohsu_2018	aml_ohsu_2018_2281	aml_ohsu_2018_15-00702	35	35	42	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	0.6	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	10	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	20.3	6.8	NA	NA	Complete Response	Negative	46,XX,inv(16)(p13.3q22)[21]	0	Negative	Negative	319	False	No	No	102.5	112	Standard Chemotherapy	No	8	False	Negative	p.Q61P; MAF 15%	AMLCBFBMYH11	6.18	LIVING	3.5	54	23	1.7	29.6	0.9	0	40	18.3	7.8	0.2	63	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	6.7	Negative	Standard Chemotherapy	Standard Chemotherapy	12.78	Yes
aml_ohsu_2018	aml_ohsu_2018_2282	aml_ohsu_2018_15-00704	40	47	NA	NA	Leukemia	AML without Maturation	Dead-Disease	No	NA	1	Yes	1	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	8	Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	6	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	10	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Transplant|Post-Chemotherapy	35.2	11.7	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	107.3	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AWM	106.61	DECEASED	3.6	51	35	0.4	NA	0	1.6	46.5	15.6	35.9	0	125	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML without maturation	AML without maturation	NA	6.9	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.56	Yes
aml_ohsu_2018	aml_ohsu_2018_2295	aml_ohsu_2018_15-00717	61	61	68	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.51	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.S714C; MAF 35%	Yes	6	Favorable	Favorable	White	Yes	Yes	M5	Negative	Negative	None	Initial Acute Leukemia Diagnosis	27.7	8.9	Negative	Negative	Complete Response	Negative	46,XY[20]	0	NA	Negative	296	False	No	No	104.9	6	Standard Chemotherapy	No	5	False	Positive	p.G13V; MAF 6%	AMLNPM1	4.05	LIVING	3.7	29	17	0.4	0	0.1	3	17	62.6	16.9	0.1	74	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	8	Negative	Standard Chemotherapy	Standard Chemotherapy	16.84	Yes
aml_ohsu_2018	aml_ohsu_2018_2287	aml_ohsu_2018_15-00724	51	51	51	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Favorable or Intermediate	HispNative	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	11	False	Positive	NA	AMLNPM1	14.87	LIVING	NA	NA	NA	NA	54	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	12	Yes
aml_ohsu_2018	aml_ohsu_2018_2288	aml_ohsu_2018_15-00726	70	70	25	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	NA	3+7 (Cytarabine, Daunorubicin)|MiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	46,XX[19]	0	Negative	Negative	NA	False	No	No	NA	78	Standard Chemotherapy	No	18	False	Positive	Negative	AMLNPM1	6.68	LIVING	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD117 and subset MPO positive	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2290	aml_ohsu_2018_15-00731	66	66	13	NA	Leukemia	Myeloid Sarcoma	Alive	No	Negative	1	Yes	1.1	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	20	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	24.4	7.7	Negative	Negative	Complete Response i	Negative	46,XX[20]	0	Negative	Negative	NA	False	No	No	86.8	-1	Standard Chemotherapy	No	12	False	Negative	Negative	MS	6.02	LIVING	2.7	58	48	0.5	NA	2.5	0.5	24.7	9.7	62.1	0	226	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	Myeloid sarcoma	Myeloid sarcoma	CD13, CD33, CD34, CD38, CD58, CD117 and  HLA-DR	6.7	Negative	Standard Chemotherapy	Standard Chemotherapy	4.33	Yes
aml_ohsu_2018	aml_ohsu_2018_2293	aml_ohsu_2018_15-00734	53	53	93	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.79	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	153	Favorable	Favorable	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.8	8.8	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	977	False	No	No	92.1	153	Standard Chemotherapy	No	10	False	Positive	NA	AMLNPM1	6.64	LIVING	3.1	47	37	0	80	0	1.7	19.3	20.2	13.2	0.6	36	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	6	NA	Standard Chemotherapy	Standard Chemotherapy	42.34	Yes
aml_ohsu_2018	aml_ohsu_2018_2300	aml_ohsu_2018_15-00742	34	34	96	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.58	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Adverse	Favorable	White	Yes	Yes	M3	Negative	Negative	PML-RARA	Initial Acute Leukemia Diagnosis	30.1	10.7	Negative	Negative	Unknown	Negative	46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]	1	Negative	Negative	191	False	No	No	95.9	-1	Standard Chemotherapy	No	1	False	Negative	Negative	APLPMLRARA	NA	LIVING	4	21	15	0	47	0	4	60	14	22	0	32	WES	No	Pituitary macroadenoma	No	No	No	Yes	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive	7	Negative	Standard Chemotherapy	Standard Chemotherapy	0.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2304	aml_ohsu_2018_15-00755	59	59	93.2	NA	Leukemia	AML with Mutated NPM1	Dead-Treatment	No	NA	3	Yes	NA	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2251T>C; MAF 36.9% (33.1% on 3/13/15)	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Relapse|Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Positive	NA	AMLNPM1	8.42	DECEASED	NA	NA	NA	NA	47.5	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	NA	NA	Standard Chemotherapy	Standard Chemotherapy	42.91	Yes
aml_ohsu_2018	aml_ohsu_2018_2305	aml_ohsu_2018_15-00756	36	36	25	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	1	Yes	0.7	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	3	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	RUNX1T1/RUNX1: (92%)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	21	7.5	NA	NA	Refractory	NA	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]	0	NA	NA	NA	False	No	No	104.5	103	Standard Chemotherapy	No	1	False	Negative	NA	AMLRUNX1RUNX1T1	7.01	LIVING	2.3	32	39	0	38	0	3.4	29.1	2.6	23.9	0	29	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	6.7	NA	Standard Chemotherapy	Standard Chemotherapy	24.98	Yes
aml_ohsu_2018	aml_ohsu_2018_2307	aml_ohsu_2018_15-00763	23	23	NA	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	62% t(8;21) (RUNX1T1;RUNX1) translocation present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]	-4	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AMLRUNX1RUNX1T1	15.33	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2308	aml_ohsu_2018_15-00764	38	40	71	NA	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	Dead-Disease	No	NA	3	Yes	NA	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	6	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Experimental | Intensification | Re-induction	7	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	Unknown	Relapse|Post-Chemotherapy|Post-Transplant	NA	NA	NA	NA	Refractory	NA	NA	0	NA	NA	NA	False	No	No	NA	38	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	NA	AMLDEKNUP214	23.59	DECEASED	NA	NA	NA	NA	46	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	Yes	No	1	Peripheral Blood	Relapse	Male	Unmatched	AML with t(6;9)(p23;q34); DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	34	Yes
aml_ohsu_2018	aml_ohsu_2018_2310	aml_ohsu_2018_15-00766	71	71	60	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Other	No	Negative	5	Yes	NA	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q2	0	Negative	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	16	False	Negative	NA	TMN	0.36	DECEASED	NA	NA	NA	NA	14	NA	NA	NA	7	NA	NA	17	WES + RNA-seq	No	Non-Hodgkins Lymphoma	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.	NA	p.P19H; MAF 8.9%	Standard Chemotherapy	NA	21.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2311	aml_ohsu_2018_15-00767	78	78	25	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	NA	2	Yes	0.82	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	47.3	15.3	Negative	Negative	NA	NA	46,XY[20]	0	NA	NA	NA	False	Yes	No	NA	-1	Standard Chemotherapy	No	34	False	Negative	NA	AMLCEBPA	11.41	DECEASED	4.5	22	21	0.2	4	1	NA	25	10	60	NA	15	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)	7.5	NA	Standard Chemotherapy	NA	5.79	Yes
aml_ohsu_2018	aml_ohsu_2018_2314	aml_ohsu_2018_15-00777	68	68	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	2.67	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Adverse	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	35.5	11.4	p.R132L; MAF 47%	NA	Refractory	NA	46,XY[20]	-1	NA	p.G12A; MAF 36%	3615	False	No	Yes	92.4	7	Standard Chemotherapy	No	5	False	Negative	NA	AMLMRC	4.01	DECEASED	3.3	29	137	0	83	0	0.8	8.1	9.8	1.6	0.7	104	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Leukapheresis	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive	6.4	NA	Standard Chemotherapy	Standard Chemotherapy	140.18	Yes
aml_ohsu_2018	aml_ohsu_2018_2315	aml_ohsu_2018_15-00778	62	62	21	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	1	Yes	0.81	Decitabine|Hydroxyurea	2	Induction | Re-induction	2	Standard Chemotherapy	1	Hydroxyurea	Re-induction	EGR1 (73.5%) ;  TP53: (85.5%)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	20.6	6.8	Negative	Negative	Complete Response i	NA	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	0	Negative	Negative	NA	False	No	No	100.5	-1	Standard Chemotherapy	Yes	11	False	Negative	Negative	AMLMRC	13.95	DECEASED	3.2	22	9	0	2.5	1.7	0	68.3	1.7	25	0	174	WES + RNA-seq	No	NA	Yes	No	Yes	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	5.8	p.G266V; MAF 55%	Standard Chemotherapy	Standard Chemotherapy	3.74	Yes
aml_ohsu_2018	aml_ohsu_2018_2320	aml_ohsu_2018_15-00782	61	61	45	NA	Leukemia	AML, NOS	NA	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.7	7.6	R132C; MAF 42%	Negative	Complete Response	NA	46,XY[19]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	25	False	Negative	NA	AMLNOS	NA	NA	3.8	12	15	0	48	2	NA	69	4	2	NA	27	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	6.8	NA	Standard Chemotherapy	Standard Chemotherapy	1.39	Yes
aml_ohsu_2018	aml_ohsu_2018_2322	aml_ohsu_2018_15-00786	40	40	80	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	p.S28fs*81; MAF 28%	1	Yes	0.78	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	37.6	13.2	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	91.7	5	Standard Chemotherapy	No	8	False	Negative	NA	AMLCEBPA	5.39	LIVING	3.9	26	22	0	27.8	0	0	62.6	4.4	5.2	0	66	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	7.4	NA	Standard Chemotherapy	Standard Chemotherapy	2.68	Yes
aml_ohsu_2018	aml_ohsu_2018_1690	aml_ohsu_2018_15-00805	60	62	6	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.8	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy|Relapse	33.7	11.7	NA	NA	Complete Response	NA	46,XX[18]	-178	NA	NA	NA	False	No	No	100.3	-1	Bone Marrow Transplant	No	21	False	Positive	NA	AMLNPM1	24.01	LIVING	3.7	27	22	0	0	1.1	NA	50.8	3.9	44.2	NA	15	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD7, CD13, CD33, CD34, CD38, and CD123 positive	6.5	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2333	aml_ohsu_2018_15-00807	14	14	NA	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	1	Yes	NA	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	2	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	189	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	NA	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	5	False	Negative	p.G12D; MAF 45%	AMLRUNX1RUNX1T1	8.29	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2337	aml_ohsu_2018_15-00811	53	54	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.71	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 0.9%	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	27	9.1	NA	NA	Unknown	NA	46,XY,add(3)(p24)[cp4]/46,XY[14]	-7	NA	NA	321	False	No	No	95.1	-1	Targeted Therapy - Kinase Inhibitor(s)	No	19	False	Positive	NA	AMLNPM1	5.53	DECEASED	3.4	38	29	0	NA	1.7	0.9	6.1	8.8	43	0.4	170	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	4	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.7	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	16.65	Yes
aml_ohsu_2018	aml_ohsu_2018_2339	aml_ohsu_2018_15-00813	53	53	45	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.88	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 45%	Yes	4	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	29.4	9.6	NA	NA	Refractory	NA	46,XX[20]	1	NA	NA	2008	False	No	No	109.3	7	Standard Chemotherapy	No	2	False	Negative	p.G13D; MAF 35%	AMLNOS	3.91	LIVING	3.3	73	83	0	50	0	19.4	6.4	1.6	11.3	0	33	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	6.8	NA	Standard Chemotherapy	Standard Chemotherapy	137.54	Yes
aml_ohsu_2018	aml_ohsu_2018_2342	aml_ohsu_2018_15-00819	64	64	90	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	0.79	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	4	Consolidation | Induction | CNS	3	Standard Chemotherapy | Intrathecal	2	MiDAC	Consolidation	CBFB	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	6	Favorable	Favorable	White	Yes	No	M5	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	22.7	7.7	Negative	Negative	Complete Response	Negative	46,XY,inv(16)(p13q22)[20]	0	NA	Negative	1151	False	No	No	93.8	82	Standard Chemotherapy	No	10	False	Negative	Negative	AMLCBFBMYH11	6.48	LIVING	2.6	31	45	0.9	25.2	4.3	0.9	9.6	44.3	13.9	0.1	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO	5.5	Negative	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	24.64	Yes
aml_ohsu_2018	aml_ohsu_2018_2343	aml_ohsu_2018_15-00821	66	66	0	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	NA	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	32.1	10.2	NA	NA	Refractory	NA	46,XY[20]	-20	NA	NA	NA	False	No	No	94.7	-1	Bone Marrow Transplant	No	7	False	Negative	NA	AMLMRC	7.6	DECEASED	NA	NA	NA	0.8	0	0	2	18.6	9.3	69.3	0	345	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expres	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	8.94	Yes
aml_ohsu_2018	aml_ohsu_2018_2001	aml_ohsu_2018_15-00829	67	68	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	NA	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	4	Salvage | Experimental | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	4	Sorafenib	Experimental	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	Black	Yes	Yes	NA	Positive	Negative	None	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	20.4	6.8	p.R132G; MAF 51%	Negative	NA	NA	47,XX,+11[5]/48,idem,+19[15]	-17	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Negative	NA	TMN	14.77	DECEASED	4.1	18	25	NA	NA	NA	NA	NA	NA	NA	NA	24	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	7.4	p.R283C; MAF 49%	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	NA	27.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2350	aml_ohsu_2018_15-00837	72	72	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Dead-Disease	No	NA	3	Yes	NA	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[20]	-141	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	Yes	3	False	Negative	NA	AMLCBFBMYH11	6.18	DECEASED	NA	NA	NA	NA	58	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	NA	8.21	Yes
aml_ohsu_2018	aml_ohsu_2018_2347	aml_ohsu_2018_15-00839	48	48	13	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.95	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Intermediate-I	Favorable or Intermediate	White	Yes	No	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	42.1	14	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	231	False	No	No	89.2	7	Standard Chemotherapy	No	6	False	Positive	NA	AMLNPM1	1.09	DECEASED	3.9	84	28	0.2	NA	0	0.5	10.2	4.4	84.7	0	330	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD33, CD117 positive, negative for CD34 and HLA-DR	8.2	NA	Standard Chemotherapy	Standard Chemotherapy	6.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2357	aml_ohsu_2018_15-00850	62	62	50	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	positive for rearrangement of CBFB in 60.5% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Complete Response	Negative	46,XY,inv(16)(p13.1q22)[20]	1	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	15	False	Negative	NA	AMLCBFBMYH11	NA	NA	NA	NA	NA	NA	20	NA	NA	NA	NA	NA	NA	32	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7.	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	52.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2360	aml_ohsu_2018_15-00855	8	8	NA	NA	Leukemia	Myeloid Leukemia Associated with Down Syndrome	Alive	No	Negative	1	Yes	0.72	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction | CNS	2	Standard Chemotherapy | Intrathecal	2	Cytarabine	CNS	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	151	Intermediate-II	Favorable	HispNative	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	26.8	9.3	Negative	Negative	Complete Response	Negative	47,XY,+21c[20]	-2	Negative	Negative	NA	False	No	No	90.5	151	Intrathecal	No	1	False	Positive	Negative	MLADS	5.66	LIVING	3.2	13	25	10.8	NA	0	1.8	8.1	13.5	8.1	0	40	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	Myeloid leukaemia associated with Down syndrome	Myeloid leukaemia associated with Down syndrome	NA	8.2	Negative	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	67.53	Yes
aml_ohsu_2018	aml_ohsu_2018_2362	aml_ohsu_2018_15-00858	76	76	95	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	Yes	1.33	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction | Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R736H; MAF 45%	Yes	8	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	31.5	10.3	Negative	Negative	Refractory	Negative	46,XX[22]	0	Negative	Negative	244	False	No	No	92.6	4	Standard Chemotherapy	No	11	False	Positive	Negative	AMLNPM1	0.86	DECEASED	3.5	23	22	0	0	0	0.9	16.8	3.5	24.8	1.1	29	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	7	Negative	Standard Chemotherapy	Standard Chemotherapy	27.17	Yes
aml_ohsu_2018	aml_ohsu_2018_2337	aml_ohsu_2018_15-00864	53	54	8	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.73	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C, MAF 6%	No	6	Not Enough Information	Favorable or Intermediate	White	Yes	No	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy	20.2	7.1	NA	NA	Unknown	NA	46,XY[12]	0	NA	NA	235	False	No	No	93.5	-1	Targeted Therapy - Kinase Inhibitor(s)	No	1	False	Positive	NA	AMLNPM1	5.53	DECEASED	3.8	40	34	0	1	4.7	0.9	40.6	10.4	43.4	0	17	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	4	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	6.8	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	1.06	Yes
aml_ohsu_2018	aml_ohsu_2018_2364	aml_ohsu_2018_15-00870	71	71	20	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	6	Yes	1.57	Vidaza|Rituximab|Decitabine	3	Consolidation | Maintenance	2	Standard Chemotherapy	1	Decitabine	Maintenance	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	26	8.1	NA	NA	NA	NA	46,XY[20]	0	NA	p.G12V; MAF 49%	NA	False	No	Yes	91.9	86	Standard Chemotherapy	No	6	False	Negative	NA	AMLMRC	1.68	DECEASED	3.7	6	33	NA	10	1	NA	22	48	16	NA	13	WES + RNA-seq	No	Non-Hodgkins Lymphoma	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3	7	NA	Standard Chemotherapy	NA	44.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2367	aml_ohsu_2018_15-00872	65	65	74	NA	Leukemia	AML with Mutated NPM1	Alive	No	p.K298Q; MAF 25%	1	Yes	0.78	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation | Unknown | Induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant | Other	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 44%	Yes	6	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	21.6	7.2	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	905	False	No	No	100.5	-1	Bone Marrow Transplant	No	6	False	Positive	NA	AMLNPM1	5.95	LIVING	2.6	23	32	0	60	1.9	15.1	21.7	50	11.3	0	150	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive	6.7	NA	Standard Chemotherapy|Bone Marrow Transplant|Other	Standard Chemotherapy	84.69	Yes
aml_ohsu_2018	aml_ohsu_2018_1973	aml_ohsu_2018_15-00874	70	71	90	NA	Leukemia	AML with Minimal Differentiation	Alive	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	31.9	10.2	NA	NA	Refractory	NA	47,XY,+4[2]/46,XY[18]	0	NA	NA	235	False	No	No	94.7	-1	Supportive/Palliative Care	No	6	False	Negative	NA	AMLMD	17.2	LIVING	3.3	81	43	0	90	0	0	27.8	2.9	8.6	0.4	91	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Bone Marrow Aspirate	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	6.6	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	73.42	Yes
aml_ohsu_2018	aml_ohsu_2018_2416	aml_ohsu_2018_15-00883	72	72	90	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	p.E163*; MAF 39%	1	Yes	0.56	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	10	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	31.7	9.9	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	261	False	No	No	98.1	15	Targeted Therapy - Kinase Inhibitor(s)	No	17	False	Positive	NA	AMLNPM1	3.88	DECEASED	2.8	28	23	0.9	78	0	0	2.7	3.6	17.3	1.4	211	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	6.5	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	24.01	Yes
aml_ohsu_2018	aml_ohsu_2018_2421	aml_ohsu_2018_15-00892	72	72	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	3	No	NA	SGN-CD33A	1	Experimental	1	Targeted Therapy - Other	1	SGN-CD33A	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2645G>A; MAF 45.4%	Yes	NA	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Targeted Therapy - Other	No	5	False	Positive	NA	AMLNPM1	5.89	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Targeted Therapy - Other	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2418	aml_ohsu_2018_15-00895	54	54	4	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.92	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	1% RUNX1T1	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	5	Intermediate-II	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	39.5	13.2	Negative	Negative	Complete Response	Negative	47,XY,+8[3]/46,XY[17]	0	Negative	Negative	491	False	No	No	87.8	5	Standard Chemotherapy	No	3	False	Positive	Negative	AMLNPM1	1.58	LIVING	3.6	124	106	0.4	NA	1.2	0.5	18.4	9.4	70.1	0	358	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	7.9	Negative	Standard Chemotherapy	Standard Chemotherapy	8.43	Yes
aml_ohsu_2018	aml_ohsu_2018_2422	aml_ohsu_2018_15-00898	44	44	18	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	2	Yes	0.84	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	31.5	10.6	Negative	Negative	Complete Response	NA	46,XX[20]	0	NA	NA	252	False	No	No	NA	4	Standard Chemotherapy	No	15	False	Positive	NA	AMLNPM1	19.28	LIVING	4.2	13	13	0	2	1	NA	29	2	66	NA	36	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2 (-), CD4(partial +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34 (-), CD36(-), CD38(bright +/variable), CD45(+), CD56(-), CD64(-), CD117(+) and HLA-DR(partial +).	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	3.63	Yes
aml_ohsu_2018	aml_ohsu_2018_2420	aml_ohsu_2018_15-00900	24	24	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	1	Yes	0.95	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	32.3	11.3	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	243	False	No	No	92.8	-1	Bone Marrow Transplant	No	13	False	Negative	p.G12C; MAF 40%	AML	6.15	LIVING	3.7	37	28	0	NA	1.8	0.9	23.9	23	7.9	0	102	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	7.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	21.84	Yes
aml_ohsu_2018	aml_ohsu_2018_2423	aml_ohsu_2018_15-00903	73	73	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	3	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	NA	NA	NA	NA	NA	NA	45,X,-Y[20]	-24	NA	NA	NA	False	No	No	NA	7	Standard Chemotherapy	No	1	False	Negative	NA	TMN	1.18	DECEASED	NA	NA	NA	NA	79	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Lung Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	Standard Chemotherapy	NA	19.64	Yes
aml_ohsu_2018	aml_ohsu_2018_2425	aml_ohsu_2018_15-00909	44	47	90	NA	Leukemia	AML with Minimal Differentiation	NA	No	NA	6	No	0.82	Radiation	1	Unknown	1	Targeted Therapy - Other	1	Radiation	Unknown	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells e	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Adverse	Black	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	29.3	9.6	NA	NA	NA	NA	46,XX[20]	0	NA	NA	NA	False	No	No	89.9	14	Targeted Therapy - Other	No	6	False	Negative	NA	AMLMD	NA	NA	3.3	30	41	NA	45	0	NA	28	5	1	NA	5	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with minimal differentiation	AML with minimal differentiation	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.	7.3	NA	Targeted Therapy - Other	NA	6.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2426	aml_ohsu_2018_15-00912	76	77	86	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	NA	6	Yes	0.62	Azacitidine	1	Unknown	1	Unknown	1	Azacitidine	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	24.3	7.8	NA	NA	NA	NA	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]	0	NA	NA	NA	False	No	No	84.1	424	Unknown	No	1	False	Negative	NA	TMN	4.97	DECEASED	2.9	32	20	NA	50	1	NA	14	5	20	NA	27	WES + RNA-seq	Yes	Breast Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.	5.4	NA	Unknown	NA	14.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2429	aml_ohsu_2018_15-00921	75	74	NA	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.8	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	4	Consolidation | Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	8	Not Enough Information	Unknown	White	No	No	NA	NA	NA	None	Post-Chemotherapy	38.7	13	NA	NA	Refractory	NA	46,XX[20]	-105	NA	NA	NA	False	No	No	102.9	3	Standard Chemotherapy	No	NA	False	NA	NA	AMLNOS	8.39	LIVING	4.3	30	36	0.9	NA	1.9	0.2	27.7	3.5	65.8	0	206	RNA-seq	No	Not specified	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	7.3	NA	Standard Chemotherapy	Standard Chemotherapy	4.26	No
aml_ohsu_2018	aml_ohsu_2018_2433	aml_ohsu_2018_15-00929	50	50	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Treatment	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation | Induction | Re-induction | Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-I	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	46,XX[20]	-1	NA	NA	NA	False	No	No	NA	8	Standard Chemotherapy	No	1	False	Negative	NA	AMLMRC	13.98	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	10.08	Yes
aml_ohsu_2018	aml_ohsu_2018_2337	aml_ohsu_2018_15-00936	53	54	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 45%	Yes	6	Not Enough Information	Adverse	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	20.9	6.9	NA	NA	Unknown	NA	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	2	NA	NA	NA	False	No	No	96.3	-1	Targeted Therapy - Kinase Inhibitor(s)	No	20	False	Positive	NA	AMLNPM1	5.53	DECEASED	3.6	29	41	1.8	NA	3.6	6.2	23.2	18.7	17	1.3	21	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	4	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.8	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	20.77	Yes
aml_ohsu_2018	aml_ohsu_2018_2314	aml_ohsu_2018_15-00939	68	68	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	0.9	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	20.6	6.4	NA	NA	Refractory	NA	46,XY[19]	-39	NA	NA	NA	False	No	Yes	90.4	7	Standard Chemotherapy	No	5	False	Negative	NA	AMLMRC	4.01	DECEASED	2.5	12	14	0.8	NA	0.9	0	9.3	0	0	0.5	60	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.3	NA	Standard Chemotherapy	Standard Chemotherapy	6.21	Yes
aml_ohsu_2018	aml_ohsu_2018_2437	aml_ohsu_2018_15-00942	30	31	27	NA	Leukemia	AML with Recurrent Genetic Abnormalities	NA	No	NA	6	Yes	1.01	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	27	Intermediate-II	Intermediate	Black	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Post-Chemotherapy|Residual Disease	26.1	8.5	NA	NA	Complete Response i	NA	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]	0	NA	NA	NA	False	No	No	90.6	93	Standard Chemotherapy	No	4	False	Negative	NA	AMLRGA	NA	NA	4.6	35	62	NA	43	NA	NA	12	40	5	NA	5	WES	No	NA	No	No	No	Yes	No	2	Peripheral Blood	NA	Female	Unmatched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.	7.3	NA	Standard Chemotherapy	Standard Chemotherapy	5.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2439	aml_ohsu_2018_15-00947	66	66	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	1	Yes	1.09	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Adverse	Adverse	White	Yes	No	M0	Negative	Negative	None	Initial Acute Leukemia Diagnosis	27.1	8.4	Negative	Negative	Unknown	NA	46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1]	0	Negative	Negative	NA	False	No	No	98.9	-1	Standard Chemotherapy	Yes	13	False	Negative	Negative	AMLMRC	4.38	LIVING	3.8	17	20	0	23	3.5	4.3	39.1	4.4	34.8	4.5	21	WES	No	NA	No	No	Yes	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD38, CD58, CD117, and HLA-DR positive	7	Negative	Standard Chemotherapy	Standard Chemotherapy	4.42	Yes
aml_ohsu_2018	aml_ohsu_2018_2444	aml_ohsu_2018_15-00961	52	52	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	1	Yes	0.84	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	18.8	6.5	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	98.9	81	Standard Chemotherapy	No	1	False	Negative	NA	AML	5.95	LIVING	2.2	54	50	0	NA	30	13	9	21	19	0.1	21	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	6.5	NA	Standard Chemotherapy	Standard Chemotherapy	65.58	Yes
aml_ohsu_2018	aml_ohsu_2018_2337	aml_ohsu_2018_15-00964	53	54	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.86	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 45%	Yes	6	Not Enough Information	Adverse	White	Yes	Yes	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy	22.9	7.6	NA	NA	Unknown	NA	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	-10	NA	NA	346	False	No	No	92.3	-1	Targeted Therapy - Kinase Inhibitor(s)	No	17	False	Positive	NA	AMLNPM1	5.53	DECEASED	2.6	41	36	0	NA	0	0	14.3	2.4	3.2	1.3	23	WES	No	NA	No	No	No	No	No	4	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	5.9	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	19.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2447	aml_ohsu_2018_15-00965	61	61	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	19.5	6.5	NA	NA	Refractory	NA	NA	0	NA	NA	313	False	No	No	92.4	-1	Bone Marrow Transplant	No	6	False	Positive	NA	AMLNPM1	6.15	LIVING	2.4	43	31	0	NA	0	0	89.9	9.3	0.8	0	32	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	5.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	67.36	Yes
aml_ohsu_2018	aml_ohsu_2018_2416	aml_ohsu_2018_15-00967	72	72	70	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	p.E163*; MAF 40%	1	Yes	0.55	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	10	Not Enough Information	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	22.7	7.5	NA	NA	Refractory	NA	46,XX[5]	-15	NA	NA	339	False	No	No	89.7	15	Targeted Therapy - Kinase Inhibitor(s)	No	16	False	Positive	NA	AMLNPM1	3.88	DECEASED	3.2	13	40	0	3.56	0	1.8	34.8	3.6	0.9	23.2	32	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+	6.4	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	6.04	Yes
aml_ohsu_2018	aml_ohsu_2018_1745	aml_ohsu_2018_15-00974	36	38	NA	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	NA	1	Yes	NA	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	5	DLI | Standard Chemotherapy | Bone Marrow Transplant	3	Decitabine	Hypomethylating/Low Dose Cytarabine	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in t	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	4	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	GATA2-MECOM	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	32.6	10.3	NA	NA	Refractory	NA	46,XX,inv(3)(q21q26)[5]	-11	NA	NA	NA	False	No	No	99.4	4	Standard Chemotherapy	No	3	False	Negative	NA	AMLRGA	17.53	DECEASED	2.8	59	28	0	NA	0.9	0	13.9	0	0.9	0.4	38	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	6.7	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	7.08	Yes
aml_ohsu_2018	aml_ohsu_2018_2452	aml_ohsu_2018_15-00975	70	70	90	NA	Leukemia	AML, NOS	NA	No	NA	6	Yes	0.76	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Positive for 5q deletion in 91% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	37	Adverse	Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	25	8.2	NA	NA	Unknown	NA	46,XX,del(5)(q22q35)[20]	0	NA	NA	NA	False	No	No	87.7	37	Standard Chemotherapy	No	4	False	Negative	NA	AMLNOS	NA	NA	3.8	24	26	NA	17	NA	NA	20	18	2	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.	6.2	NA	Standard Chemotherapy	Standard Chemotherapy	7.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2453	aml_ohsu_2018_15-00976	83	83	12	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	1.3	AG-221|Azacitidine, SGN-CD33A	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Relapse|Post-Chemotherapy	21.1	6.8	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	No	Yes	87.9	-1	Targeted Therapy - Other	No	17	False	Negative	p.G12D; MAF 49%	AMLMRC	14.28	DECEASED	3.2	42	47	0.3	3	0	9.4	26.9	24.5	38.9	0	213	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive	6	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	3.72	Yes
aml_ohsu_2018	aml_ohsu_2018_2455	aml_ohsu_2018_15-00979	44	44	75	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.25	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	6	Allogeneic - Sibling | Induction | Experimental | Re-induction | Post-Transplant Relapse	5	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 48%	Yes	28	Intermediate-I	Favorable or Intermediate	White	No	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	22.9	7.4	NA	NA	Complete Response i	NA	46,XX[20]	0	NA	NA	705	False	No	No	96.2	-1	Targeted Therapy - Kinase Inhibitor(s)	No	NA	False	Positive	NA	AMLNPM1	10.49	DECEASED	2.4	21	25	0	80	0	7.7	10.3	22.2	6.8	0	42	RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	6.2	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	69.84	No
aml_ohsu_2018	aml_ohsu_2018_2454	aml_ohsu_2018_15-00981	75	75	90	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	No	0.97	Hydroxyurea|Decitabine	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.3	8.5	NA	NA	NA	NA	46,XY[20]	0	NA	NA	728	False	No	No	91.3	4	Supportive/Palliative Care	No	11	False	Positive	NA	TMN	0.56	DECEASED	2.9	23	51	0	90	0	0	5.1	0.8	0.9	1	28	WES + RNA-seq	No	Rectal Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	6.6	NA	Supportive/Palliative Care	NA	62.87	Yes
aml_ohsu_2018	aml_ohsu_2018_2420	aml_ohsu_2018_15-00988	24	24	80	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	1	Yes	0.92	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	5	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	22.5	8.1	NA	NA	Refractory	NA	46,XY[21]	0	NA	NA	176	False	No	No	81.2	-1	Bone Marrow Transplant	No	10	False	Negative	NA	AML	6.15	LIVING	3.7	48	29	0	NA	0	0	47.9	45.5	0	0	8	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	6.6	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2459	aml_ohsu_2018_15-00990	81	81	90	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	No	4.22	Azacitidine	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Azacitidine	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Favorable	Favorable	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	22.8	7.3	NA	NA	NA	NA	46,XX[20]	0	NA	NA	262	False	No	No	90.8	6	Supportive/Palliative Care	No	5	False	Positive	NA	AMLNPM1	0.46	DECEASED	2.9	62	50	0	70	0	0.8	6.1	72.2	12.2	0.4	29	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	5.8	NA	Supportive/Palliative Care	NA	97.26	Yes
aml_ohsu_2018	aml_ohsu_2018_2460	aml_ohsu_2018_16-00001	36	36	40	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	NA	1	Yes	0.53	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea	4	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	HiDAC	Consolidation	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	22.9	7.6	NA	NA	Refractory	NA	46,XX,t(16;16)(p13.2;q22)[20]	-2	NA	NA	508	False	No	No	99.6	122	Standard Chemotherapy	No	12	False	Negative	NA	AMLCBFBMYH11	6.88	LIVING	3.2	38	28	0	60	1.7	0	33.4	5.1	18.8	0.1	24	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	7.3	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	20.44	Yes
aml_ohsu_2018	aml_ohsu_2018_2461	aml_ohsu_2018_16-00003	26	27	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	16	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[15]	-7	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Positive	NA	AMLNPM1	19.84	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2462	aml_ohsu_2018_16-00004	82	82	50	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	1.03	NA	0	NA	0	NA	0	NONE	NONE	trisomy 8 in 5 of 20 metaphase cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 39%	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	27.7	9.2	NA	NA	NA	NA	46,XX	0	NA	NA	279	False	No	No	91.1	NA	NONE	No	3	False	Negative	NA	TMN	8.82	DECEASED	2.8	13	18	0	NA	0	1.8	42.8	0	5.4	3.7	44	WES + RNA-seq	Yes	Breast Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	7	NA	NA	NA	1.36	Yes
aml_ohsu_2018	aml_ohsu_2018_2464	aml_ohsu_2018_16-00006	77	77	41	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	4	Yes	NA	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction | Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	165	Intermediate-I	Intermediate or Adverse	White	Yes	No	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY[20]	0	Negative	NA	NA	False	Yes	No	NA	-1	Standard Chemotherapy	No	13	False	Negative	NA	AMLMRC	7.14	LIVING	NA	NA	NA	NA	18	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	Yes	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	NA	NA	Standard Chemotherapy	Standard Chemotherapy	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2464	aml_ohsu_2018_16-00007	77	77	41	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	4	Yes	NA	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction | Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	165	Not Enough Information	Adverse	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY[20]	0	Negative	NA	NA	False	Yes	No	NA	-1	Standard Chemotherapy	No	19	False	Negative	NA	AMLMRC	7.14	LIVING	NA	NA	NA	NA	18	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	NA	NA	Standard Chemotherapy	Standard Chemotherapy	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2437	aml_ohsu_2018_16-00010	30	31	79	NA	Leukemia	AML with Recurrent Genetic Abnormalities	NA	No	NA	6	Yes	0.52	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	27	Intermediate-II	Intermediate	Black	No	Yes	NA	Negative	NA	MLLT3-KMT2A	Residual Disease|Post-Chemotherapy	29.5	9.6	NA	NA	Complete Response i	NA	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]	0	NA	NA	NA	False	No	No	89.4	93	Standard Chemotherapy	No	NA	False	Negative	NA	AMLRGA	NA	NA	4	44	53	NA	64	NA	NA	2	15	1	NA	69	RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Unmatched	AML with t(9;11)(p22;q23); MLLT3-MLL	AML with t(9;11)(p22;q23); MLLT3-MLL	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT	7.3	NA	Standard Chemotherapy	Standard Chemotherapy	20.3	No
aml_ohsu_2018	aml_ohsu_2018_2467	aml_ohsu_2018_16-00015	71	72	95	NA	Leukemia	AML with Mutated NPM1	Alive	No	p.A240fs*83 (7 bp insertion with frameshift); MAF 19%	1	Yes	1.22	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Post-Transplant Relapse | Supportive/Palliative Care	7	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	32	Intermediate-I	Favorable or Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Transplant|Relapse|Post-Chemotherapy	27.2	9.6	NA	NA	Complete Response	NA	46,XY[18]	-1	NA	NA	230	False	No	No	96.8	-1	Targeted Therapy - Kinase Inhibitor(s)	No	4	False	Positive	NA	AMLNPM1	32.76	LIVING	2.8	15	18	0	50	2.6	0.9	29.8	0	30.7	0.4	103	WES	No	Squamous cell carcinoma	No	No	No	No	No	1	Peripheral Blood	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	5.6	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	7.92	Yes
aml_ohsu_2018	aml_ohsu_2018_2468	aml_ohsu_2018_16-00017	68	68	1	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Alive	No	NA	1	Yes	0.84	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	3	Consolidation | Induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	MiDAC	Consolidation	Normal	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	p.R882H; MAF 34%	No	23	Favorable	Favorable	White	Yes	No	M4	Negative	NA	None	Unknown	21.9	7.5	NA	NA	Complete Response	NA	46,XX[20]	0	NA	p.G13D; MAF 8%	533	True	No	No	96.1	100	Standard Chemotherapy	No	24	False	Positive	NA	CMML	6.18	LIVING	1.9	NA	NA	0	NA	0	2.1	41.7	47.9	8.3	0	20	WES	No	Colon Cancer	No	Yes	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Chronic myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	CD19, CD20, and surface kappa light chain positive	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	3.38	Yes
aml_ohsu_2018	aml_ohsu_2018_2472	aml_ohsu_2018_16-00026	56	56	89.6	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Val716Asp; MAF 45%	Yes	12	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response i	NA	46,XY[20]	-1	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	20	False	Positive	NA	AMLNPM1	17.07	LIVING	NA	NA	NA	NA	51	NA	NA	NA	NA	NA	NA	54	WES	No	Prostate Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocy	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	31.02	Yes
aml_ohsu_2018	aml_ohsu_2018_2473	aml_ohsu_2018_16-00027	55	55	91	NA	Leukemia	AML, NOS	Alive	No	Negative	2	Yes	0.85	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation | Induction | Allogeneic - Child | Maintenance	4	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide	Maintenance	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-I	Adverse	AdmixedWhite	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	18.8	6.2	R132H; MAF 47.0%	Negative	Complete Response	NA	46,XY[29]	0	NA	NA	808	False	No	No	NA	1	Standard Chemotherapy	No	16	False	Negative	NA	AMLNOS	12.93	LIVING	3	33	27	0	99.2	0	NA	0.8	0	0	NA	28	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(	6.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	181.08	Yes
aml_ohsu_2018	aml_ohsu_2018_2477	aml_ohsu_2018_16-00031	50	50	75	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	1	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Not Available (no FISH done)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	24.8	8	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	91.5	97	Bone Marrow Transplant	No	15	False	Negative	NA	AMLNOS	18.95	LIVING	3.5	44	20	NA	73	NA	NA	6	6	8	NA	26	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.	5.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	17.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2474	aml_ohsu_2018_16-00033	58	58	23	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	1	Yes	0.76	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Favorable	Favorable	White	Yes	No	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	35.2	11.9	NA	NA	Complete Response	NA	46,XX,inv(16)(p13.1q22)[16]/46,XX[4]	0	NA	p.G12D; MAF 4%	NA	False	No	No	99.7	-1	Standard Chemotherapy	No	8	False	Negative	p.G12S; MAF 6%	TMN	9.01	LIVING	3.8	33	25	0	3	0	0.9	50.2	29.8	19.1	0	119	WES	Yes	Breast Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD13, variable CD15, CD33, CD34, variable CD64, CD117, dim CD123, dim HLA-DR, MPO and subset TdT-positive	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	2.35	Yes
aml_ohsu_2018	aml_ohsu_2018_2475	aml_ohsu_2018_16-00035	54	54	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	2	Yes	0.51	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	19.4	6.6	Negative	NA	Complete Response	NA	NA	0	NA	NA	1259	False	No	No	NA	88	Standard Chemotherapy	No	17	False	Positive	NA	AMLNPM1	18.62	LIVING	2.7	135	113	0	97	0	NA	1	0	2	NA	28	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	5.3	NA	Standard Chemotherapy	Standard Chemotherapy	175.91	Yes
aml_ohsu_2018	aml_ohsu_2018_2480	aml_ohsu_2018_16-00041	70	70	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	4	Yes	NA	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Negative	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 50%	Yes	1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Positive	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	NA	0	Negative	NA	NA	False	No	No	NA	1	Standard Chemotherapy	No	12	False	Positive	NA	AMLNPM1	0.13	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	Prostate Cancer	No	No	No	No	No	1	Peripheral Blood	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	96	Yes
aml_ohsu_2018	aml_ohsu_2018_2482	aml_ohsu_2018_16-00046	62	62	40	NA	Leukemia	AML, NOS	Dead-Unknown	No	NA	1	Yes	0.87	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction | Re-induction	2	Standard Chemotherapy	1	Azacitidine	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	7	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	25.4	8.2	NA	NA	Refractory	NA	46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15]	0	NA	NA	NA	False	No	No	100.8	-1	Standard Chemotherapy	No	18	False	Negative	NA	AMLNOS	19.11	DECEASED	3.8	15	9	0	8	0	1	80	3	8	15.4	35	WES	No	Lung Cancer|Multiple Sclerosis	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	dim/partial cCD3, variable CD7, CD13, dimCD33, CD34,  CD38, CD117, dim CD123, dim HLA-DR, partial TdT, and partial MPO positive Monoclonal B cell population identified	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	1.04	Yes
aml_ohsu_2018	aml_ohsu_2018_2483	aml_ohsu_2018_16-00048	46	46	25	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	0.64	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	7	Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.I824V; VAF 50%	Yes	1	Adverse	Adverse	Asian	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	32	9.5	NA	NA	Refractory	NA	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	0	NA	NA	440	False	No	No	80.6	-1	Bone Marrow Transplant	No	24	False	Negative	p.G13R; MAF 50%	TMN	20.95	DECEASED	3.1	14	15	0.9	26.7	1.7	4.3	6.1	32.2	48.7	0.2	92	WES + RNA-seq	No	Anaplastic Astrocytoma	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	42.57	Yes
aml_ohsu_2018	aml_ohsu_2018_2485	aml_ohsu_2018_16-00050	77	77	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	NA	1	Yes	1.01	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal in	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.E285D; MAF 40%	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	NA	Unknown	Residual Disease	24.2	7.9	NA	NA	NA	NA	NA	0	NA	NA	241	False	No	No	87.7	253	Standard Chemotherapy	No	1	False	Negative	NA	TMN	11.22	DECEASED	3.3	62	28	0.8	NA	2.5	0	15.8	0	70.9	0	16	WES + RNA-seq	Yes	Breast Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	8	p.V272_R273insL; MAF 75% (previously 71% in 4/21/15 peripheral blood)	Standard Chemotherapy	NA	8.29	Yes
aml_ohsu_2018	aml_ohsu_2018_2490	aml_ohsu_2018_16-00056	51	51	95	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.93	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	2	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	20.6	6.6	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	189	False	No	No	112.6	-1	Standard Chemotherapy	No	22	False	Positive	NA	AMLNPM1	6.61	LIVING	2.9	22	12	0	95	0	0	7.8	0	3.1	0.1	57	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	6.5	NA	Standard Chemotherapy	Standard Chemotherapy	25.02	Yes
aml_ohsu_2018	aml_ohsu_2018_2492	aml_ohsu_2018_16-00062	63	63	6	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	NA	No	NA	2	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	NA	Adverse	White	Yes	No	NA	Negative	NA	None	Residual Disease	26.7	8.8	Negative	Negative	NA	NA	46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4].	0	NA	NA	NA	True	No	No	91.8	-1	Standard Chemotherapy	No	12	False	Negative	NA	MDSU	NA	NA	NA	NA	NA	0.3	NA	3	NA	54.1	3.7	38.4	NA	31	WES	No	Breast Cancer|Breast Cancer	Yes	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	The cytospin and smear preparations reveal maturing hematopoietic precursors and scattered small lymphocytes.	NA	H193Y; MAF 65.0%	Standard Chemotherapy	NA	2.68	Yes
aml_ohsu_2018	aml_ohsu_2018_2496	aml_ohsu_2018_16-00067	53	53	20	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	2	Yes	0.86	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI	4	Consolidation | Induction | Allogeneic - Child | Maintenance	4	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Cyclophosphamide	Maintenance	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	20	6.2	Negative	NA	Complete Response	NA	46,XX[20]	-1	NA	NA	426	False	No	No	105.3	1	Supportive/Palliative Care	No	10	False	Negative	NA	AML	17.01	LIVING	3.3	18	23	0	8	0	NA	37	20	30	NA	38	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	7	NA	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	6.63	Yes
aml_ohsu_2018	aml_ohsu_2018_2497	aml_ohsu_2018_16-00070	24	24	86	NA	Leukemia	APL with PML-RARA	Alive	No	NA	1	Yes	1	Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	24	Intermediate-II	Favorable	White	Yes	Yes	NA	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	23.8	8.3	NA	NA	Complete Response	NA	46,XY,t(15;17)(q22;q21)[20]	0	NA	NA	467	False	No	No	86.2	24	Standard Chemotherapy	No	7	False	Negative	NA	APLPMLRARA	0.92	LIVING	3.5	76	35	3.6	73	0	46	12.6	2.7	5.4	0.6	55	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+).	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	42.35	Yes
aml_ohsu_2018	aml_ohsu_2018_2443	aml_ohsu_2018_16-00073	63	64	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	1.3	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Maintenance | Supportive/Palliative Care	6	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Relapse	21.1	7.1	NA	NA	Complete Response	NA	48,XX,+8,+21[16]/46,XX[4]	-44	NA	NA	NA	False	No	No	91.3	29	Supportive/Palliative Care	No	22	False	Negative	NA	AMLMRC	11.45	DECEASED	3.8	25	22	1.5	38.5	0	0	55	3.5	1.5	0	18	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.7	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	Standard Chemotherapy	19.76	Yes
aml_ohsu_2018	aml_ohsu_2018_2498	aml_ohsu_2018_16-00075	69	69	39	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	4	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]	0	Negative	NA	NA	False	No	No	NA	7	Standard Chemotherapy	No	13	False	Negative	NA	AMLMRC	0.43	LIVING	NA	NA	NA	NA	11	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive	NA	NA	Standard Chemotherapy	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2500	aml_ohsu_2018_16-00077	78	80	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	1.28	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	5	Consolidation | Induction | Experimental | Maintenance	4	Standard Chemotherapy | Targeted Therapy - Other	2	AG-120	Experimental	nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	25.6	8.1	NA	Negative	Complete Response	NA	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	-29	NA	NA	1897	False	No	No	NA	-1	Targeted Therapy - Other	No	2	False	Negative	NA	TMN	19.9	DECEASED	2.6	11	57	0	70	0	NA	7	3	9	NA	23	WES + RNA-seq	No	Esophageal Cancer	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).	4.3	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	240.43	Yes
aml_ohsu_2018	aml_ohsu_2018_2499	aml_ohsu_2018_16-00078	67	67	85	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	2	Yes	0.66	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	28.7	9.5	Negative	Negative	NA	NA	46,XX[20]	0	NA	NA	670	False	No	No	102.5	-1	Standard Chemotherapy	No	20	False	Positive	Q61K; MAF 43.0%	AMLNPM1	NA	NA	1.9	27	41	0.8	7.7	0	NA	5.1	42.7	40.2	NA	42	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).	5.7	NA	Standard Chemotherapy	NA	56.03	Yes
aml_ohsu_2018	aml_ohsu_2018_2495	aml_ohsu_2018_16-00087	24	24	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	1	Yes	0.51	ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation | Induction | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Not Enough Information	Favorable or Intermediate	White	Yes	No	NA	Positive	NA	Unknown	Post-Chemotherapy	19.6	6.2	p.W288fs*12; MAF 50%	NA	Complete Response	NA	NA	0	NA	NA	364	False	No	No	108.3	114	Standard Chemotherapy	No	2	False	Positive	NA	TMN	8.59	LIVING	2.7	14	18	0	97	0	0	1.9	0	1.9	0.2	15	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Leukapheresis	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	6.4	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	181.66	Yes
aml_ohsu_2018	aml_ohsu_2018_2442	aml_ohsu_2018_16-00088	25	26	98	NA	Leukemia	AML, NOS	Dead-Unknown	No	NA	6	Yes	0.54	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	4	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	AdmixedBlack	Yes	Yes	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy	27.2	8.9	NA	NA	Unknown	NA	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	0	NA	NA	NA	False	No	No	90.4	67	Standard Chemotherapy	No	4	False	Negative	NA	AMLNOS	10.66	DECEASED	4.1	46	30	NA	95	NA	NA	2	3	NA	NA	81	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.	6.9	NA	Standard Chemotherapy	Standard Chemotherapy	67.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2501	aml_ohsu_2018_16-00094	37	37	95	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.46	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	4	Standard Chemotherapy	1	Azacitidine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	27.9	9.2	NA	NA	Refractory	NA	46,XX[20]	0	NA	p.K117N; MAF 48%	NA	False	No	No	89.4	-1	Standard Chemotherapy	No	5	False	Negative	NA	AMLNOS	0.56	LIVING	3.1	23	14	1.7	74	2.5	0.8	13.6	14.4	10.2	0.4	49	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	7	NA	Standard Chemotherapy	Standard Chemotherapy	26.57	Yes
aml_ohsu_2018	aml_ohsu_2018_2508	aml_ohsu_2018_16-00102	72	72	97	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	4	Yes	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Favorable	White	Yes	Yes	M1	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[5]	0	Negative	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	11	False	Positive	NA	AMLNPM1	3.13	LIVING	NA	NA	NA	NA	96	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	NA	NA	Standard Chemotherapy	Standard Chemotherapy	125.9	Yes
aml_ohsu_2018	aml_ohsu_2018_2511	aml_ohsu_2018_16-00109	76	76	96	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	No	0.46	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Favorable	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	31	10.4	NA	NA	NA	NA	46,XY[20]	-1	NA	NA	839	False	Yes	No	93.9	7	Supportive/Palliative Care	No	5	False	Positive	NA	AMLNPM1	0.26	DECEASED	2.3	23	43	0	93.3	0	0.7	4.7	0	1.3	0.6	17	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Leukapheresis	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	5.1	NA	Supportive/Palliative Care	NA	230.05	Yes
aml_ohsu_2018	aml_ohsu_2018_2521	aml_ohsu_2018_16-00113	85	85	2	NA	Leukemia	Myeloid Sarcoma	NA	No	Negative	5	No	1.2	NA	0	NA	0	NA	0	NONE	NONE	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	48.8	16.1	Negative	Negative	NA	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	NA	NONE	No	5	False	Negative	Negative	MS	NA	NA	3.7	4	8	1.5	NA	24	NA	11.5	8	55	NA	141	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	Myeloid sarcoma	Myeloid sarcoma	NA	6.3	Negative	NA	NA	11.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2522	aml_ohsu_2018_16-00115	74	74	19	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	6	No	0.86	NA	0	NA	0	NA	0	NONE	NONE	Monosomy 7 is detected in 87% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	24.2	7.8	NA	NA	NA	NA	45,XY,-7,del(12)(p11.2p13)[20]	0	NA	NA	NA	False	No	No	90.6	NA	NONE	No	5	False	Negative	NA	AMLNOS	0.46	DECEASED	3.7	29	38	NA	7	4	NA	12	2	51	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.6	NA	NA	NA	47.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2443	aml_ohsu_2018_16-00118	63	64	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	1.57	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Maintenance | Supportive/Palliative Care	6	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Relapse	20.9	7	NA	NA	Complete Response	NA	48,XX,+8,+21[16]/46,XX[4]	-58	NA	NA	887	False	No	No	89.7	29	Supportive/Palliative Care	No	31	False	Negative	NA	AMLMRC	11.45	DECEASED	3.1	16	36	0	NA	0	0	12.6	0	0	0.2	21	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.3	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	Standard Chemotherapy	49.93	Yes
aml_ohsu_2018	aml_ohsu_2018_2515	aml_ohsu_2018_16-00120	36	36	91.8	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	3	Yes	NA	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation | Induction | Maintenance	3	Standard Chemotherapy	1	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Favorable	White	Yes	Yes	NA	Positive	NA	PML-RARA	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	1	False	Negative	NA	APLPMLRARA	16.91	LIVING	NA	NA	NA	NA	95	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	NA	NA	Standard Chemotherapy	Standard Chemotherapy	55.42	Yes
aml_ohsu_2018	aml_ohsu_2018_2477	aml_ohsu_2018_16-00124	50	50	NA	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	0.81	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Not Available (no FISH done)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.r882H; MAF 45%	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Positive	Negative	None	Post-Chemotherapy|Residual Disease	24.1	7.9	NA	NA	Unknown	NA	46,XY[20]	-30	NA	NA	NA	False	No	No	89.6	97	Bone Marrow Transplant	No	14	False	Negative	NA	AMLNOS	18.95	LIVING	3.8	20	11	NA	68	NA	NA	12	NA	3	NA	39	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	6.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2519	aml_ohsu_2018_16-00129	42	42	90	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	5	Yes	0.98	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.7	7.3	Negative	Negative	Complete Response	Negative	46,XX[19]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	10	False	Positive	Negative	AMLNPM1	3.42	LIVING	3.6	17	13	0	NA	0	NA	17	NA	20	NA	71	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	6.6	Negative	Standard Chemotherapy	Standard Chemotherapy	18.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2526	aml_ohsu_2018_16-00132	74	75	6	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	NA	6	Yes	0.73	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	498	Not Enough Information	Adverse	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	36.5	12.7	NA	NA	Complete Response	NA	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]	0	NA	NA	NA	False	No	No	94.8	498	Standard Chemotherapy	No	3	False	Negative	NA	AMLMRC	NA	NA	4.4	41	25	NA	NA	3.8	NA	48.1	9.5	38.1	NA	43	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	These are positive for CD34, CD117, HLA-DR, and CD33.	6.4	NA	Standard Chemotherapy	Standard Chemotherapy	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2429	aml_ohsu_2018_16-00135	75	75	95	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	1	Yes	NA	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	85% MLL rearrangement (c/w karyotype)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Intermediate-II	Intermediate	White	Yes	No	NA	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	17.1	6.1	NA	NA	NA	NA	46,XX,t(9;11)(p22;q23)[20]	0	NA	NA	NA	False	No	No	97.7	-1	Standard Chemotherapy	No	2	False	Negative	NA	TMN	8.39	LIVING	2.8	21	23	NA	NA	NA	NA	NA	NA	NA	0	19	WES	No	Not specified	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	dim CD13, CD33, CD56, bright CD64, CD117, CD123 and HLA-DR-positive; MPO and CD34-negative	6.1	NA	Standard Chemotherapy	NA	0.39	Yes
aml_ohsu_2018	aml_ohsu_2018_2530	aml_ohsu_2018_16-00139	73	73	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	6	Yes	0.87	Ruxolitinib	1	Induction	1	Standard Chemotherapy	1	Ruxolitinib	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	28	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy	34.1	10.9	NA	NA	Unknown	NA	NA	0	NA	NA	NA	False	No	No	92.4	28	Standard Chemotherapy	Yes	6	False	Positive	NA	AMLNPM1	18.42	DECEASED	4.5	10	21	NA	NA	0.5	NA	39.2	7.5	52.5	NA	6	WES + RNA-seq	No	Breast Cancer	No	No	Yes	Yes	Yes	3	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	7.6	NA	Standard Chemotherapy	Standard Chemotherapy	3.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2532	aml_ohsu_2018_16-00143	58	58	57	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	4	Yes	NA	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Induction | Experimental	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	t(8;22) clone observed, consistent with a neoplastic process	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	1	Intermediate-II	Intermediate	HispNative	Yes	No	M2	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	47,XY,t(8;22)(p11.2;q11.2),+19[20]	-1	Negative	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	5	False	Negative	NA	AMLMRC	6.32	LIVING	NA	NA	NA	NA	24	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	100.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2533	aml_ohsu_2018_16-00145	75	75	27	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	0.98	Vidaza|Decitabine|Fludarabine, Cytarabine	3	Salvage | Supportive/Palliative Care	2	Standard Chemotherapy	1	Fludarabine, Cytarabine	Salvage	nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Adverse	Asian	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	30.7	9.3	Negative	Negative	NA	NA	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	0	NA	G12R; MAF 5.0%	215	False	No	Yes	NA	-1	Standard Chemotherapy	No	18	False	Negative	NA	AMLMRC	5.23	DECEASED	4.8	12	15	0	2	0	NA	60.2	8.4	29.4	NA	121	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).	7.5	NA	Standard Chemotherapy	NA	3.09	Yes
aml_ohsu_2018	aml_ohsu_2018_2546	aml_ohsu_2018_16-00150	67	67	60	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	6	Yes	NA	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy	1	Decitabine	Salvage	Trisomy 8 is detected in 28% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	0	NA	NA	NA	False	No	Yes	NA	106	Standard Chemotherapy	No	25	False	Negative	p.G12A; MAF 24%	AMLMRC	3.68	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2547	aml_ohsu_2018_16-00151	67	67	80	NA	Leukemia	AML, NOS	NA	No	NA	6	Yes	0.85	3+7 (Cytarabine, Daunorubicin)	1	Unknown	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Unknown	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	21.2	7.2	p.R132C MAF 12%	NA	NA	NA	46,XY[20]	0	NA	NA	NA	False	No	No	110.4	-1	Standard Chemotherapy	Yes	20	False	Negative	NA	AMLNOS	NA	NA	3.9	8	10	NA	10	2	NA	68	4	8	NA	84	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b.	5.9	p.Y220C; MAF 35%	Standard Chemotherapy	NA	0.9	Yes
aml_ohsu_2018	aml_ohsu_2018_2538	aml_ohsu_2018_16-00157	67	67	93	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	1.23	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Salvage | Induction | Experimental	4	Standard Chemotherapy | Targeted Therapy - Other	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 46%	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	31.2	10.1	p.R132H; MAF 46%	Negative	Complete Response	NA	46,XY[20]	0	Negative	Negative	NA	False	No	No	96.3	-1	Standard Chemotherapy	No	4	False	Positive	Negative	AMLNPM1	17.37	LIVING	2.4	20	30	0	94	0	0	1	2.8	1.9	0.1	30	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.	NA	Negative	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	125.16	Yes
aml_ohsu_2018	aml_ohsu_2018_2543	aml_ohsu_2018_16-00161	65	65	40	NA	Leukemia	AML with Minimal Differentiation	Dead-Unknown	No	NA	1	Yes	0.71	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	12	Not Enough Information	Intermediate	White	Yes	No	M0	Negative	NA	None	Initial Acute Leukemia Diagnosis	28.5	10.2	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	122	False	No	No	96	-1	Standard Chemotherapy	No	8	False	Negative	NA	AMLMD	6.22	DECEASED	3.7	32	14	0.3	3	1.4	0	76.5	2.9	18.9	0	41	WES	No	Prostate Cancer	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	CD13, CD33, bright CD34, CD38, CD58, CD117, and TdT	6.4	NA	Standard Chemotherapy	Standard Chemotherapy	3.49	Yes
aml_ohsu_2018	aml_ohsu_2018_2569	aml_ohsu_2018_16-00217	86	86	23	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	p.R343fs*79; MAF 40%	1	Yes	1.52	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Experimental	3	Standard Chemotherapy | Targeted Therapy - Other	2	Hydroxyurea	Consolidation	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.G707fs*72; MAF 45%	Yes	NA	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	27.8	9	NA	NA	NA	NA	47,XY,+8[20]	0	NA	NA	398	False	No	No	97.5	55	Standard Chemotherapy	No	10	False	Negative	NA	AMLCEBPA	19.61	DECEASED	3.4	16	15	0	12.1	0	0.8	8.6	19	59.5	0	299	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	7.6	NA	Standard Chemotherapy|Targeted Therapy - Other	NA	10	Yes
aml_ohsu_2018	aml_ohsu_2018_2571	aml_ohsu_2018_16-00220	67	67	71.5	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	IDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	24	False	Positive	NA	AMLNPM1	1.02	LIVING	NA	NA	NA	NA	56	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD33, CD38, CD56, CD117, and myeloperoxidase	NA	NA	Standard Chemotherapy	Standard Chemotherapy	16.24	Yes
aml_ohsu_2018	aml_ohsu_2018_2503	aml_ohsu_2018_16-00226	79	79	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	2.11	Azacitidine|Decitabine|Hydroxyurea|V212	4	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care	2	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	25.5	7.8	NA	NA	NA	NA	46,XY[22]	-35	NA	NA	722	False	Yes	No	95.5	-1	Supportive/Palliative Care	No	2	False	Negative	NA	AMLMRC	1.74	LIVING	3.1	9	22	1.7	35	0	0	0.9	64.4	8.7	0.2	438	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	5.8	NA	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	NA	116.52	Yes
aml_ohsu_2018	aml_ohsu_2018_2584	aml_ohsu_2018_16-00232	58	58	78.3	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction | Re-induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	- 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7]	-1	NA	NA	NA	False	No	No	NA	143	Standard Chemotherapy	No	9	False	Negative	NA	AMLMRC	8.88	DECEASED	NA	NA	NA	NA	37	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, partial CD15, CD33, CD34, weak CD64,  very weak partial CD117, and myeloperoxidase	NA	NA	Standard Chemotherapy	Standard Chemotherapy	2.64	Yes
aml_ohsu_2018	aml_ohsu_2018_2581	aml_ohsu_2018_16-00249	75	75	60	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	NA	Vidaza	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Vidaza	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	NA	NA	46,XY[20]	0	NA	NA	NA	False	No	Yes	NA	-1	Standard Chemotherapy	No	9	False	Negative	NA	AMLNOS	9.93	LIVING	NA	NA	NA	NA	50	NA	NA	NA	2	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers	NA	NA	Standard Chemotherapy	NA	25	Yes
aml_ohsu_2018	aml_ohsu_2018_2477	aml_ohsu_2018_16-00261	50	50	20	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	0.8	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Not Available (no FISH done)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	20.3	6.9	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	85.7	97	Bone Marrow Transplant	No	13	False	Negative	NA	AMLNOS	18.95	LIVING	3.6	15	11	NA	NA	0	NA	90	0	10	NA	48	WES	No	NA	No	No	No	No	No	3	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD117 stains clusters and scattered immature mononuclear cells with atypia, 20%. CD34 is negative.	6.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	0.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2225	aml_ohsu_2018_16-00264	71	72	95	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	5	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Intermediate-II	Intermediate	White	Yes	No	NA	Positive	NA	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	-37	NA	NA	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	26	False	Negative	NA	TMN	9.21	DECEASED	NA	NA	NA	NA	99	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Follicular lymphoma	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	20.39	Yes
aml_ohsu_2018	aml_ohsu_2018_1241	aml_ohsu_2018_16-00267	57	60	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	1	Yes	1.2	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Consolidation | Induction | Re-induction | Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	26.9	9.5	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	420	False	No	No	97.5	-1	Standard Chemotherapy	No	7	False	Negative	NA	AML	31.35	LIVING	3.1	50	59	0.9	1	0	8.9	18.8	15.2	56.2	5	152	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increa	6.2	NA	Standard Chemotherapy	Standard Chemotherapy	4	Yes
aml_ohsu_2018	aml_ohsu_2018_2593	aml_ohsu_2018_16-00269	44	44	65	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.53	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	23.7	7.8	p.R132H; MAF 44%	NA	Complete Response	NA	NA	0	NA	NA	197	False	No	No	100.4	99	Standard Chemotherapy	No	9	False	Positive	NA	AMLNPM1	5.59	LIVING	2.8	19	11	0	11.2	3.5	0	76.7	0	8.6	0	222	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD117, CD123, dim HLA-DR and MPO	6.1	NA	Standard Chemotherapy	Standard Chemotherapy	2.41	Yes
aml_ohsu_2018	aml_ohsu_2018_2594	aml_ohsu_2018_16-00271	22	22	63	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	2	Yes	0.68	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling | Induction | Experimental	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan	Allogeneic - Sibling	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	39	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	19.3	6	NA	NA	Complete Response	NA	46,XX[20]	-1	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	8	False	Positive	NA	AMLNPM1	15.26	LIVING	3.1	27	39	0	42	0	NA	32.7	4.4	26.6	NA	176	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	6.3	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	22.01	Yes
aml_ohsu_2018	aml_ohsu_2018_2595	aml_ohsu_2018_16-00273	62	62	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Dead-Disease	No	c.68dup; MAF 21%	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2645G>A; MAF 43.9%	Yes	7	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	46,XX[20]	-2	NA	NA	NA	False	No	No	NA	7	Standard Chemotherapy	No	5	False	Negative	c.35G>A; MAF 30.2%	AMLCEBPA	5.56	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2597	aml_ohsu_2018_16-00278	64	64	83	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	5	Yes	1.27	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2645G>A; p.R882H	Yes	41	Intermediate-I	Favorable	White	Yes	Yes	NA	Positive	Negative	None	Initial Acute Leukemia Diagnosis	25.2	8.7	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	16	False	Positive	Negative	AMLNPM1	14.47	LIVING	4	15	45	0	74	0	NA	13	0	13	NA	39	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	6	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	53.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2606	aml_ohsu_2018_16-00289	65	65	95	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.83	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation | Induction	2	Standard Chemotherapy	1	Azacitidine	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	45	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	37	12.4	NA	NA	Complete Response i	NA	46,XX[20]	0	NA	NA	697	False	No	No	95.1	34	Standard Chemotherapy	No	8	False	Positive	NA	AMLNPM1	4.67	DECEASED	3.2	101	55	0	92.9	0	0.7	3.6	1.4	1.4	0.1	42	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	6.3	NA	Standard Chemotherapy	Standard Chemotherapy	166.91	Yes
aml_ohsu_2018	aml_ohsu_2018_2607	aml_ohsu_2018_16-00292	73	73	90	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.44	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R326P; MAF 50%	Yes	3	Intermediate-I	Favorable	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	25.9	8.2	NA	NA	Unknown	NA	46,XX[20]	0	NA	NA	NA	False	No	No	90.6	3	Standard Chemotherapy	No	8	False	Positive	NA	AMLNPM1	0.13	DECEASED	2.9	18	36	0	98.4	0	0	0.8	0	0.8	0.1	19	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	7.7	NA	Standard Chemotherapy	Standard Chemotherapy	122.89	Yes
aml_ohsu_2018	aml_ohsu_2018_2547	aml_ohsu_2018_16-00294	67	67	1	NA	Leukemia	AML, NOS	NA	No	NA	6	Yes	NA	3+7 (Cytarabine, Daunorubicin)	1	Unknown	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Unknown	The translocations normally seen in AML are not detected.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	NA	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	Yes	6	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	NA	NA	266	WES	No	NA	No	No	Yes	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	No increased or immunophenotypically abnormal blast cell populations identified.	NA	NA	Standard Chemotherapy	NA	3.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2611	aml_ohsu_2018_16-00303	56	56	1.5	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	5	Yes	1.87	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation | Salvage | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy | Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2644C>T; p.R882C	Yes	27	Intermediate-I	Favorable	HispNative	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	29	9.5	Negative	Negative	Complete Response	Negative	46,XX[19]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	5	False	Positive	Negative	AMLNPM1	10.63	DECEASED	3	67	33	0	2	0	NA	23	57	13	NA	28	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	7.5	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	58.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2612	aml_ohsu_2018_16-00307	71	71	75	NA	Leukemia	AML, NOS	Alive	No	Negative	6	No	1.26	NA	0	NA	0	NA	0	NONE	NONE	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Intermediate-II	Adverse	White	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	22.9	7.7	p.R132C; MAF 45%	NA	NA	NA	46,XY,del(7)(q32),add(13)(p11.2)[15]	0	NA	NA	NA	False	No	No	81.8	NA	NONE	Yes	19	False	Negative	NA	AMLNOS	13.22	LIVING	3.8	118	53	NA	26	2	NA	15	8	43	NA	24	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are positive for CD34, CD117, HLADR, CD33 and CD13	8.7	NA	NA	NA	5	Yes
aml_ohsu_2018	aml_ohsu_2018_1973	aml_ohsu_2018_16-00315	70	72	NA	NA	Leukemia	AML with Minimal Differentiation	Alive	No	NA	1	Yes	0.8	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	27.9	9.1	NA	NA	Refractory	NA	47,XY,+4[2]/46,XY[18]	-142	NA	NA	NA	False	No	No	87.7	-1	Supportive/Palliative Care	No	4	False	Negative	NA	AMLMD	17.2	LIVING	3.1	79	38	0	NA	0	0	15.5	6.9	5.2	0	44	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Male	Matched	AML with minimal differentiation	AML with minimal differentiation	NA	6.3	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	50.58	Yes
aml_ohsu_2018	aml_ohsu_2018_2615	aml_ohsu_2018_16-00316	72	73	20	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	HispNative	Yes	No	NA	Negative	NA	Unknown	Residual Disease	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	4	True	Negative	NA	AML	NA	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	unknown	unknown	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2621	aml_ohsu_2018_16-00332	72	73	NA	NA	Myelodysplastic Syndromes	MDS, Unclassifiable	Dead-Unknown	No	NA	6	Yes	1.83	Vidaza	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Vidaza	Supportive/Palliative Care	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	Yes	NA	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	Unknown	Residual Disease	25	8.2	NA	NA	NA	NA	NA	0	NA	p.Q61P, MAF 13%	NA	True	No	No	105.9	268	Standard Chemotherapy	No	8	False	Negative	NA	MDSU	9.61	DECEASED	2.5	13	57	NA	4	1	NA	13	5	23	NA	32	WES + RNA-seq	No	Lung Cancer	Yes	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	Myelodysplastic syndrome, unclassifiable	Myelodysplastic syndrome, unclassifiable	NA	5.8	NA	Standard Chemotherapy	NA	66.7	Yes
aml_ohsu_2018	aml_ohsu_2018_2626	aml_ohsu_2018_16-00339	70	70	13	NA	Myelodysplastic/Myeloproliferative Neoplasms	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	Alive	No	NA	1	No	0.95	Hydroxyurea	1	Induction	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	Induction	Normal	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	NA	Yes	-1	NA	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Unknown	29.1	8.9	NA	NA	Unknown	NA	46,XX[20]	0	NA	NA	953	True	No	No	105.1	-1	Targeted Therapy - Kinase Inhibitor(s)	No	10	False	Negative	NA	ACML	0.03	LIVING	2.9	24	36	1.6	6.8	0.8	0	5.7	2.5	72.1	5.7	208	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	6.7	NA	Targeted Therapy - Kinase Inhibitor(s)	Targeted Therapy - Kinase Inhibitor(s)	109.77	Yes
aml_ohsu_2018	aml_ohsu_2018_2628	aml_ohsu_2018_16-00344	59	59	30	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.01	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 40%	Yes	7	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.4	8.9	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	479	False	No	No	96.4	96	Standard Chemotherapy	No	17	False	Positive	NA	AMLNPM1	6.18	LIVING	3.4	77	27	0	10.5	0	0	19.7	0.9	71.4	0	101	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	CD13, CD33, CD117, CD123, and HLA-DR	6.4	NA	Standard Chemotherapy	Standard Chemotherapy	4.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2630	aml_ohsu_2018_16-00351	46	46	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	p.T98fs*10 ; MAF 40%	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Favorable	Favorable	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	-3	NA	NA	NA	False	No	No	NA	120	Standard Chemotherapy	No	18	False	Negative	NA	AMLCEBPA	6.32	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2632	aml_ohsu_2018_16-00354	79	79	86	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	NA	3	No	NA	NA	0	NA	0	NA	0	NONE	NONE	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]	-1	NA	NA	NA	False	No	No	NA	NA	NONE	No	3	False	Negative	NA	AMLMRC	NA	NA	NA	NA	NA	NA	87	NA	NA	NA	NA	NA	NA	27	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	p.?; MAF 91%	NA	NA	70.01	Yes
aml_ohsu_2018	aml_ohsu_2018_2633	aml_ohsu_2018_16-00356	59	59	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	6	Yes	0.79	Lenalidomide|3+7 (Cytarabine, Daunorubicin)	2	Unknown | Supportive/Palliative Care	2	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	HispNative	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	21.6	7.3	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	Yes	85	-1	Standard Chemotherapy	No	2	False	Negative	p.Q61H, MAF 21%	AMLMRC	6.81	DECEASED	3.2	135	44	NA	1	9	NA	1	6	58	NA	22	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	5.9	NA	Standard Chemotherapy	NA	9.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2530	aml_ohsu_2018_16-00358	73	73	5	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	6	Yes	NA	Ruxolitinib	1	Induction	1	Standard Chemotherapy	1	Ruxolitinib	Induction	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	28	Favorable	Favorable	White	No	Yes	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XX[20]	1	NA	NA	NA	False	No	No	NA	28	Standard Chemotherapy	Yes	NA	False	Positive	NA	AMLNPM1	18.42	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	1	NA	NA	24	RNA-seq	No	Breast Cancer	No	No	Yes	Yes	Yes	3	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD34 positive blasts are rare, <1%	NA	NA	Standard Chemotherapy	Standard Chemotherapy	1.8	No
aml_ohsu_2018	aml_ohsu_2018_2546	aml_ohsu_2018_16-00359	67	67	2	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	6	Yes	NA	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy	1	Decitabine	Salvage	Trisomy 8 is detected in 28% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Not Enough Information	Adverse	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	-55	NA	NA	NA	False	No	Yes	NA	106	Standard Chemotherapy	No	9	False	Negative	NA	AMLMRC	3.68	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	1	NA	NA	47	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive for CD34, CD117, CD13, HLA-DR, CD33 and CD38	NA	NA	Standard Chemotherapy	Standard Chemotherapy	2.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2640	aml_ohsu_2018_16-00366	50	50	63	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.N321D; MAF 20%	1	Yes	0.95	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 20%	Yes	13	Favorable	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	30.2	9.8	p.R132C; MAF 20%	NA	Refractory	NA	46,XX[20]	0	NA	NA	NA	False	No	No	92.1	-1	Bone Marrow Transplant	No	11	False	Negative	NA	AMLCEBPA	5.49	LIVING	3.2	26	9	0.8	12	0.8	0	80.9	1.7	7.5	0	94	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD13, dimCD33, CD34, CD38, CD117, dimCD123, dim HLA-DR, and dim MPO positive.	6.2	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.13	Yes
aml_ohsu_2018	aml_ohsu_2018_2653	aml_ohsu_2018_16-00373	37	37	1	NA	Leukemia	Myeloid Sarcoma	Alive	No	NA	1	Yes	0.93	7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Supportive/Palliative Care	4	Standard Chemotherapy | Bone Marrow Transplant | Other	3	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	24	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	39.2	14.4	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	154	False	No	No	94.9	-1	Bone Marrow Transplant	No	4	False	Negative	NA	MS	15.59	LIVING	4.2	34	20	1.1	0	2.8	0.2	30.3	5.2	60.4	0	162	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Myeloid sarcoma	Myeloid sarcoma	dim/partial CD1a, dimCD4, dimCD5, CD33, CD43, dimCD45, CD56, CD68, CD117, and lysozyme positive with Ki67 activity >90%.	7.5	NA	Standard Chemotherapy|Bone Marrow Transplant|Other	Standard Chemotherapy	5.35	Yes
aml_ohsu_2018	aml_ohsu_2018_2654	aml_ohsu_2018_16-00374	64	64	1	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	6	Yes	NA	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	5	Symptom Control | Supportive/Palliative Care	2	Supportive/Palliative Care | Other	2	Paclitaxel	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	NA	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	274	Supportive/Palliative Care	No	8	False	Negative	NA	TMN	14.74	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	100	WES	No	Endometrial cancer	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Granulocytes are significantly decreased	NA	NA	Supportive/Palliative Care|Other	NA	4.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2664	aml_ohsu_2018_16-00392	78	78	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	0.41	Ruxolitinib|Hydroxyurea|Decitabine	3	Consolidation | Experimental	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Ruxolitinib	Experimental	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	M7	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.2	8.2	NA	NA	NA	NA	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	-1	NA	NA	1024	False	No	No	89.4	7	Targeted Therapy - Kinase Inhibitor(s)	Yes	10	False	Negative	NA	AMLMRC	0.79	DECEASED	2	27	39	0	NA	0	1.6	43.7	9.4	29.7	5.5	17	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	5.5	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	NA	6.28	Yes
aml_ohsu_2018	aml_ohsu_2018_2665	aml_ohsu_2018_16-00400	65	66	50	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	0.9	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	29.8	10.3	NA	NA	UNKNOWN	NA	41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7]	0	NA	NA	2840	False	No	No	85.4	-1	Standard Chemotherapy	No	12	False	Negative	NA	AMLMRC	4.61	LIVING	3.4	39	27	4.5	33	0	0	47.3	8.9	6.3	3.7	29	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	dimCD7, CD13, CD33, CD34, partial CD56, CD117, dimCD123	7.1	p.R248W; MAF 57%	Standard Chemotherapy	Standard Chemotherapy	3.49	Yes
aml_ohsu_2018	aml_ohsu_2018_2675	aml_ohsu_2018_16-00406	75	75	23	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.55	Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction | Frontline | Re-induction	3	Standard Chemotherapy	1	Vidaza	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 41%	No	7	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	27.1	9.1	NA	NA	Complete Response	NA	46,XY[19]	0	NA	NA	178	False	No	No	88	-1	Standard Chemotherapy	No	19	False	Negative	NA	AMLNOS	4.97	LIVING	3.4	23	16	0	NA	1	NA	51	11.2	36.8	NA	28	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	6.4	NA	Standard Chemotherapy	Standard Chemotherapy	1	Yes
aml_ohsu_2018	aml_ohsu_2018_2678	aml_ohsu_2018_16-00410	62	62	90	NA	Leukemia	APL with PML-RARA	Alive	No	NA	1	Yes	1.12	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Favorable	White	Yes	Yes	M3	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	19.8	7	NA	NA	Complete Response	NA	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	0	NA	NA	519	False	No	No	85.7	-1	Standard Chemotherapy	No	4	False	Negative	NA	APLPMLRARA	10.53	LIVING	2.8	28	24	0	53	0.9	3.5	35.7	1.7	5.2	0.7	38	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	5.4	NA	Standard Chemotherapy	Standard Chemotherapy	9.87	Yes
aml_ohsu_2018	aml_ohsu_2018_2687	aml_ohsu_2018_16-00459	61	61	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.68	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Intermediate-I	Intermediate	HispNative	Yes	Yes	NA	Positive	NA	Unknown	Post-Chemotherapy|Residual Disease	25.4	8.2	NA	NA	Complete Response	NA	NA	0	NA	NA	1033	False	No	No	95.5	55	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	8.65	DECEASED	3.6	195	75	0	NA	0	0	30.8	10.3	0	0.3	49	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	6.7	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	73.28	Yes
aml_ohsu_2018	aml_ohsu_2018_2688	aml_ohsu_2018_16-00460	58	58	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage | Induction | Symptom Control	3	Standard Chemotherapy | Supportive/Palliative Care	2	Azacitidine	Symptom Control	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Trp297* (NM_175629.2); MAF 82.1%	No	10	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	p.Arg132Cys (NM_005896.3); MAF 39.1%	NA	Refractory	NA	[46,XY]	-3	NA	NA	NA	False	No	No	NA	-1	Supportive/Palliative Care	No	11	False	Negative	NA	AMLNOS	9.14	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	4.17	Yes
aml_ohsu_2018	aml_ohsu_2018_2690	aml_ohsu_2018_16-00465	12	12	70	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	1	Yes	0.64	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	4	Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	RUNX1T1 signal consistent with the trisomy 8 clone	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	0	Intermediate-II	Adverse	HispNative	Yes	Yes	M4	Positive	NA	None	Initial Acute Leukemia Diagnosis	14.3	4.6	NA	NA	Refractory	NA	47,XY,+8[19]/46,XY[1]	1	NA	NA	NA	False	No	No	132.4	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AML	7.66	LIVING	3.7	28	150	0	85	0	1.8	14.7	51.4	8.3	50	49	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Leukapheresis	Denovo	Male	Unmatched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	7.1	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Intrathecal	214.49	Yes
aml_ohsu_2018	aml_ohsu_2018_2685	aml_ohsu_2018_16-00466	59	59	30	NA	Myeloproliferative Neoplasms	Primary Myelofibrosis	Dead-Disease	No	NA	1	Yes	NA	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q,	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic Syndromes	NA	Yes	153	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy	27.3	8.6	NA	NA	Refractory	NA	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	0	NA	NA	NA	False	No	Yes	97.2	56	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	NA	PMF	2.37	DECEASED	2.7	39	22	0	25	0.9	0	23.2	11.6	36.6	0	11	WES	No	Bladder Cancer	Yes	No	No	Yes	No	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Therapy-related myeloid neoplasms	Primary myelofibrosis	CD13, dim CD33, CD43, CD117	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	4.54	Yes
aml_ohsu_2018	aml_ohsu_2018_2694	aml_ohsu_2018_16-00474	50	50	70	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	6	Yes	0.66	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	20	Favorable	Favorable	Black	No	Yes	NA	Negative	NA	RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	26.6	8.7	NA	NA	Unknown	NA	46,XY,t(8;21)(q22;q22)[20]	-1	NA	NA	NA	False	No	No	94.7	182	Standard Chemotherapy	No	NA	False	Negative	NA	AMLRUNX1RUNX1T1	13.95	LIVING	2.4	23	25	NA	91	0	NA	7	2	0	NA	28	RNA-seq	No	NA	No	No	No	Yes	Yes	4	Peripheral Blood	Denovo	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NA	6.3	NA	Standard Chemotherapy	Standard Chemotherapy	71.1	No
aml_ohsu_2018	aml_ohsu_2018_2695	aml_ohsu_2018_16-00477	49	51	NA	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Alive	No	NA	1	Yes	NA	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	13	Favorable	Intermediate	Black	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Post-Transplant	30	10.3	NA	NA	Complete Response	NA	46,XY[20]	-55	NA	NA	NA	False	No	No	87.7	115	Supportive/Palliative Care	No	2	False	Negative	NA	AMOL	27.4	LIVING	2.8	44	29	0	NA	0	0	19.8	12.9	53.5	5.3	193	WES	No	NA	No	No	No	Yes	No	3	Peripheral Blood	NA	Male	Unmatched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	NA	6.8	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	4.53	Yes
aml_ohsu_2018	aml_ohsu_2018_2697	aml_ohsu_2018_16-00479	39	40	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	NA	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling | Salvage | Induction | Re-induction | Supportive/Palliative Care	5	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	30	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy|Post-Transplant	NA	NA	NA	NA	Refractory	NA	46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]	0	NA	NA	NA	False	No	Yes	NA	4	Standard Chemotherapy	No	2	False	Negative	NA	TMN	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Leiomyosarcoma	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Increased atypical CD34 positive, CD7 positive myeloblasts	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2699	aml_ohsu_2018_16-00481	60	61	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	IDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	CBFB-MYH11	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	UNKNOWN	NA	46,XX,inv(16)(p13q22)[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	2	False	Negative	NA	TMN	11.05	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	Adenocarcinoma	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Female	Unmatched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2612	aml_ohsu_2018_16-00483	71	71	33	NA	Leukemia	AML, NOS	Alive	No	NA	6	No	NA	NA	0	NA	0	NA	0	NONE	NONE	Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	NA	NA	46,XY,del(7)(q32),add(13)(p11.2)[20]	0	NA	NA	NA	False	No	No	NA	NA	NONE	Yes	20	False	Negative	NA	AMLNOS	13.22	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	8	NA	NA	22	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2701	aml_ohsu_2018_16-00484	NA	74	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN, Unclassifiable	NA	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	No	NA	NA	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Unknown	NA	NA	NA	NA	NA	NA	46,XX[20], normal female chromosome complement.	-2	NA	NA	NA	True	u	No	NA	NA	NONE	No	NA	False	Negative	NA	MDSMPNU	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	Yes	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2687	aml_ohsu_2018_16-00486	61	61	98	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.56	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.P777S; MAF 90%	No	7	Intermediate-I	Favorable or Intermediate	HispNative	Yes	No	NA	Positive	NA	None	Post-Chemotherapy|Residual Disease	32.9	11	p.R132H; MAF 45%;p.R132H; MAF 41%	NA	Complete Response	NA	46,XX[19]	0	NA	NA	NA	False	No	No	91.9	55	Targeted Therapy - Kinase Inhibitor(s)	No	3	False	Positive	NA	AMLNPM1	8.65	DECEASED	3.6	101	36	0	90	0	0	34.5	5.5	0	0	23	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	6.9	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	5.84	Yes
aml_ohsu_2018	aml_ohsu_2018_2704	aml_ohsu_2018_16-00491	29	29	98	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.69	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	27.2	9.4	NA	NA	Refractory	NA	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	-1	NA	NA	NA	False	No	No	105.4	2	Supportive/Palliative Care	No	2	False	Positive	NA	AMLNPM1	4.24	DECEASED	2.5	393	350	0	3.1	2	1	60	13	24	1.7	18	WES + RNA-seq	No	Basal Cell Carcinoma	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	5.4	NA	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	2.42	Yes
aml_ohsu_2018	aml_ohsu_2018_2705	aml_ohsu_2018_16-00494	72	72	90	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	0.93	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	4	Salvage | Induction | Re-induction	3	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.E283*; MAF 30%	Yes	6	Adverse	Adverse	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	37.1	11.9	NA	NA	Refractory	NA	46,XX,t(1;11)(p32;q23)[20]	0	NA	NA	NA	False	No	No	96.6	5	Standard Chemotherapy	No	4	False	Negative	NA	TMN	4.87	DECEASED	2.8	NA	NA	0	94	1.9	0	4.6	89.8	3.7	0.2	33	WES + RNA-seq	No	Non-Hodgkins Lymphoma	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive	NA	NA	Standard Chemotherapy	Standard Chemotherapy	104.44	Yes
aml_ohsu_2018	aml_ohsu_2018_2706	aml_ohsu_2018_16-00498	33	33	NA	NA	Leukemia	APL with PML-RARA	Alive	No	NA	3	Yes	NA	ATRA, Arsenic Trioxide	1	Consolidation | Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Favorable	White	Yes	Yes	NA	Positive	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	1	False	Negative	NA	APLPMLRARA	15.39	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	26	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	12.75	Yes
aml_ohsu_2018	aml_ohsu_2018_2708	aml_ohsu_2018_16-00504	60	60	2	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	2	Yes	0.99	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation | Salvage | Induction | Experimental	4	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221	Experimental	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Favorable	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	33.5	11.4	Negative	Negative	Complete Response	NA	46,XX[20]	0	NA	NA	NA	False	No	No	95.4	-1	Targeted Therapy - Other	No	NA	False	Positive	NA	TMN	8.52	DECEASED	4.4	27	NA	2	0	1	NA	12	12	71	NA	219	WES + RNA-seq	No	Breast Cancer	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.	7.1	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	5.54	Yes
aml_ohsu_2018	aml_ohsu_2018_2712	aml_ohsu_2018_16-00510	34	34	60	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Dead-Disease	No	NA	1	Yes	1	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	5	Induction | Experimental | Re-induction	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	anti-CD33	Experimental	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the me	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	NA	GATA2-MECOM	Initial Acute Leukemia Diagnosis	35.6	11.7	NA	NA	Refractory	NA	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	0	NA	NA	424	False	No	No	96	-1	Targeted Therapy - Kinase Inhibitor(s)	No	12	False	Negative	p.Q61H; MAF 45%	AMLRGA	9.57	DECEASED	3.9	117	61	0	28.9	0	2.1	44.3	8.2	16.5	5.5	916	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	7.7	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	6.13	Yes
aml_ohsu_2018	aml_ohsu_2018_2713	aml_ohsu_2018_16-00519	47	47	NA	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	p.R35fs*125; MAF 50%	1	Yes	1.08	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	42.6	15	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	353	False	No	No	86.8	-1	Bone Marrow Transplant	No	7	False	Negative	NA	AMLCEBPA	12.53	LIVING	3.5	49	21	0	72.9	0	0	20.3	3.4	3.4	6.9	34	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	8.98	Yes
aml_ohsu_2018	aml_ohsu_2018_2714	aml_ohsu_2018_16-00524	34	34	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	1	Yes	0.71	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	30.6	10.6	Negative	Negative	Complete Response i	Negative	46,XX,inv(16)(p13,1q22)[17]/46,XX[3]	-20	Negative	Negative	310	False	No	No	104.4	-1	Standard Chemotherapy	No	NA	False	Negative	p.G12D; MAF 6%	AMLCBFBMYH11	6.64	LIVING	3.4	41	22	1	NA	0	0	72.2	0.9	3.7	0	148	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	7.6	Negative	Standard Chemotherapy	Standard Chemotherapy	3.21	Yes
aml_ohsu_2018	aml_ohsu_2018_2715	aml_ohsu_2018_16-00525	26	26	95	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	0.69	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Adverse	Adverse	Asian	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	22.3	7.4	NA	NA	Refractory	NA	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]	0	NA	NA	NA	False	No	No	97.8	-1	Bone Marrow Transplant	No	15	False	Negative	NA	AMLMRC	11.58	LIVING	3.1	32	58	0	40.2	0	0	45.5	9.8	4.5	0.2	154	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	5.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	9.27	Yes
aml_ohsu_2018	aml_ohsu_2018_2685	aml_ohsu_2018_16-00533	59	59	70	NA	Myeloproliferative Neoplasms	Primary Myelofibrosis	Dead-Disease	No	NA	1	Yes	1.62	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic Syndromes	NA	Yes	153	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Post-Transplant|Residual Disease	20.4	6.8	NA	NA	Refractory	NA	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	-21	NA	NA	1805	False	No	Yes	91.5	56	Targeted Therapy - Kinase Inhibitor(s)	No	1	False	Negative	NA	PMF	2.37	DECEASED	2.5	16	43	0.9	50	0.9	0	22.8	2.6	36.8	0.2	8	WES	No	Bladder Cancer	Yes	No	No	Yes	No	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Therapy-related myeloid neoplasms	Primary myelofibrosis	CD13, dim CD33, partial CD34, dim CD117	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	8.35	Yes
aml_ohsu_2018	aml_ohsu_2018_2694	aml_ohsu_2018_16-00538	50	50	8	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	6	Yes	0.51	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	20	Favorable	Favorable	Black	Yes	Yes	NA	Negative	NA	RUNX1-RUNX1T1	Residual Disease	22.8	7.5	NA	NA	Unknown	NA	46,XY,t(8;21)(q22;q22)[20]	-22	NA	NA	NA	False	No	No	88.7	182	Standard Chemotherapy	No	2	False	Negative	NA	AMLRUNX1RUNX1T1	13.95	LIVING	2.3	19	9	NA	0	0	NA	12	29	54	NA	224	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	4	Peripheral Blood	NA	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NA	5.1	NA	Standard Chemotherapy	Standard Chemotherapy	6.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2721	aml_ohsu_2018_16-00540	66	66	NA	NA	Leukemia	AML, NOS	NA	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-II	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	UNKNOWN	NA	47,XX,+8[18]	0	NA	NA	NA	False	No	No	NA	6	Standard Chemotherapy	No	2	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	16	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	129.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2720	aml_ohsu_2018_16-00541	63	63	NA	NA	Mature B-Cell Neoplasms	Plasma Cell Myeloma	Alive	No	NA	1	Yes	0.99	CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide)	2	Induction | Re-induction	2	Standard Chemotherapy	1	RVD (Bortezomib, Dexamethasone, Lenalidomide)	Re-induction	Abnormal	Mature B-Cell Neoplasms	Mature B-Cell Neoplasms	NA	No	16	NA	Adverse	White	No	Yes	NA	Negative	NA	None	Unknown	22	7	NA	NA	Unknown	NA	44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7]	0	NA	NA	249	False	No	No	102.8	-1	Standard Chemotherapy	No	NA	True	Negative	NA	PCM	NA	LIVING	2.6	22	24	0	NA	0	0.9	28.7	8.3	60.2	0.6	69	WES + RNA-seq	No	NA	No	No	No	Yes	No	1	Peripheral Blood	NA	Female	Matched	Plasma cell myeloma	Plasma cell myeloma	NA	4.9	NA	Standard Chemotherapy	Standard Chemotherapy	7.14	Yes
aml_ohsu_2018	aml_ohsu_2018_2723	aml_ohsu_2018_16-00547	29	29	82	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	NA	1	Yes	0.84	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction | Re-induction	2	Standard Chemotherapy	1	HiDAC	Re-induction	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	19	Intermediate-II	Adverse	HispNative	Yes	Yes	NA	Negative	NA	MLLT3-KMT2A	Initial Acute Leukemia Diagnosis	27.3	9.1	NA	NA	Complete Response	NA	46,XY,t(9;11)(p22;q23)[20]	0	NA	NA	324	False	No	No	89.5	4	Standard Chemotherapy	No	5	False	Negative	NA	TMN	2.14	DECEASED	3.1	40	19	0.9	20	0	2.6	26.3	33.4	7.9	3.6	52	WES + RNA-seq	No	Non-Hodgkins Lymphoma	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	6.7	NA	Standard Chemotherapy	Standard Chemotherapy	3.88	Yes
aml_ohsu_2018	aml_ohsu_2018_2119	aml_ohsu_2018_16-00548	76	77	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation | Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal change	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	35	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Relapse	24.2	8.6	NA	NA	Complete Response	NA	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	6	NA	NA	261	False	No	No	102.5	77	Standard Chemotherapy	No	14	False	Negative	NA	AMLMRC	17.11	DECEASED	3.2	19	19	0	NA	0.9	NA	60.3	38.5	0.3	NA	7	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	Relapse	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	3.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2739	aml_ohsu_2018_16-00562	66	67	5	p.G469A, MAF 7%	Myeloproliferative Neoplasms	Primary Myelofibrosis	Alive	No	NA	6	Yes	NA	Hydroxyurea	1	Unknown	1	Standard Chemotherapy	1	Hydroxyurea	Unknown	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	Yes	NA	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease	NA	NA	NA	NA	NA	NA	46,XY[17]	0	NA	NA	NA	True	No	No	NA	263	Standard Chemotherapy	No	9	False	Negative	p.G12S, MAF 18%	PMF	6.22	LIVING	NA	NA	NA	NA	5	NA	NA	NA	1	NA	NA	37	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Matched	Primary myelofibrosis	Primary myelofibrosis	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZ	NA	NA	Standard Chemotherapy	NA	239	Yes
aml_ohsu_2018	aml_ohsu_2018_2740	aml_ohsu_2018_16-00564	81	81	5	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Alive	No	NA	6	Yes	NA	Radiation	1	Unknown	1	Other	1	Radiation	Unknown	9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with T	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Unknown	NA	NA	NA	NA	NA	NA	45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]	0	NA	NA	NA	True	No	No	NA	22	Other	No	11	False	Negative	NA	CMML	NA	LIVING	NA	NA	NA	NA	0	NA	NA	NA	2	NA	NA	30	WES	Yes	Rectal Cancer	No	Yes	No	Yes	No	1	Bone Marrow Aspirate	NA	Female	Matched	Chronic myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significanc	NA	NA	Other	NA	35.1	Yes
aml_ohsu_2018	aml_ohsu_2018_2741	aml_ohsu_2018_16-00566	39	40	41	NA	Leukemia	AML with Mutated NPM1	NA	No	Negative	5	Yes	0.83	GCLAC (GCSF, Clofarabine & Cytarabine)	1	Re-induction	1	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Negative	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Positive	Negative	None	Post-Chemotherapy|Residual Disease	29.4	10.2	Negative	Negative	NA	Negative	46,XY[15]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	4	False	Positive	Negative	AMLNPM1	NA	NA	3.6	12	17	0	14	0	NA	5	5	76	NA	24	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Positive	5.9	Negative	Standard Chemotherapy	NA	3.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2483	aml_ohsu_2018_16-00593	46	46	NA	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Disease	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	7	Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	1	Not Enough Information	Intermediate	Asian	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Chemotherapy	36.3	11.7	NA	NA	Refractory	NA	46,XX[19]	-11	NA	NA	NA	False	No	No	94.3	-1	Bone Marrow Transplant	No	30	False	Negative	p.G13R;MAF 47%	TMN	20.95	DECEASED	3.9	38	27	2.6	NA	0.6	NA	16.2	14	66.6	NA	71	WES	No	Anaplastic Astrocytoma	No	No	No	No	No	2	Peripheral Blood	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	NA	6.9	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	6.8	Yes
aml_ohsu_2018	aml_ohsu_2018_2754	aml_ohsu_2018_16-00595	58	58	60	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction | Re-induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Refractory	NA	44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2]	-1	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	Yes	2	False	Negative	NA	AMLMRC	2.07	DECEASED	NA	NA	NA	NA	25	NA	NA	NA	NA	NA	NA	75	WES	No	NA	No	No	Yes	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML	NA	NA	Standard Chemotherapy	Standard Chemotherapy	6.69	Yes
aml_ohsu_2018	aml_ohsu_2018_2760	aml_ohsu_2018_16-00599	68	68	70	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	NA	Vidaza|Fludarabine, Melphalan|HiDAC	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	22	Intermediate-I	Intermediate	White	Yes	No	NA	Positive	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	18	False	Negative	NA	AMLNOS	9.21	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	1	NA	NA	66	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	These are positive for CD34, CD117, HLADR, CD33, and CD13.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	3.5	Yes
aml_ohsu_2018	aml_ohsu_2018_2695	aml_ohsu_2018_16-00611	49	51	NA	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Alive	No	NA	1	Yes	NA	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	13	Not Enough Information	Favorable	Black	Yes	Yes	NA	Negative	NA	None	Residual Disease|Post-Transplant|Post-Chemotherapy	29.9	10.8	NA	NA	Complete Response	NA	46,XY[19]	-32	NA	NA	NA	False	No	No	85.4	115	Supportive/Palliative Care	No	6	False	Positive	NA	AMOL	27.4	LIVING	3.5	91	102	0	NA	0	0	4.2	1.7	6.8	0.6	31	WES	No	NA	No	No	No	Yes	No	3	Peripheral Blood	NA	Male	Unmatched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	NA	6.9	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	162.21	Yes
aml_ohsu_2018	aml_ohsu_2018_2780	aml_ohsu_2018_16-00618	64	65	35	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	Negative	5	Yes	NA	FLX925|7+3 (Cytarabine, Idarubicin)	2	Induction | Experimental	2	Standard Chemotherapy | Targeted Therapy - Other	2	FLX925	Experimental	MLL Rearrangment	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Intermediate-II	Intermediate	HispNative	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	20.4	6.6	Negative	Negative	Complete Response	Negative	46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]	0	Negative	Negative	369	False	No	No	NA	-1	Targeted Therapy - Other	No	18	False	Negative	Negative	AMLMRC	12.66	DECEASED	2.7	11	23	0	40	0	NA	30	14	12	NA	35	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Negative	5.9	Negative	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	42.9	Yes
aml_ohsu_2018	aml_ohsu_2018_2785	aml_ohsu_2018_16-00627	67	66	17	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	NA	No	NA	7	Yes	NA	Cytarabine|Decitabine	2	Induction | Supportive/Palliative Care	2	Standard Chemotherapy	1	Cytarabine	Induction	Trisomy 8	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	Unknown	Residual Disease	NA	NA	NA	NA	UNKNOWN	NA	NA	0	NA	NA	NA	True	No	No	NA	-1	Standard Chemotherapy	Yes	26	False	Negative	NA	CMML	NA	NA	NA	NA	NA	NA	7	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Chronic myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2786	aml_ohsu_2018_16-00632	59	59	NA	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Arg882His	No	NA	Not Enough Information	Favorable or Intermediate	White	Yes	No	NA	Positive	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	5	False	Positive	NA	AMLNPM1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2204	aml_ohsu_2018_16-00684	2	3	53.74	NA	Leukemia	AML without Maturation	Alive	No	NA	1	Yes	0.31	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	136	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Relapse|Post-Chemotherapy	30	10.5	NA	NA	Complete Response	NA	46,XX,t(6;11)(q27;q23)[12]/46,XX[8]	0	NA	NA	276	False	No	No	87	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AWM	14.08	LIVING	4.2	23	24	0	50	1.7	0	68	5.5	24.8	0	166	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML without maturation	AML without maturation	CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive	7	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	Standard Chemotherapy	1.81	Yes
aml_ohsu_2018	aml_ohsu_2018_3975	aml_ohsu_2018_16-00699	46	46	92	NA	Leukemia	AML, NOS	Dead-Treatment	No	NA	2	Yes	1.13	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	HispNative	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	18.4	6.2	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	113.6	6	Standard Chemotherapy	No	8	False	Negative	NA	AMLNOS	0.3	DECEASED	2.8	NA	NA	NA	75	NA	NA	5	19	1	NA	31	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(	NA	NA	Standard Chemotherapy	Standard Chemotherapy	151.6	Yes
aml_ohsu_2018	aml_ohsu_2018_2747	aml_ohsu_2018_16-00701	62	62	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Alive	No	NA	6	Yes	1.03	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	The abnormalities normally seen in MDS are not detected.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	38.2	12.4	NA	NA	NA	NA	46, XY [20]	-34	NA	NA	NA	False	No	No	91	-1	Bone Marrow Transplant	No	6	False	Negative	NA	CMML	8.42	LIVING	4.7	37	29	NA	1	0	NA	22	28	42	NA	237	WES	No	NA	No	Yes	No	Yes	No	3	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	NA	7.8	NA	Standard Chemotherapy|Bone Marrow Transplant	NA	16.4	Yes
aml_ohsu_2018	aml_ohsu_2018_3976	aml_ohsu_2018_16-00702	77	79	NA	NA	Leukemia	AML with Mutated NPM1	NA	No	NA	7	Yes	NA	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Favorable or Intermediate	White	Yes	Yes	NA	Positive	NA	Unknown	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	1	False	Positive	NA	AMLNPM1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_3978	aml_ohsu_2018_16-00705	59	64	59.5	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Relapse	25.2	8.3	NA	NA	Complete Response	NA	47,XY,+13[2]/94,slx2[2]/46,XY[19]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	12	False	Negative	NA	AMLMRC	60	DECEASED	4.1	37	22	0	12	0	NA	55	3	29	NA	46	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Negative	6.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_3979	aml_ohsu_2018_16-00708	70	71	44	NA	Leukemia	AML with Myelodysplasia-Related Changes	NA	No	NA	2	Yes	0.91	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Foundation; R882H; MAFs: 44%	Yes	NA	Intermediate-II	Adverse	HispNative	Yes	Yes	NA	Positive	Negative	None	Post-Chemotherapy|Residual Disease	21.6	7.1	Negative	Negative	NA	NA	47,XY,+21[19]/46,XY[1]	0	NA	NA	91	False	No	No	NA	98	Standard Chemotherapy	No	8	False	Negative	NA	AMLMRC	NA	NA	3.7	41	18	0	31	2	NA	46	0	14	NA	35	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly	7.7	NA	Standard Chemotherapy	NA	5.05	Yes
aml_ohsu_2018	aml_ohsu_2018_3980	aml_ohsu_2018_16-00709	71	71	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	2	False	Positive	NA	AMLNPM1	NA	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	Pyoderma Gangrenosum	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Relative increase in CD117pos,CD34neg myeloid blasts, representing 16% of total leukocytes, most consistent with myeloid neoplasm such as advanced MDS or AML.	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2694	aml_ohsu_2018_16-00710	50	50	0	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	6	Yes	NA	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	RUNX1/RUNX1T1 fusion negative	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	20	Favorable	Intermediate	Black	Yes	Yes	NA	Negative	NA	RUNX1-RUNX1T1	Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	182	Standard Chemotherapy	No	10	False	Negative	NA	AMLRUNX1RUNX1T1	13.95	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	126	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	4	Bone Marrow Aspirate	NA	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	No morphological evidence of acute leukemia	NA	NA	Standard Chemotherapy	Standard Chemotherapy	7.7	Yes
aml_ohsu_2018	aml_ohsu_2018_3986	aml_ohsu_2018_16-00724	62	62	34	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	Yes	0.5	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	3	Standard Chemotherapy | Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	32.4	10.7	Negative	Negative	Refractory	NA	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11	0	NA	NA	304	False	No	Yes	NA	-1	Supportive/Palliative Care	No	20	False	Negative	NA	AMLMRC	6.51	DECEASED	2.6	13	11	0.8	3.3	1.6	NA	14.9	5	68.6	NA	36	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).	5.3	R213fs; MAF 34%	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	8.35	Yes
aml_ohsu_2018	aml_ohsu_2018_3990	aml_ohsu_2018_16-00731	69	69	40	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	0.64	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	7	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	3	ALRN-6924	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-I	Adverse	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	23.5	7.1	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	399	False	No	No	103.5	-1	Targeted Therapy - Other	No	5	False	Negative	NA	AMLNOS	14.54	LIVING	3.4	27	22	1.8	42.1	0.9	8.8	10.5	9.6	26.3	2.8	12	WES + RNA-seq	No	Breast Cancer	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	6.5	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	Standard Chemotherapy	61.22	Yes
aml_ohsu_2018	aml_ohsu_2018_2119	aml_ohsu_2018_16-00733	76	77	54	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	1	Yes	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation | Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	35	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	25.4	8.6	NA	NA	Complete Response	NA	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	0	NA	NA	NA	False	No	No	92	77	Standard Chemotherapy	No	18	False	Negative	NA	AMLMRC	17.11	DECEASED	3.2	20	23	0	13	6.9	NA	51.6	39.6	1.9	NA	22	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant a	7.2	NA	Standard Chemotherapy	Standard Chemotherapy	4.5	Yes
aml_ohsu_2018	aml_ohsu_2018_4001	aml_ohsu_2018_16-00755	58	58	21	NA	Leukemia	AML with Recurrent Genetic Abnormalities	Alive	No	NA	1	Yes	NA	SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	2	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Abnormal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	70	Adverse	Adverse	White	Yes	No	NA	Negative	NA	GATA2-MECOM	Initial Acute Leukemia Diagnosis	35.1	11	NA	NA	Complete Response	NA	46,XX,t(3;3)(q21;q26)[20]	0	NA	NA	NA	False	No	No	107	0	Bone Marrow Transplant	No	13	False	Negative	p.G12D; MAF 47%	AMLRGA	5.16	LIVING	NA	NA	NA	0	0	0	2.3	41.7	25.9	30.1	0.1	360	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	13.83	Yes
aml_ohsu_2018	aml_ohsu_2018_2704	aml_ohsu_2018_16-00765	29	29	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	NA	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Transplant|Post-Chemotherapy|Relapse	NA	NA	NA	NA	Refractory	NA	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	-83	NA	p.G12V, Mutant Allele frequency: 76%	NA	False	No	No	NA	2	Supportive/Palliative Care	No	1	False	Positive	NA	AMLNPM1	4.24	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	Basal Cell Carcinoma	No	No	No	Yes	No	3	Peripheral Blood	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4006	aml_ohsu_2018_16-00766	81	81	33	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	No	1.07	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care	2	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	27.5	9.5	Negative	Negative	NA	NA	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	-32	NA	NA	333	False	No	Yes	NA	3	Supportive/Palliative Care	No	19	False	Negative	NA	AMLMRC	3.19	DECEASED	4.1	22	20	NA	8	4	NA	28	24	44	NA	28	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-)	6.6	Foundation; L206fs*41; MAFs: 31%	Supportive/Palliative Care	NA	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_4007	aml_ohsu_2018_16-00770	50	51	12	NA	Leukemia	AML without Maturation	Alive	No	NA	6	Yes	NA	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	4	Unknown | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	4	False	Negative	NA	AWM	18.26	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	17	NA	NA	16	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	AML without maturation	AML without maturation	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.5	Yes
aml_ohsu_2018	aml_ohsu_2018_4008	aml_ohsu_2018_16-00771	34	34	15	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Dead-Unknown	No	NA	6	Yes	NA	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown | Induction | Re-induction	3	Standard Chemotherapy | Intrathecal	2	Cytarabine	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C, MAF 51%	Yes	35	Not Enough Information	Adverse	HispNative	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	6	Intrathecal	No	5	False	Negative	p.G13R, MAF 48%	AMOL	5.16	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	12	NA	NA	426	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	NA	NA	p.R282Q, MAF 51%	Standard Chemotherapy|Intrathecal	Standard Chemotherapy	26.4	Yes
aml_ohsu_2018	aml_ohsu_2018_2654	aml_ohsu_2018_16-00783	64	64	0	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Alive	No	NA	6	Yes	NA	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	5	Symptom Control | Supportive/Palliative Care	2	Supportive/Palliative Care | Other	2	Paclitaxel	Supportive/Palliative Care	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	NA	NA	NA	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	274	Supportive/Palliative Care	No	4	False	Negative	NA	TMN	14.74	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	2	NA	NA	202	WES	No	Endometrial cancer	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	No increased or immunophenotypically abnormal nlast cell populations identified.	NA	NA	Supportive/Palliative Care|Other	NA	3.3	Yes
aml_ohsu_2018	aml_ohsu_2018_4028	aml_ohsu_2018_16-00810	61	61	83	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.87	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Favorable	Favorable	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	34.7	11.6	p.R132H; MAF 37%	NA	Complete Response	NA	46,XX[20]	0	NA	NA	337	False	No	No	95.6	-1	Bone Marrow Transplant	No	7	False	Positive	p.G13D; MAF 38%	AMLNPM1	6.22	LIVING	3	69	35	0	11.5	1.8	1.8	13.3	63.7	7.9	0.1	146	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	6.1	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	44.83	Yes
aml_ohsu_2018	aml_ohsu_2018_4030	aml_ohsu_2018_16-00815	60	60	75	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.19	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	5	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	18	Favorable	Favorable	White	Yes	Yes	M5	Negative	NA	None	Initial Acute Leukemia Diagnosis	26.4	8.8	NA	NA	Complete Response	NA	46,XX[20]	-1	NA	NA	222	False	No	No	96.4	-1	Bone Marrow Transplant	No	4	False	Positive	p.G12S; MAF 40%	AMLNPM1	6.48	LIVING	2.9	18	13	0	44	0	0.9	28.7	46.1	24.3	0	175	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	6.9	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	34.6	Yes
aml_ohsu_2018	aml_ohsu_2018_4029	aml_ohsu_2018_16-00818	65	65	NA	NA	Leukemia	AML with Recurrent Genetic Abnormalities	NA	No	NA	3	No	NA	NA	0	NA	0	NA	0	NONE	NONE	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Ala571Pro; MAF 51.5%	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	GATA2-MECOM	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]	-3	NA	NA	NA	False	No	No	NA	NA	NONE	Yes	2	False	Negative	NA	AMLRGA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4032	aml_ohsu_2018_16-00820	67	67	42.5	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	2.62	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	4	Allogeneic - Sibling | Induction | Re-induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 ch	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.G570E; MAF 44%	No	1932	Adverse	Adverse	White	Yes	No	NA	Negative	NA	None	Residual Disease	23.1	7.9	NA	NA	Refractory	NA	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]	0	NA	NA	NA	False	No	No	91.7	-1	Bone Marrow Transplant	Yes	16	False	Negative	NA	AMLMRC	5.89	LIVING	2	21	15	2.6	54	0.9	0	44.2	2.7	0.9	0	22	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Positive	5.3	p.K132R; MAF 45%	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.27	Yes
aml_ohsu_2018	aml_ohsu_2018_2747	aml_ohsu_2018_16-00822	62	62	9	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Alive	No	NA	6	Yes	NA	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	The abnormalities normally seen in MDS are not detected.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	NA	NA	NA	NA	NA	NA	46,XY[12]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	6	False	Negative	NA	CMML	8.42	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	7	NA	NA	NA	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	3	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent bl	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4038	aml_ohsu_2018_16-00831	73	77	95	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	No	1.1	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	6	Hypomethylating/Low Dose Cytarabine | Experimental | Supportive/Palliative Care	3	Supportive/Palliative Care | Targeted Therapy - Other	2	AG-221	Experimental	nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	Black	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	27.3	9.4	Negative	NA	NA	NA	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	0	NA	NA	453	False	No	No	NA	267	Targeted Therapy - Other	No	9	False	Negative	NA	AMLNOS	49.01	DECEASED	3.5	14	14	NA	48	1	NA	42	6	2	NA	23	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(par	6.5	NA	Supportive/Palliative Care|Targeted Therapy - Other	NA	3	Yes
aml_ohsu_2018	aml_ohsu_2018_4039	aml_ohsu_2018_16-00836	73	73	88	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.2	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 42%	Yes	167	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	33	11.2	NA	NA	Refractory	NA	46,XY[20]	0	NA	NA	NA	False	Yes	No	105.8	21	Standard Chemotherapy	No	7	False	Positive	NA	AMLNPM1	0.92	DECEASED	3	27	40	0	38	0	1.7	20.9	60.9	1.7	0.1	55	WES + RNA-seq	No	NA	No	Yes	No	Yes	Yes	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	Positive	7.5	NA	Standard Chemotherapy	Standard Chemotherapy	58.97	Yes
aml_ohsu_2018	aml_ohsu_2018_4043	aml_ohsu_2018_16-00846	25	26	NA	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	0.79	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Unknown | Induction	3	Standard Chemotherapy	1	Bu/Cy/ATG	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	79	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Post-Chemotherapy|Relapse	19.3	6.5	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	101	22	Standard Chemotherapy	No	1	False	Negative	NA	AMLNOS	14.61	LIVING	3.2	39	49	NA	14	8	NA	17	2	54	NA	33	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Relapse	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	4.9	NA	Standard Chemotherapy	Standard Chemotherapy	1.6	Yes
aml_ohsu_2018	aml_ohsu_2018_3990	aml_ohsu_2018_16-00852	69	69	3	NA	Leukemia	AML, NOS	Alive	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	7	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	3	ALRN-6924	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Post-Chemotherapy	31.1	9.9	NA	NA	Refractory	NA	46,XX[20]	-46	NA	NA	217	False	No	No	95.4	-1	Targeted Therapy - Other	No	2	False	Negative	NA	AMLNOS	14.54	LIVING	3.4	23	16	0.5	NA	0	NA	50	25.7	23.8	NA	201	WES	No	Breast Cancer	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	Positive	7.1	NA	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	Standard Chemotherapy	2.1	Yes
aml_ohsu_2018	aml_ohsu_2018_4042	aml_ohsu_2018_16-00867	61	61	93	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	0.78	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	8	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	21.1	7.1	NA	NA	Unknown	NA	46,XX[20]	-5	NA	NA	360	False	No	No	84.4	8	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	0.26	DECEASED	2.7	19	21	0	85	0.8	0	16.5	0.8	1.6	0.2	43	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	5.7	NA	Standard Chemotherapy	Standard Chemotherapy	30.54	Yes
aml_ohsu_2018	aml_ohsu_2018_4052	aml_ohsu_2018_16-00875	45	46	3	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation | Salvage | Induction | Re-induction	4	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	25	Adverse	Adverse	Black	Yes	No	NA	Negative	Negative	None	Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	0	NA	NA	NA	False	No	No	NA	23	Standard Chemotherapy	No	6	False	Negative	NA	AMLNOS	15.3	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	4	NA	NA	69	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	1.3	Yes
aml_ohsu_2018	aml_ohsu_2018_4055	aml_ohsu_2018_16-00880	55	55	40	NA	Leukemia	AML with Mutated NPM1	Alive	Yes	p.Ala40fs; MAF 20.3%	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Arg882His; MAF 39.1%	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	17	False	Positive	NA	AMLNPM1	5.89	LIVING	NA	NA	NA	NA	57	NA	NA	NA	NA	NA	NA	75	WES	No	Multiple Sclerosis	No	No	No	No	No	1	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	16.43	Yes
aml_ohsu_2018	aml_ohsu_2018_4006	aml_ohsu_2018_16-00882	81	81	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	2	No	1.26	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care	2	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	24.1	8.1	NA	NA	NA	NA	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	-73	NA	NA	853	False	No	Yes	98	3	Supportive/Palliative Care	No	20	False	Negative	NA	AMLMRC	3.19	DECEASED	4.1	25	33	0	70	0	NA	3	1	36	NA	74	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	2	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	negative	NA	NA	Supportive/Palliative Care	NA	39.12	Yes
aml_ohsu_2018	aml_ohsu_2018_2695	aml_ohsu_2018_16-00883	49	51	NA	NA	Leukemia	Acute Monoblastic/Monocytic Leukemia	Alive	No	NA	1	Yes	NA	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	6	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	Positive	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	13	Not Enough Information	Favorable	Black	Yes	Yes	NA	Negative	NA	None	Post-Transplant|Residual Disease|Post-Chemotherapy	26.2	8.9	NA	NA	Complete Response	NA	46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]	-22	NA	NA	NA	False	No	No	84.5	115	Supportive/Palliative Care	No	6	False	Positive	NA	AMOL	27.4	LIVING	3.1	30	26	0	NA	6.1	0	7.9	0	6.1	0.1	32	WES	No	NA	No	No	No	Yes	No	3	Peripheral Blood	NA	Male	Unmatched	Acute monoblastic and monocytic leukaemia	Acute monoblastic and monocytic leukaemia	NA	7	NA	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	39.25	Yes
aml_ohsu_2018	aml_ohsu_2018_2704	aml_ohsu_2018_16-00886	29	29	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.68	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	5	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease|Post-Transplant	28.2	9.7	NA	NA	Refractory	NA	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	-127	NA	NA	9928	False	No	No	90.4	2	Supportive/Palliative Care	No	4	False	Positive	NA	AMLNPM1	4.24	DECEASED	3.3	65	152	0	NA	0	0	0	79.2	1	0.2	43	WES	No	Basal Cell Carcinoma	No	No	No	Yes	No	3	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	6.3	NA	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	Standard Chemotherapy	12.98	Yes
aml_ohsu_2018	aml_ohsu_2018_4074	aml_ohsu_2018_16-00950	83	85	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	1	Yes	1.12	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	27.4	9.2	NA	NA	NA	NA	NA	0	NA	NA	394	False	No	No	88.4	-1	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	19.87	DECEASED	3.7	17	23	0	NA	0	0	21.2	1.5	0.8	2.3	46	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	8.7	NA	Standard Chemotherapy	NA	19.67	Yes
aml_ohsu_2018	aml_ohsu_2018_4075	aml_ohsu_2018_16-00951	42	42	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling | Consolidation | Salvage | Induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]	-3	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	NA	False	Negative	NA	AMLMRC	7.34	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4077	aml_ohsu_2018_16-00968	50	54	1	NA	Leukemia	AML, NOS	Alive	No	NA	2	Yes	0.71	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Intermediate-II	Intermediate	Black	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	31.2	9.8	Negative	NA	Complete Response	NA	46,X,t(X;2)(q22;p13)[20]	0	NA	NA	195	False	No	No	NA	58	Standard Chemotherapy	No	20	False	Negative	NA	AMLNOS	61.64	LIVING	4.2	65	45	0	NA	0	NA	62	22	16	NA	143	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	The findings reveal a small population of CD34(+) myeloblasts demonstrating immunophenotypic variation of unclear significance	6.7	NA	Standard Chemotherapy	Standard Chemotherapy	2.49	Yes
aml_ohsu_2018	aml_ohsu_2018_4078	aml_ohsu_2018_16-00970	52	52	26	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Other	No	NA	2	Yes	0.51	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Adverse	Adverse	Black	Yes	No	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	20.9	6.7	Negative	Negative	Unknown	NA	39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12]	0	NA	NA	249	False	No	No	NA	-1	Standard Chemotherapy	No	23	False	Negative	NA	AMLMRC	0.33	DECEASED	3	27	32	0	9.5	0	NA	50	0	40.5	NA	44	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD4(+), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(+), CD36(-/small subset +), CD38(partial +), CD45(+),CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), MPO(-), and TdT(-)	7.1	NA	Standard Chemotherapy	Standard Chemotherapy	1.04	Yes
aml_ohsu_2018	aml_ohsu_2018_4083	aml_ohsu_2018_16-00981	69	69	NA	NA	Leukemia	AML, NOS	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	18	False	Negative	NA	AMLNOS	8.39	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4195	aml_ohsu_2018_16-01004	70	70	85	NA	Leukemia	Acute Myeloid Leukemia	Alive	No	NA	2	Yes	0.62	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	3	Standard Chemotherapy	1	Vidaza	Hypomethylating/Low Dose Cytarabine	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	21.8	7	Negative	Negative	Complete Response	NA	NA	0	NA	NA	1195	False	No	No	NA	4	Standard Chemotherapy	No	NA	False	Negative	NA	AML	3.13	LIVING	2.8	12	32	0	77.8	0	NA	7.4	0	11.1	NA	103	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	NA	Male	Matched	Acute myelomonocytic leukaemia	Acute myelomonocytic leukaemia	NA	5.2	NA	Standard Chemotherapy	Standard Chemotherapy	25.85	Yes
aml_ohsu_2018	aml_ohsu_2018_4196	aml_ohsu_2018_16-01005	55	55	30	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	2	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Probe: 8 centromere/20q12	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	32.4	9.9	Negative	NA	Complete Response	Negative	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	12	False	Negative	Negative	AMLMRC	5.03	LIVING	4.3	10	11	1	0	0	NA	31	4	6.8	NA	83	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	Negative	7.2	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	10.6	Yes
aml_ohsu_2018	aml_ohsu_2018_4028	aml_ohsu_2018_16-01009	61	61	3.5	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	0.74	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy	32.7	10.8	NA	NA	Complete Response	NA	46,XX[19]	0	NA	NA	278	False	No	No	92.6	-1	Bone Marrow Transplant	No	7	False	Negative	NA	AMLNPM1	6.22	LIVING	3.7	27	12	0.7	0	0	0.7	16.5	5.7	76.4	0	295	WES	No	NA	No	No	No	No	No	2	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD34+ blasts comprise 1% of WBCs. Lymphocytes	7.4	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	4.05	Yes
aml_ohsu_2018	aml_ohsu_2018_4197	aml_ohsu_2018_16-01010	45	46	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	1.04	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Sunitinib	Consolidation	Positive	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	32	Not Enough Information	Favorable	White	Yes	Yes	NA	Positive	NA	Unknown	Residual Disease|Post-Chemotherapy	23.8	8.1	NA	NA	Complete Response	NA	NA	0	NA	NA	401	False	No	No	88.5	2	Standard Chemotherapy	No	13	False	Positive	NA	AMLNPM1	20.86	DECEASED	3.3	58	44	0	NA	0	0	20.4	0	66.7	1	14	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	7.3	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	6.18	Yes
aml_ohsu_2018	aml_ohsu_2018_4043	aml_ohsu_2018_16-01017	25	26	70	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	NA	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Unknown | Induction	3	Standard Chemotherapy	1	Bu/Cy/ATG	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	79	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	Complete Response	NA	46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]	0	NA	NA	NA	False	No	No	NA	22	Standard Chemotherapy	No	1	False	Negative	p.Q61K; MAF45%	AMLNOS	14.61	LIVING	NA	NA	NA	NA	8	NA	NA	NA	4	NA	NA	10	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR	NA	NA	Standard Chemotherapy	Standard Chemotherapy	30.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2739	aml_ohsu_2018_16-01018	66	67	5	NA	Myeloproliferative Neoplasms	Primary Myelofibrosis	Alive	No	NA	6	Yes	0.93	Hydroxyurea	1	Unknown	1	Standard Chemotherapy	1	Hydroxyurea	Unknown	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited	Myelodysplastic Syndromes	Myelodysplastic Syndromes	NA	No	NA	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Residual Disease	28.7	8.9	NA	NA	NA	NA	46,XY[17]	-119	NA	NA	NA	True	No	No	81.8	263	Standard Chemotherapy	No	11	False	Negative	NA	PMF	6.22	LIVING	NA	NA	NA	NA	0	0	NA	12	8	80	NA	88	WES	No	NA	Yes	No	No	No	No	2	Bone Marrow Aspirate	NA	Male	Matched	Primary myelofibrosis	Primary myelofibrosis	These are positive for CD34, CD117, HLADR, CD33 and CD13.	0	NA	Standard Chemotherapy	NA	5.6	Yes
aml_ohsu_2018	aml_ohsu_2018_4201	aml_ohsu_2018_16-01022	52	52	51.5	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	1.16	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	FLAG-IDA plus Midostaurin	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 45%	Yes	-1	Favorable	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	30.6	10.2	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	608	False	No	No	102.3	-1	Standard Chemotherapy	No	9	False	Positive	p.G12D; 17%	AMLNPM1	13.62	LIVING	3.6	52	25	0	0	0	0	13.2	79.8	4.4	0	45	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive	7	NA	Standard Chemotherapy	Standard Chemotherapy	116.57	Yes
aml_ohsu_2018	aml_ohsu_2018_4202	aml_ohsu_2018_16-01024	62	62	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	2	Yes	0.78	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Induction	2	Standard Chemotherapy | Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	5	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	7.2	Negative	Negative	Refractory	Negative	NA	0	NA	NA	183	False	No	No	NA	5	Supportive/Palliative Care	No	NA	False	Negative	NA	AMLMRC	4.9	DECEASED	3.8	17	14	0	7	0	NA	50.4	5.2	36.5	NA	32	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	7	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	2.18	Yes
aml_ohsu_2018	aml_ohsu_2018_4205	aml_ohsu_2018_16-01047	67	69	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	6	Yes	1.03	Cytarabine|Idarubicin and Cytarabine	2	Consolidation | Induction	2	Standard Chemotherapy	1	Cytarabine	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	9	Not Enough Information	Intermediate	White	Yes	No	NA	Positive	NA	Unknown	Post-Chemotherapy|Relapse	24.6	8.6	p.R132S, MAF 46%	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	93.5	40	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	30.49	LIVING	3.2	18	52	NA	94	0	NA	3	0	1	NA	28	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5.7	NA	Standard Chemotherapy	Standard Chemotherapy	108.9	Yes
aml_ohsu_2018	aml_ohsu_2018_4207	aml_ohsu_2018_16-01049	78	78	20	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	1.41	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	5	Induction | Re-induction | Maintenance | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Etoposide, Cytarabine	Supportive/Palliative Care	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Intermediate	Asian	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	25.7	8.5	Negative	Negative	Refractory	NA	46,XY[20]	0	NA	NA	675	False	No	No	NA	-1	Standard Chemotherapy	No	3	False	Negative	NA	AMLNOS	12.24	DECEASED	3.1	9	49	0	3.8	7.8	NA	40	5.2	40	NA	30	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	6.9	NA	Standard Chemotherapy|Supportive/Palliative Care	Supportive/Palliative Care	4.9	Yes
aml_ohsu_2018	aml_ohsu_2018_4210	aml_ohsu_2018_16-01055	56	56	73	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	1	Yes	0.74	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Salvage | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 46%	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	17	5.9	NA	NA	Refractory	NA	46,XX[20]	0	NA	NA	NA	False	Yes	No	91.9	-1	Bone Marrow Transplant	No	31	False	Negative	p.Q61K; MAF 9%	AMLMRC	6.02	LIVING	3.4	46	25	0	68	0	0.8	19.3	7.6	3.4	0.1	53	WES	No	NA	No	Yes	No	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	CD13, CD34, CD38, CD117, and dim HLA-DR +.	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	40.02	Yes
aml_ohsu_2018	aml_ohsu_2018_2530	aml_ohsu_2018_16-01059	73	74	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	6	Yes	NA	Ruxolitinib	1	Induction	1	Standard Chemotherapy	1	Ruxolitinib	Induction	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	28	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XX[20]	-195	NA	NA	NA	False	No	No	NA	28	Standard Chemotherapy	Yes	4	False	Negative	NA	AMLNPM1	18.42	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	Breast Cancer	No	No	Yes	No	No	3	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4197	aml_ohsu_2018_16-01061	45	47	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Sunitinib	Consolidation	Positive	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	32	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	NA	2	Standard Chemotherapy	No	14	False	Positive	NA	AMLNPM1	20.86	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4225	aml_ohsu_2018_16-01080	69	69	90	NA	Leukemia	APL with PML-RARA	NA	No	Negative	1	Yes	1.09	ATRA, Idarubicin	1	Induction	1	Standard Chemotherapy	1	ATRA, Idarubicin	Induction	PML/RARA fusion	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	No	-1	Intermediate-II	Favorable	White	Yes	No	M3	Positive	NA	PML-RARA	Initial Acute Leukemia Diagnosis	24.1	8.6	Negative	Negative	Complete Response	Negative	46,XX,t(15;17)(q24;q21)[20]	-1	Negative	Negative	NA	False	No	No	92.7	-1	Standard Chemotherapy	No	3	False	Negative	Negative	APLPMLRARA	NA	NA	3.4	45	41	1.7	59.5	1.7	0.8	13.5	5	6.7	0.9	39	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	6.5	Negative	Standard Chemotherapy	Standard Chemotherapy	34.36	Yes
aml_ohsu_2018	aml_ohsu_2018_4226	aml_ohsu_2018_16-01082	68	68	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	NA	1	Yes	1	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	CBFB, D7S486/ CEP 7	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	NA	CBFB-MYH11	Initial Acute Leukemia Diagnosis	33.6	11.9	NA	NA	Complete Response	NA	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	0	NA	NA	330	False	No	No	106.7	-1	Standard Chemotherapy	No	2	False	Negative	NA	AMLCBFBMYH11	NA	NA	4.1	27	26	0	10	0.9	0	81.8	4.6	10.9	0	106	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	6.9	NA	Standard Chemotherapy	Standard Chemotherapy	2.16	Yes
aml_ohsu_2018	aml_ohsu_2018_4229	aml_ohsu_2018_16-01093	61	61	48	NA	Leukemia	AML, NOS	NA	No	NA	2	No	0.86	NA	0	NA	0	NA	0	NONE	NONE	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	36.9	12.6	NA	NA	NA	NA	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	0	NA	NA	294	False	No	No	NA	NA	NONE	No	18	False	Negative	NA	AMLNOS	NA	NA	4.2	27	27	0	6	0	NA	31	14	47	NA	175	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	7	NA	NA	NA	2.43	Yes
aml_ohsu_2018	aml_ohsu_2018_2254	aml_ohsu_2018_16-01094	52	53	76	NA	Leukemia	AML, NOS	Dead-Disease	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	7	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Relapse	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	-463	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	4	False	Negative	NA	AMLNOS	20.82	DECEASED	NA	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Relapse	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2116	aml_ohsu_2018_16-01097	10	12	46	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	No	NA	1	Yes	0.53	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Induction | Re-induction	2	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	33	Intermediate-II	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Relapse	30.5	10.2	NA	NA	Complete Response	NA	47,XX,+10[19]/46,XX[1]	0	NA	NA	NA	False	No	No	96.8	-1	Standard Chemotherapy	No	2	False	Negative	NA	AMLCEBPA	18.72	LIVING	3.8	31	27	0	NA	0	0	81.3	8.3	10.4	18.1	11	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML with mutated CEBPA	AML with mutated CEBPA	variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	7	NA	Standard Chemotherapy	Standard Chemotherapy	1.93	Yes
aml_ohsu_2018	aml_ohsu_2018_4230	aml_ohsu_2018_16-01098	44	44	64	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	2	Yes	NA	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	45,XX,der(13;14)(q10;q10)?c[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	15	False	Positive	NA	AMLNPM1	7.11	LIVING	NA	21	34	NA	74	NA	NA	NA	NA	NA	NA	90	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	99.87	Yes
aml_ohsu_2018	aml_ohsu_2018_4231	aml_ohsu_2018_16-01100	65	65	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Unknown	No	NA	2	Yes	NA	Cytarabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Cytarabine	Supportive/Palliative Care	nuc ish (PML,RARA)x2[199]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	17	False	Positive	NA	AMLNPM1	0.07	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4232	aml_ohsu_2018_16-01102	72	72	30	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	2	Yes	NA	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBF	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	NA	False	Negative	NA	AMLMRC	11.78	LIVING	NA	37	93	NA	5	NA	NA	NA	NA	NA	NA	16	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Female	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy	NA	44.63	Yes
aml_ohsu_2018	aml_ohsu_2018_4197	aml_ohsu_2018_16-01103	45	47	90	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.93	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation | Salvage | Induction | Supportive/Palliative Care	4	Standard Chemotherapy | Supportive/Palliative Care	2	Sunitinib	Consolidation	Positive	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	32	Not Enough Information	Intermediate	White	Yes	Yes	NA	Positive	NA	Unknown	Residual Disease|Post-Chemotherapy	22.5	7.9	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	82.1	2	Standard Chemotherapy	No	14	False	Positive	NA	AMLNPM1	20.86	DECEASED	1.6	27	43	0	90	0	0	5	0	0	0	43	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	3	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	5.1	NA	Standard Chemotherapy|Supportive/Palliative Care	Standard Chemotherapy	18.38	Yes
aml_ohsu_2018	aml_ohsu_2018_4235	aml_ohsu_2018_16-01109	33	33	72	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	Alive	No	Negative	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Positive for CBFB rearrangment for 91% of cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Favorable	Favorable	Black	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Initial Acute Leukemia Diagnosis	19.8	6.5	Negative	Negative	Complete Response	Negative	46,XY,inv(16)(p13.1q22)[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Negative	Negative	AMLCBFBMYH11	3.82	LIVING	3.4	29	24	0	95	0	NA	3	0	1	NA	31	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Positive	6.6	Negative	Standard Chemotherapy	Standard Chemotherapy	93.2	Yes
aml_ohsu_2018	aml_ohsu_2018_2611	aml_ohsu_2018_16-01118	56	56	90	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	5	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation | Salvage | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy | Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	27	Not Enough Information	Intermediate	HispNative	Yes	Yes	NA	Positive	NA	None	Post-Transplant|Relapse	NA	NA	NA	NA	Complete Response	NA	46,XX[19]	-224	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	6	False	Positive	NA	AMLNPM1	10.63	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	Yes	No	2	Bone Marrow Aspirate	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4239	aml_ohsu_2018_16-01121	61	61	86	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Arg326Cys; MAF 44.5%	Yes	-1	Intermediate-I	Favorable	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	15	False	Positive	NA	AMLNPM1	6.05	LIVING	NA	NA	NA	NA	89	NA	NA	NA	NA	NA	NA	57	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	115.15	Yes
aml_ohsu_2018	aml_ohsu_2018_4240	aml_ohsu_2018_16-01123	46	46	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	1	Yes	0.78	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling | Consolidation | Induction | Experimental | CNS | Re-induction	6	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 35% (previously 32% on 10/10/16)	No	-1	Intermediate-I	Favorable or Intermediate	HispNative	Yes	No	NA	Positive	NA	None	Relapse	40	13.2	NA	NA	Complete Response i	NA	46,XX[20]	2	NA	NA	272	False	No	No	87.3	-1	Targeted Therapy - Kinase Inhibitor(s)	No	16	False	Positive	NA	AMLNPM1	11.84	DECEASED	3.6	51	28	0	NA	0.9	0.9	29.5	6.9	52.2	0	145	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.7	NA	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	8.16	Yes
aml_ohsu_2018	aml_ohsu_2018_2538	aml_ohsu_2018_16-01127	67	68	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	1	Yes	NA	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Salvage | Induction | Experimental	4	Standard Chemotherapy | Targeted Therapy - Other	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	-52	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	8	False	Positive	NA	AMLNPM1	17.37	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Leukapheresis	NA	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2315	aml_ohsu_2018_16-01138	62	63	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Disease	No	NA	1	Yes	1.43	Decitabine|Hydroxyurea	2	Induction | Re-induction	2	Standard Chemotherapy	1	Hydroxyurea	Re-induction	EGR1 (73.5%) ;  TP53: (85.5%)	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Relapse	25	8.2	NA	NA	Complete Response i	NA	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	-412	NA	NA	564	False	No	No	102.5	-1	Standard Chemotherapy	Yes	9	False	Negative	NA	AMLMRC	13.95	DECEASED	2.8	18	21	0.9	NA	0	0	7.8	1.7	4.3	0.1	139	WES + RNA-seq	No	NA	Yes	No	Yes	Yes	Yes	2	Peripheral Blood	Transformation from another heme malignancy and Relapse	Male	Matched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	6.6	NA	Standard Chemotherapy	Standard Chemotherapy	46.79	Yes
aml_ohsu_2018	aml_ohsu_2018_4245	aml_ohsu_2018_16-01139	77	79	NA	NA	Leukemia	AML, NOS	NA	No	NA	1	No	NA	Lenalidomide|Azacitidine	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Lenalidomide	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Residual Disease	NA	NA	NA	NA	NA	NA	46,XX[20]	-19	NA	NA	NA	False	No	No	NA	45	Supportive/Palliative Care	No	2	False	Negative	NA	AMLNOS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	NA	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Supportive/Palliative Care	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4247	aml_ohsu_2018_16-01142	28	29	50	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	p.Q311*; MAF 15%	1	Yes	0.61	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab	5	Allogeneic - Sibling | Consolidation | Induction | Re-induction	4	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI, Rituximab	Allogeneic - Sibling	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	-1	Favorable	Favorable	White	Yes	No	NA	Negative	NA	None	Post-Chemotherapy|Residual Relapse	25.5	9	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	174	False	No	No	87.3	-1	Bone Marrow Transplant	No	15	False	Negative	NA	AMLCEBPA	15.53	LIVING	3.6	24	11	0	NA	1.8	0.9	21	2.6	71.9	1.8	42	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	NA	Female	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, partial CD56, CD117,  HLA-DR,          MPO and dim TdT-positive	6.8	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	1.65	Yes
aml_ohsu_2018	aml_ohsu_2018_4248	aml_ohsu_2018_16-01151	81	81	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	1.3	Vidaza, BI836858 (anti-CD33)	1	Induction	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	25.1	8.8	Negative	NA	Complete Response	Negative	46,XY[19]	0	Negative	Negative	665	False	No	No	85.1	-1	Standard Chemotherapy	No	15	False	Positive	Negative	AMLNPM1	11.68	LIVING	3.2	31	42	0	80	0	7	7.8	0	6.9	0.5	16	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	AML with mutated NPM1	AML with mutated NPM1	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	7.2	Negative	Standard Chemotherapy	Standard Chemotherapy	33.81	Yes
aml_ohsu_2018	aml_ohsu_2018_4252	aml_ohsu_2018_16-01185	50	50	75	NA	Leukemia	Therapy-Related Myeloid Neoplasms	Dead-Unknown	No	Negative	5	Yes	NA	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Loss of 5q31 sequences for 99% of total cells	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Adverse	Adverse	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	20.1	6.5	Negative	Negative	Complete Response	Negative	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]	0	Negative	Negative	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	10	False	Negative	Negative	TMN	6.61	DECEASED	3.7	39	45	0	82	2	NA	4	0	8	NA	12	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Matched	Therapy-related myeloid neoplasms	Therapy-related myeloid neoplasms	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR	6.3	Negative	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	119.6	Yes
aml_ohsu_2018	aml_ohsu_2018_4256	aml_ohsu_2018_16-01191	65	65	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	3	Yes	NA	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	7cen (D7Z1), 7q31 (D7S486): monosomy present	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Gln231fs; MAF 33.2%	Yes	-1	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	45,XX,-7[20]	0	NA	NA	NA	False	No	Yes	NA	-1	Bone Marrow Transplant	No	4	False	Negative	p.Gln61Glu; MAF 47.8%	AMLMRC	8.09	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	Yes	No	No	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4201	aml_ohsu_2018_16-01192	52	52	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	0.76	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib	3	Consolidation | Salvage | Induction	3	Standard Chemotherapy	1	FLAG-IDA plus Midostaurin	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882C; MAF 14%	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy	28.4	9.2	Negative	Negative	Complete Response	Negative	46,XX[20]	-6	Negative	Negative	380	False	No	No	93.4	-1	Standard Chemotherapy	No	3	False	Negative	Negative	AMLNPM1	13.62	LIVING	3.2	119	151	1.4	NA	0.2	NA	9.2	24.3	64.9	NA	395	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	NA	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	NA	6.6	Negative	Standard Chemotherapy	Standard Chemotherapy	6.5	Yes
aml_ohsu_2018	aml_ohsu_2018_4260	aml_ohsu_2018_16-01201	53	54	75	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	1	Yes	0.84	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	7	Salvage | Induction | Experimental | Re-induction | Maintenance	5	Standard Chemotherapy | Targeted Therapy - Other	2	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 49%	Yes	6	Intermediate-II	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Post-Chemotherapy|Residual Disease	25.5	8.1	p.R132S; MAF 48%	Negative	Refractory	Negative	46,XY,t(4;12)(q12;p13)[10]/46,XY[10]	0	NA	Negative	706	False	No	No	91.4	-1	Standard Chemotherapy	No	6	False	Negative	Negative	AMLNOS	17.86	DECEASED	1.8	19	33	0	90	0	0	22.1	6.2	1.8	0	25	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive	6.6	Negative	Standard Chemotherapy|Targeted Therapy - Other	Standard Chemotherapy	118	Yes
aml_ohsu_2018	aml_ohsu_2018_4263	aml_ohsu_2018_16-01210	63	63	26.3	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation | Induction | Allogeneic - Child	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Child	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Thr835Met; MAF 47%	No	-1	Not Enough Information	Intermediate	White	Yes	No	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	p.Arg132Cys; MAF 2.9%	NA	Complete Response	NA	46,XY[11]	-17	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	2	False	Negative	NA	AMLMRC	12.99	LIVING	NA	NA	NA	NA	12	NA	NA	NA	NA	NA	NA	69	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	9.28	Yes
aml_ohsu_2018	aml_ohsu_2018_4263	aml_ohsu_2018_16-01216	63	63	NA	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	3	Yes	NA	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation | Induction | Allogeneic - Child	3	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Child	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Thr835Met; MAF 47%	Yes	-1	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	p.Arg132Cys; MAF 2.9%	NA	Complete Response	NA	46,XY[11]	-18	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	3	False	Negative	NA	AMLMRC	12.99	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Denovo	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NA	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4271	aml_ohsu_2018_16-01219	47	47	83	NA	Leukemia	AML with Biallelic Mutations of CEBPA	Alive	Yes	p.I68fs; MAF 50%	1	Yes	0.95	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	7	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	31.1	10.2	Negative	Negative	Complete Response	Negative	46,XY[20]	0	Negative	NA	290	False	No	No	88.9	-1	Standard Chemotherapy	No	14	False	Negative	p.G13D, MAF 3%	AMLCEBPA	10.43	LIVING	3.5	23	11	0	82	3.4	0	23.1	3.4	0	1.6	24	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Male	Matched	AML with mutated CEBPA	AML with mutated CEBPA	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO	6.5	Negative	Standard Chemotherapy	Standard Chemotherapy	18.71	Yes
aml_ohsu_2018	aml_ohsu_2018_4273	aml_ohsu_2018_16-01223	73	73	83	NA	Leukemia	AML, NOS	Dead-Unknown	No	NA	2	Yes	NA	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	NA	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	21	False	Negative	NA	AMLNOS	1.02	DECEASED	NA	21	23	NA	59	NA	NA	NA	NA	NA	NA	22	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Denovo	Male	Matched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy	NA	24.23	Yes
aml_ohsu_2018	aml_ohsu_2018_4274	aml_ohsu_2018_16-01225	61	61	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	1	No	NA	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	NA	Negative	46,XX[20]	-2	Negative	Negative	NA	False	No	No	NA	-1	Supportive/Palliative Care	Yes	3	False	Positive	Negative	AMLNPM1	10.39	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	Yes	Yes	Yes	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	Negative	Supportive/Palliative Care	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4275	aml_ohsu_2018_16-01227	39	40	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	6	Yes	0.49	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	39	Not Enough Information	Favorable	HispNative	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Relapse	29.3	9.9	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	93.6	-1	Standard Chemotherapy	No	4	False	Positive	NA	AMLNPM1	13.13	LIVING	3.8	21	34	NA	91	NA	NA	9	NA	NA	NA	66	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Peripheral Blood	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	5.8	NA	Standard Chemotherapy	Standard Chemotherapy	73	Yes
aml_ohsu_2018	aml_ohsu_2018_4291	aml_ohsu_2018_16-01237	73	73	71	NA	Leukemia	AML with Myelodysplasia-Related Changes	Alive	No	NA	6	Yes	0.51	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Adverse	Adverse	HispNative	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	24.9	7.8	NA	NA	NA	NA	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]	0	NA	NA	NA	False	No	No	110.7	-1	Standard Chemotherapy	No	2	False	Negative	NA	AMLMRC	4.01	LIVING	2.9	11	23	NA	3	1	NA	68	8	11	NA	95	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.	4.8	NA	Standard Chemotherapy	NA	63.4	Yes
aml_ohsu_2018	aml_ohsu_2018_4299	aml_ohsu_2018_16-01254	38	38	47	NA	Leukemia	AML with Mutated NPM1	Alive	No	Negative	1	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.R882H; MAF 46%	Yes	6	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	p.R132H; MAF 25%	Negative	Complete Response	Negative	46,XX[20]	0	Negative	p.Q61L; MAF 10%	NA	False	No	No	NA	-1	Standard Chemotherapy	No	14	False	Positive	p.G13D; MAF 24%	AMLNPM1	9.97	LIVING	NA	NA	NA	NA	21.7	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	AML with mutated NPM1	AML with mutated NPM1	CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive	NA	Negative	Standard Chemotherapy	Standard Chemotherapy	46.27	Yes
aml_ohsu_2018	aml_ohsu_2018_4303	aml_ohsu_2018_16-01262	59	59	90	NA	Leukemia	APL with PML-RARA	Alive	No	Negative	1	Yes	0.86	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide, Idarubicin	Induction	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Intermediate-II	Favorable	White	Yes	Yes	M3	Negative	NA	PML-RARA	Initial Acute Leukemia Diagnosis	19.8	6.7	Negative	Negative	Complete Response	Negative	46,XX,t(15;17)(q22;q21)[20]	0	Negative	Negative	NA	False	No	No	88.4	-1	Standard Chemotherapy	No	8	False	Negative	Negative	APLPMLRARA	0.92	LIVING	2.4	110	255	0.9	90	1.7	44	8.6	0	6	1.5	30	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	Denovo	Female	Matched	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	CD13, CD33, CD58, CD64, CD117, CD123, MPO	5.4	Negative	Standard Chemotherapy	Standard Chemotherapy	47.35	Yes
aml_ohsu_2018	aml_ohsu_2018_4307	aml_ohsu_2018_16-01267	61	62	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	7	No	NA	NA	0	NA	0	NA	0	NONE	NONE	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	VAF: 42.8%	Yes	NA	Favorable	Favorable	AdmixedBlack	Yes	Yes	NA	Negative	NA	None	Post-Chemotherapy|Relapse	NA	NA	NA	NA	NA	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	NA	NONE	No	7	False	Positive	NA	AMLNPM1	11.88	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Relapse	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	NA	NA	NA	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4317	aml_ohsu_2018_16-01270	72	74	NA	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	NA	1	No	NA	Dasatinib	1	Experimental	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	Experimental	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	NA	Favorable	Intermediate	White	Yes	Yes	NA	Negative	NA	Unknown	Relapse	NA	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	False	No	No	NA	16	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	NA	AMLCBFBMYH11	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES + RNA-seq	No	NA	No	No	No	Yes	Yes	2	Peripheral Blood	Relapse	Female	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	NA	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_4310	aml_ohsu_2018_16-01272	64	64	17	NA	Leukemia	AML with Myelodysplasia-Related Changes	Dead-Unknown	No	NA	6	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36         c.2656C>T; pQ886*    MAF 43%, 36%	No	6	Adverse	Adverse	White	Yes	No	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	NA	NA	NA	NA	Refractory	NA	42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10]	0	NA	NA	NA	False	No	No	NA	6	Standard Chemotherapy	No	3	False	Negative	NA	AMLMRC	2.63	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	5	NA	NA	43	WES + RNA-seq	No	Not specified	No	No	No	Yes	Yes	1	Bone Marrow Aspirate	NA	Male	Unmatched	AML with myelodysplasia-related changes	AML with myelodysplasia-related changes	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.	NA	c.610G>T;p.E204*    MAF 51%	Standard Chemotherapy	Standard Chemotherapy	2.2	Yes
aml_ohsu_2018	aml_ohsu_2018_4324	aml_ohsu_2018_17-00021	66	67	NA	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	6	Yes	0.88	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	23	Not Enough Information	Favorable	White	Yes	Yes	NA	Negative	NA	Unknown	Post-Chemotherapy|Relapse	38.3	12.5	NA	NA	Complete Response	NA	NA	0	NA	NA	NA	False	No	No	97.2	63	Standard Chemotherapy	No	6	False	Positive	NA	AMLNPM1	9.87	LIVING	4.3	15	22	NA	8	1	NA	14	19	46	NA	165	WES	No	NA	No	No	No	No	No	1	Peripheral Blood	Relapse	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	NA	6.2	NA	Standard Chemotherapy	Standard Chemotherapy	9	Yes
aml_ohsu_2018	aml_ohsu_2018_4325	aml_ohsu_2018_17-00025	39	39	70	NA	Leukemia	AML with Mutated NPM1	Alive	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling | Consolidation | Induction	3	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Sibling	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	p.Arg882His; MAF 41.8%	Yes	-1	Intermediate-I	Intermediate	White	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	-1	Bone Marrow Transplant	No	4	False	Positive	NA	AMLNPM1	5.69	LIVING	NA	NA	NA	NA	80	NA	NA	NA	NA	NA	NA	NA	WES	No	Cervical Cancer	No	No	No	No	No	1	Peripheral Blood	NA	Female	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	NA	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	190	Yes
aml_ohsu_2018	aml_ohsu_2018_4336	aml_ohsu_2018_17-00029	44	45	83	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	0.93	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy | Bone Marrow Transplant	2	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	No	6	Not Enough Information	Adverse	White	Yes	No	NA	Positive	Negative	Unknown	Post-Transplant|Post-Chemotherapy|Relapse	29.7	9.9	NA	NA	Unknown	NA	NA	0	NA	NA	NA	False	No	No	96.1	0	Bone Marrow Transplant	No	4	False	Negative	NA	AMLNOS	17.24	LIVING	4.1	19	20	NA	80	NA	NA	16	1	4	NA	63	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Relapse	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.	7.5	NA	Standard Chemotherapy|Bone Marrow Transplant	Standard Chemotherapy	85.5	Yes
aml_ohsu_2018	aml_ohsu_2018_4359	aml_ohsu_2018_17-00033	74	74	NA	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	NA	3	Yes	NA	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Supportive/Palliative Care	2	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	-1	Intermediate-II	Favorable	White	Yes	Yes	NA	Negative	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	UNKNOWN	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	-1	Standard Chemotherapy	No	5	False	Positive	NA	AMLNPM1	1.91	DECEASED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WES	No	Bladder Cancer	No	No	No	No	No	1	Peripheral Blood	NA	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	NA	Yes
aml_ohsu_2018	aml_ohsu_2018_2694	aml_ohsu_2018_17-00059	50	51	1	NA	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	Alive	No	NA	6	Yes	NA	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	RUNX1/RUNX1T1 fusion negative	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	20	Favorable	Intermediate	Black	Yes	Yes	NA	Negative	Negative	RUNX1-RUNX1T1	Post-Chemotherapy	NA	NA	NA	NA	Unknown	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	182	Standard Chemotherapy	No	15	False	Negative	NA	AMLRUNX1RUNX1T1	13.95	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	6	NA	NA	94	WES	No	NA	No	No	No	No	No	4	Bone Marrow Aspirate	NA	Male	Matched	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Positive for CD34, CD117, HLADR, CD13 AND CD33.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	6.6	Yes
aml_ohsu_2018	aml_ohsu_2018_4363	aml_ohsu_2018_17-00064	55	55	88.5	NA	Leukemia	AML with Mutated NPM1	Dead-Disease	No	Negative	5	Yes	NA	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction | Double Umbilical Cord Blood Transplant (DUCBT) | Maintenance	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	-1	Intermediate-I	Intermediate	HispNative	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	31.3	10.9	c.395G>A; p.R132H; 44%	Negative	Complete Response	Negative	46,XY[19]	0	Negative	Negative	NA	False	No	No	NA	44	Targeted Therapy - Kinase Inhibitor(s)	No	6	False	Positive	Negative	AMLNPM1	9.28	DECEASED	3.3	34	36	0	64	0	NA	25	4	7	NA	54	WES	No	NA	No	No	No	No	No	1	Bone Marrow Aspirate	Denovo	Male	Unmatched	AML with mutated NPM1	AML with mutated NPM1	Negative	7.4	Negative	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	24.9	Yes
aml_ohsu_2018	aml_ohsu_2018_4366	aml_ohsu_2018_17-00072	70	70	NA	NA	Leukemia	AML, NOS	Dead-Disease	No	Negative	1	Yes	1.5	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage | Induction | Experimental | Re-induction	4	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Normal	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	61	Intermediate-I	Intermediate	White	Yes	Yes	NA	Negative	Negative	None	Residual Disease|Post-Chemotherapy	31.5	9.8	Negative	Negative	Refractory	Negative	46,XY[20]	0	Negative	Negative	851	False	No	No	92.6	-1	Standard Chemotherapy	Yes	7	False	Negative	p.G13D; MAF 34%	AMLNOS	11.91	DECEASED	4.6	20	45	0	53.2	0	16.2	16.2	8.1	6.3	4.5	14	WES	No	NA	No	No	Yes	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	7.6	Negative	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	Standard Chemotherapy	92.55	Yes
aml_ohsu_2018	aml_ohsu_2018_4317	aml_ohsu_2018_17-00077	72	74	90	NA	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA	No	Negative	1	No	0.69	Dasatinib	1	Experimental	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	Experimental	CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Negative	Yes	NA	Favorable	Favorable	White	Yes	Yes	NA	Negative	Negative	CBFB-MYH11	Post-Chemotherapy|Residual Relapse	19.5	6.5	Negative	Negative	NA	Negative	46,XX,inv(16)(p13q22)[cp20]	-25	NA	Negative	807	False	No	No	86.7	16	Targeted Therapy - Kinase Inhibitor(s)	No	2	False	Negative	Negative	AMLCBFBMYH11	NA	NA	2.7	12	22	2.6	74	0	0	6	2.6	2.6	0	9	WES	No	NA	No	No	No	No	No	2	Bone Marrow Aspirate	NA	Female	Unmatched	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	5.8	Negative	Targeted Therapy - Kinase Inhibitor(s)	NA	34.76	Yes
aml_ohsu_2018	aml_ohsu_2018_4379	aml_ohsu_2018_17-00093	43	43	NA	NA	Leukemia	AML, NOS	NA	No	NA	2	Yes	NA	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	NA	Yes	6	Intermediate-I	Intermediate	Black	Yes	Yes	NA	Positive	NA	None	Initial Acute Leukemia Diagnosis	NA	NA	Negative	Negative	Unknown	NA	46,XX[20]	0	NA	NA	NA	False	No	No	NA	6	Standard Chemotherapy	Yes	2	False	Negative	NA	AMLNOS	NA	NA	NA	30	21	NA	48	NA	NA	NA	NA	NA	NA	27	WES	No	NA	No	No	Yes	No	No	1	Peripheral Blood	After or at the time transformation from another heme malignancy	Female	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	NA	NA	NA	Standard Chemotherapy	Standard Chemotherapy	41.91	Yes
aml_ohsu_2018	aml_ohsu_2018_4380	aml_ohsu_2018_17-00094	57	57	20	NA	Leukemia	AML, NOS	Alive	No	NA	6	Yes	NA	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Unknown | Induction	2	Standard Chemotherapy	1	HiDAC	Unknown	NA	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	c.2644C>T; p.R882C     MAF 47%	Yes	26	Not Enough Information	Adverse	White	Yes	Yes	NA	Negative	Negative	None	Initial Acute Leukemia Diagnosis	NA	NA	NA	NA	Complete Response	NA	46,XY[20]	0	NA	NA	NA	False	No	No	NA	77	Standard Chemotherapy	Yes	6	False	Negative	NA	AMLNOS	5.03	LIVING	NA	NA	NA	NA	NA	NA	NA	NA	3	NA	NA	49	WES	No	NA	No	No	Yes	No	No	1	Bone Marrow Aspirate	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myeloid leukaemia, NOS	Acute myeloid leukaemia, NOS	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33.	NA	NA	Standard Chemotherapy	Standard Chemotherapy	19.3	Yes
aml_ohsu_2018	aml_ohsu_2018_2747	aml_ohsu_2018_17-00096	62	63	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	Alive	No	NA	6	Yes	1	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	The abnormalities normally seen in MDS are not detected.	Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	Yes	NA	Not Enough Information	Intermediate	White	Yes	Yes	NA	Negative	NA	None	Residual Disease	41.7	12.9	NA	NA	NA	NA	46,XY[12]	-151	NA	NA	NA	False	No	No	82.2	-1	Bone Marrow Transplant	No	6	False	Negative	NA	CMML	8.42	LIVING	4.9	9	17	NA	NA	0.1	NA	13.8	9.9	74.1	NA	410	WES	No	NA	No	Yes	No	No	No	3	Peripheral Blood	After or at the time transformation from another heme malignancy	Male	Unmatched	Acute myelomonocytic leukaemia	Chronic myelomonocytic leukaemia	NA	7.6	NA	Standard Chemotherapy|Bone Marrow Transplant	NA	8	Yes